Home› India› Ministry of Chemicals and Fertilizers› Fixation and Revision of 905 Scheduled Formulations...
Date: 31-Mar-2023 Category: Extra Ordinary State: Union Government Country: India

Fixation and Revision of 905 Scheduled Formulations

Issued by Ministry of Chemicals and Fertilizers · Department of Pharmaceuticals

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

Key Changes

  • S.O. 1575(E): Revises the price of Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features to Rs 0.40 per ml, effective from April 1, 2023.
  • S.O. 1576(E): Revises the price of Metronidazole Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features to Rs 0.24 per ml, effective from April 1, 2023.
  • S.O. 1577(E): Fixes ceiling prices for 127 scheduled formulations based on NLEM 2022 and WPI increase, effective from April 1, 2023.
  • S.O. 1578(E): Fixes ceiling prices for 15 scheduled formulations based on NLEM 2022 and WPI increase, effective from April 1, 2023.
  • S.O. 1579(E): Fixes ceiling prices for Oxygen and Nitrous Oxide for medical use, effective from April 1, 2023.
  • S.O. 1580(E): A corrigendum related to S.O. 484(E) dated 2nd February, 2023, correcting the unit for Salbutamol Inhalation (MDI/DPI) from '1 MDI' to '1 Dose'.
  • S.O. 1581(E): A corrigendum related to S.O. 487(E) dated 2nd February, 2023, correcting the list of manufacturers for Mannitol Injection.
  • S.O. 1582(E): A corrigendum related to S.O. 486(E) dated 2nd February, 2023, correcting the list of manufacturers for Metronidazole Injection.
  • S.O. 1568(E): Fixes ceiling prices for 6 medicines including Acetyl Salicylic Acid tablet (300mg) at Rs 0.28 per tablet, Calcium Carbonate tablet (250mg) at Rs 2.43 per tablet, Condoms at Rs 11.36 per condom, Dapsone tablet (50mg) at Rs 0.29 per tablet, Medroxy Progesterone Acetate tablet (5mg) at Rs 3.72 per tablet and Rifampicin tablet (450mg) at Rs 5.51 per tablet, effective from April 1, 2023.
  • S.O. 1569(E): Revises the price of Dextrose Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features to Rs 0.24 per ml, effective from April 1, 2023.
  • S.O. 1570(E): Revises prices for Ringer Lactate Injection in various pack sizes with special features. For example, the 100 ml pack is priced at Rs 29.90, the 250 ml pack at Rs 50.99, the 500 ml pack at Rs 64.96 and the 1000 ml pack at Rs 114.19, effective from April 1, 2023.
  • S.O. 1571(E): Revises prices for Glucose Injection (5%) and Sodium Chloride Injection (0.9%) in various non-glass packaging with special features. For example, Glucose Injection 5% (1000ml) is priced at Rs 95.10, Glucose Injection 5% (500ml) is priced at Rs 82.27, Sodium Chloride Injection 0.9% (100ml) is priced at Rs 42.05, Sodium Chloride Injection 0.9% (250ml) is priced at Rs 62.10, Sodium Chloride Injection 0.9% (500ml) is priced at Rs 87.93 and Sodium Chloride Injection 0.9% (1000ml) is priced at Rs 98.49, effective from April 1, 2023.
  • S.O. 1572(E): Revises the ceiling prices of Coronary Stents. Bare Metal Stents are priced at Rs 10509.20 and Drug Eluting Stents (DES) are priced at Rs 38265.07, effective from April 1, 2023.
  • S.O. 1573(E): Fixes ceiling prices for 233 scheduled formulations, including 5-Aminosalicylic Acid, Acetylsalicylic Acid, Amphotericin B, Anti-D Immunoglobulin, Artesunate, Azithromycin, Benzoyl Peroxide, Betamethasone, Budesonide, Calcium Carbonate, Cefazolin, Cefixime, Cetirizine, Chlorambucil, Cloxacillin, Coagulation Factor VIII, Cyclosporine, Dapsone, Dextran, Diazepam, Diclofenac, Diphtheria Antitoxin, DPT Vaccine, Efavirenz, Ethyl Alcohol, Fentanyl, Fluconazole, Folic Acid, Gadobenate, Gentamicin, Glucose, Griseofulvin, Haemodialysis Fluid, Human Normal Immunoglobulin, Hydrochlorothiazide, Hydroxocobalamin, Ibuprofen, Imatinib, Ipratropium, Isoniazid, Japanese Encephalitis Vaccine, Ketamine, Levonorgestrel, Levothyroxine, Lignocaine, Lopinavir, Measles Vaccine, Melphalan, Methotrexate, Methylrosanilinium, Methylthioninium, Midazolam, Morphine, N-acetylcysteine, Nevirapine, Omeprazole, Oral Poliomyelitis Vaccine, Oral Rehydration Salts, Oxaliplatin, Para-aminosalicylic Acid, Paracetamol, Penicillamine, Permethrin, Phenylephrine, Phenytoin, Pilocarpine, Potassium Permanganate, Povidone-Iodine, Praziquantel, Prednisolone, Pyrazinamide, Rifampicin, Ringer Lactate, Ritonavir, Salbutamol, Silver Sulphadiazine, Snake Venom Antiserum, Sodium Chloride, Sodium Nitrite, Streptokinase, Succinylcholine, Sumatriptan, Surfactant, Tacrolimus, TD Vaccine, Temozolomide, Thiopentone, Timolol, Tramadol, Verapamil, Vinblastine, Vitamin A, Warfarin, Water for Injection, Zidovudine, Zinc Sulphate and Zolpidem, effective from April 1, 2023.
  • S.O. 1574(E): Fixes ceiling prices for 476 scheduled formulations, including 6-Mercaptopurine, Abacavir, Acetazolamide, Actinomycin D, Acyclovir, Adenosine, Adrenaline, Allopurinol, Alprostadil, Amiodarone, Amitriptyline, Amlodipine, Amoxicillin, Ampicillin, Artemether, Artesunate, Atazanavir, Atorvastatin, Atropine, Azathioprine, Azithromycin, Baclofen, Bendamustine, Benzoyl Peroxide, Betamethasone Valerate, Bicalutamide, Bisacodyl, Bleomycin, Bortezomib, Buprenorphine, Caffeine, Calcium Folinate, Capecitabine, Carbamazepine, Carbimazole, Carboplatin, Carboxymethyl Cellulose, Cefadroxil, Cefixime, Cefotaxime, Ceftazidime, Ceftriaxone, Cefuroxime, Cetirizine, Chloroquine, Cholecalciferol, Ciprofloxacin, Cisplatin, Clarithromycin, Clindamycin, Clobazam, Clomiphene, Clonazepam, Clopidogrel, Clozapine, Colchicine, Cyclophosphamide, Cycloserine, Cyclosporine, Cytosine Arabinoside, Dacarbazine, Daclatasvir, Darunavir, Dexamethasone, Diazepam, Diclofenac, Diethylcarbamazine, Digoxin, Diltiazem, Dinoprostone, Docetaxel, Dolutegravir, Domperidone, Donepezil, Dopamine, Doxycycline, D-Penicillamine, Efavirenz, Enalapril, Entecavir, Erythropoietin, Escitalopram, Ethambutol, Ethinylestradiol, Ethionamide, Etoposide, Filgrastim, Fluconazole, Flunarizine, Fluoxetine, Fluphenazine, Folic Acid, Furosemide, Fusidic Acid, Gefitinib, Gemcitabine, Gentamicin, Glimepiride, Glucose, Glyceryl Trinitrate, Glycopyrrolate, Griseofulvin, Haloperidol, Halothane, Heparin, Homatropine, Hormone Releasing IUD, Human Chorionic Gonadotropin, Hydrochlorothiazide, Hydrocortisone, Hydroxypropyl Methylcellulose, Hydroxychloroquine, Hydroxyurea, Ibuprofen, Imatinib, Insulin Intermediate Acting, Iron Sucrose, Isoflurane, Isosorbide Dinitrate, Ispaghula, Itraconazole, Ketamine, Labetalol, Lactulose, Lamivudine, L-Asparaginase, Lenalidomide, Letrozole, Leuprolide Acetate, Levetiracetam, Levodopa, Levofloxacin, Levothyroxine, Lignocaine, Linezolid, Lithium, Loperamide, Lopinavir, Lorazepam, Magnesium Sulphate, Mannitol, Mebendazole, Medroxyprogesterone Acetate, Mefenamic Acid, Mefloquine, Meglumine Diatrizoate, Mesna, Metformin, Methotrexate, Methylergometrine, Metoclopramide, Metoprolol, Metronidazole, Midazolam, Mifepristone, Misoprostol, Montelukast, Morphine, Moxifloxacin, Mycophenolate Mofetil, N-acetylcysteine, Naloxone, Natamycin, Neostigmine, Nevirapine, Nifedipine, Nitrofurantoin, Noradrenaline, Norethisterone, Omeprazole, Ondansetron, Oxaliplatin, Oxytocin, Paclitaxel, Paracetamol, Penicillamine, Permethrin, Phenylephrine, Phenytoin, Pilocarpine, Piperacillin, Potassium Chloride, Povidone-Iodine, Pralidoxime Chloride, Prednisolone, Primaquine, Proparacaine, Propofol, Propranolol, Protamine Sulphate, Pyrazinamide, Pyridoxine, Quinine, Rabies Vaccine, Raltegravir, Ramipril, Ribavirin, Rifampicin, Risperidone, Ritonavir, Rituximab, Trihexyphenidyl, Tropicamide, Valganciclovir, Vancomycin, Vecuronium, Verapamil, Vincristine, Xylometazoline, Zidovudine, Zinc Sulphate and Zolpidem, effective from April 1, 2023.

Gazette Notifications Overview

  • This document contains multiple notifications issued by the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India.
  • These notifications pertain to the fixation and revision of ceiling prices for various scheduled drug formulations under the Drugs (Prices Control) Order, 2013 (DPCO, 2013).
  • The revisions are based on the annual Wholesale Price Index (WPI) increase of 12.1218% for the year 2022.

Impact Analysis

Manufacturers

  • Manufacturers launching new drugs must apply for prior price approval to the NPPA in Form I.

Retailers and Dealers

  • This ensures easy accessibility for customers wishing to consult the same.

Consumers

  • The WPI-linked price revisions allow for reasonable price adjustments while protecting consumers from excessive price increases.

Government

  • The notifications reflect the government's commitment to balancing the interests of manufacturers and consumers.

Action Items for Manufacturers

  • Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval.

Key Entities Referenced

National Pharmaceutical Pricing Authority (NPPA): The regulatory body responsible for fixing and revising drug prices in India. Drugs (Prices Control) Order, 2013 (DPCO, 2013): The legal framework for drug price control in India. Essential Commodities Act, 1955: The law under which the DPCO is issued, enabling the government to regulate the production, supply, and distribution of essential commodities, including drugs. Wholesale Price Index (WPI): An index that measures the changes in the price of goods sold and traded in bulk by wholesale businesses; used to adjust drug prices. Standing National Committee on Medicines (SNCM): An expert committee that recommends the inclusion of medicines in the National List of Essential Medicines (NLEM). National List of Essential Medicines (NLEM) 2022: A list of essential medicines that are considered necessary for the healthcare needs of the majority of the population. Empowered Group (EG): A group authorized to ensure the availability of medical oxygen.
Official Source Record View Original Source →
See Full Document Text
रजिस्ट्री स.ं डी.एल.- 33004/99 REGD. No. D. L.-33004/99 सी.जी.-डी.एल.-अ.-01042023-244884 xxxGIDHxxx CG-DL-E-01042023-244884 xxxGIDExxx असाधारण EXTRAORDINARY भाग II—खण् ड 3—उप-खण्ड (ii) PART II—Section 3—Sub-section (ii) प्राजधकार स ेप्रकाजित PUBLISHED BY AUTHORITY स.ं 1506] नई दिल्ली, िुक्रवार, मार्च 31, 2023/र्त्रै 10, 1945 No. 1506] NEW DELHI, FRIDAY, MARCH 31, 2023/CHAITRA 10, 1945 ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1568(अ).— नवम्बर 4, 6, 10, 11, 14, 17 ,16 ,4 18 a b @ (12.1218%) 12.1218% 01.04.2023 से प्रभावी) ( ) (1) (2) (3) (4) (5) 6(a) 6(b) 1 ,lhVkby xksyh 300 fexzk 1 xksyh 0.28 1503 ¼v½ 30.03.2022 2206 GI/2023 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] lkfyflfyd ,flM 2 dSfY'k;e dkcksZusV xksyh 250 fexzk 1 xksyh 2.43 1503 ¼v½ 30.03.2022 3 daMksel 1 daMkse 11.36 1503 ¼v½ 30.03.2022 4 Msilksu xksyh 50 fexzk 1 xksyh 0.29 1503 ¼v½ 30.03.2022 5 eMs ªksDlh izksxsLVsjksu xksyh 5 fexzk 1503 ¼v½ 30.03.2022 1 xksyh 3.72 ,flVsV 6 fjQefiflu xksyh 450 fexzk 1 xksyh 5.51 1503 ¼v½ 30.03.2022 - ( 12.1218% ) (5) 12.1218% घ (5) यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे सिं ोधनों को दकए िान े के पंद्रह दिनों के भीतर की अवजध म ें ङ प्रपत्र-II के रूप में इलक्ट्े रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िल्ु क लेन े की जतजथ से उस पर ब्याि सजहत पवू च-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) स ेअजधक की राजि िमा करने के जलए उत्तरिायी होगा। च V ewY; (4) ि 1 u II I झ II III II IV[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 3 ञ (ट) [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 31st March, 2023 S.O. 1568(E).— In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. No. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date Strength 01.04.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 1 Acetyl Salicylic Tablet 300mg 1 Tablet 0.28 1503 (E) 30.03.2022 Acid 2 Calcium carbonate Tablet 250 mg 1 Tablet 2.43 1503 (E) 30.03.2022 3 Condoms 1 Condom 11.36 1503 (E) 30.03.2022 4 Dapsone Tablet 50 mg 1 Tablet 0.29 1503 (E) 30.03.2022 5 Medroxy Tablet 5mg 1 Tablet 3.72 1503 (E) 30.03.2022 Progesterone Acetate 6 Rifampicin Tablet 450mg 1 Tablet 5.51 1503 (E) 30.03.2022 Notes: - (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. (c) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1569(अ).— Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 22 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkn's k dk- vk- 1506¼v½ fnukad 30.03.2022 vkSj dk-vk- 4595¼v½ fnukad 29.09.2022 vkn's k ds vf/kØe.k eas tgk¡ rd mldk lEcU/k uhp s dh lkj.kh ^d* ] uhps nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhp s dh lkj.kh ^d* ds LraHk ¼5½ eas fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i eas fu;r djrh gSA @ 12.1218% @ 12.1218% (1) (2) (3) (4) (5) 1 डेक्सट्रोज (ग्लूकोज) यरू ो हेड के साथ प्लास्टिक बोतल में गैर- प्रतत लमली 0.24 ग्लास कंिेनर में पकै ेज के ललए 100लमली पकै[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 5 में इंजेक्शन )25% डब्ल्य ू / वी( की ववशेष ववशेषताए ं हैं मैसस स ओत्सुका फामासटयुटिकल इंडडया प्रालललमिेड . मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड मेससच सजर्न पैरेंटेरल प्रा. जलजमटेड 12.1218% (5) dk- vk- 1506¼v½ fnukad 30.03.2022 vkSj dk-vk- 4595¼v½ fnukad 29.09.2022 12.1218% (5) कोई अन्य विविर्मातम जो विशेष सुविधमओ ं िमले पैके जो ं र्ें डेक्सट्रोज (ग्लूकोज) यूरो हेड के साथ प्लास्टिक बोतल में गैर- ग्लास कंिेनर में पैकेज के ललए100 लमली पैक म ेंइजं क्े शन( 25)वी / डब्ल्य ू % की ववशेष ववशेषताएं हैं के वलए अलग अवधकतर् र्ूल्य कम दमिम करतम है तो िह अलग अवधकतर् र्ूल्य अिुर्ोदि के वलए एिपीपीए को आिेदि करेगम। यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे सिं ोधनों को दकए िान े के पंद्रह दिनों के भीतर की अवजध म ें प्रपत्र-II के रूप म ें इलेकरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य म ें संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िल्ु क लेन े की जतजथ स े उस पर ब्याि सजहत पवू च-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) स ेअजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) ञ (1) u II I6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] II III II IV (ड) [dka- l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1569(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O.No.1506(E) dated 30.03.2022 and S.O. 4595(E) dated 29.09.2022, in so far as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. No Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 1 Dextrose Injection (25% w/v) in 100 ml pack forpackages Per ml 0.24 (Glucose) in non-glass container in plasticbottle with euro head having special features TABLE ‘B’ Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. 4 M/s Sachin Parenteral Pvt. Ltd. (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 7 Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O.No. 1506(E) dated 30.03.2022 and S.O. 4595(E) dated 29.09.2022 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulation. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1570(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds vkn's k dk- vk- 1501¼v½ fnukad 30 ekpZ] 2022 vkSj dk- vk- 4592¼v½ fnukad 29.09.2022, vkns'k ds vf/kØe.k eas tgk¡ rd, uhp s nh xbZ lkj.kh [k es a8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhp s dh lkj.kh ^d* ds LraHk ¼5½ eas fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i eas fu;r djrh gSA @ 12.1218% @ 12.1218% (1) (2) (3) (4) (5) 1 ररंगर लैक्ट्टेट इंिेक्ट्िन 100 जमली प्रत्येक 100 जमलीलीटर पकै म ें 29.90 जविेि जवििे ताएं ह ैं 2 ररंगर लैक्ट्टेट इंिेक्ट्िन 250 जमली प्रत्येक 250 जमलीलीटर पैक में 50.99 जविेि जवििे ताएं ह ैं 3 ररंगर लैक्ट्टेट इंिेक्ट्िन 500 जमली प्रत्येक 500 जमलीलीटर पैक में 64.96 जविेि जवििे ताएं ह ैं 4 ररंगर लैक्ट्टेट इंिेक्ट्िन 1000 जमली प्रत्येक 1000 जमलीलीटर पकै म ें 114.19 जविेि जवििे ताएं ह ैं (1) (2) 1 मैससच अल्बटच डेजवड जल. 2 मैससच एक्ट्यूलाइफ हल्े थकेयर प्रा. जलजमटेड 3 मैससच बी। ब्रौन मेजडकल प्रा (इंजडया). जलजमटेड 4 मैससच फ्रेसेजनयस काबी इंजडया प्रा. जलजमटेड 5 मैससच ओस्ट्तुका फामाचस्ट्यूटटकल्स इंजडया प्रा. जलजमटेड 6 मैससच डेजनस केम लेब जलजमटेड 7 मैससच अमान्ता हल्े थकेयर जलजमटेड 8 मैससच श्री कृष्णा केिव लेबोरेटरीि जलजमटेड 9 मसै सच अक्ट्सा पैरेंटल्स जलजमटेड 10 मसै सच रुसोमा लेबोरेटरीि जलजमटेड 11 मसै स च आर .के .लेबोरेटरीि प्रा० जलजमटेड 12 मसै सच टरयलकेड लाईफसाइंस प्रा० जलजमटेड 13. मसै सच अबैटरस हल्े थकेयर प्रा० जलजमटेड (नीर्े ukVs ¼[k½ ) 14. मसै सच जहग्स हल्े थकेयर (नीर्े ukVs ¼x½½ 15. मसै सच रूसोमा लेबोरेटरीि प्रा०जलजमटेड (यूरोहडे बोटल ब्रांड नाम ड्यूजिप के साथ) (नीर्े uksV ¼[k½½ 16. मसै सच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड (नीर्े ukVs ¼?k½½ 17. मसै सच सजर्न पैरेंटेरल प्रा .जलजमटेड ("सेफ पोट"च ब्रांड नाम) (नीर्े ukVs ¼?k½ ½[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 9 12.1218% के 2, 3 और 4 मे दशासई गई कीमते केवल मैससच मसै स सअबैररस हे्थकेयर प्रा० लललमिेड ( के 13) और मैसस स रूसोमा लेबोरेिरीज प्रा० लललमिेड ( के 15) पर लागू होंगी . के और 4 मे दशासई गई कीमत े केवल मैसस सटहग्स हे्थकेयर ( के 14) पर लागू होंगी. के 3 मे दशासई गई कीमत े केवल मैससच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड ( के 16) और मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड ( के 17) पर लागू होंगी . (5) dk- vk- 1501¼v½ fnukad 30 ekpZ] 2022 vkSj dk- vk- 4592¼v½ fnukad 29.09.2022 12.1218% (5) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐस ेसंिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप म ें इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू -च संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। (ञ) V (4) (1) u II I ड II III II IV10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ढ ण [dka- la-@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1570(E).— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1501(E) dated 30.03.2022 andS.O. 4592(E) dated 29.09.2022, in so far as it relates toformulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. No. Medicines Dosage form and Unit Ceiling price Strength (w.e.f.01.04.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 1 Ringer lactate Injection100 ml Each 100 ml pack 29.90 having special features 2 Ringer lactate Injection 250 ml Each 250 ml pack 50.99 having special features 3 Ringer lactate Injection 500 ml Each 500 ml pack 64.96 having special features 4 Ringer lactate Injection 1000 ml Each 1000 ml pack 114.19 having special features TABLE ‘B’ Sl. Name of Manufacturer No. (1) (2) 1 M/s Albert David Ltd. 2 M/s Aculife Healthcare Pvt. Ltd. 3 M/s B. Braun Medical (India) Pvt. Ltd. 4 M/s Fresenius Kabi India Pvt. Ltd. 5 M/s Ostuka Pharmaceuticals India Pvt. Ltd. 6 M/s Denis Chem lab Ltd. 7 M/s Amanta Healthcare Ltd. 8 M/s Shree Krishna Keshav Laboratories Ltd. 9 M/s AxaParenterals Ltd. 10 M/s Rusoma Laboratories Pvt. Ltd. 11 M/s R. K. Laboratories Pvt. Ltd.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 11 12 M/s RealcadeLifesciencePvt. Ltd. 13 M/s Abaris Healthcare Pvt. Ltd (Note (b) below) 14 M/s Higgs Healthcare (Note (c) below) 15 M/s Rusoma Laboratories Pvt. Ltd. (Eurohead Bottles with Brand name “Dewdrip”) (Note (b) below) 16 M/s Puerto life Sciences Private Limited (Note (d) below) 17 M/s Sachin Parenteral Pvt. Ltd. (Brand name “SAFE PORT”) (Note (d) below) Notes: (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) In case of M/s Abaris Healthcare Pvt. Ltd(Sl. No. 13 of Table B) &M/s Rusoma Laboratories Pvt. Ltd.(Sl. No. 15 of Table B), only the prices of the formulations specified in Sl. No. 2, 3&4 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 14 of Table B, only the prices of the formulations specified in Sl. No. 3&4 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited(Sl. No. 16 of Table B) &M/s Sachin Parenteral Pvt. Ltd.(Sl. No. 17 of Table B), only the prices of the formulations specified in Sl. No. 3 of Table A are applicable. (e) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (f) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1501(E) dated 30.03.2022 and S.O. 4592(E) dated 29.09.2022 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022 over the year 2021 in accordance with paragraph 16(2) of DPCO, 2013. (g) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (h) Any other manufacturer claiming separate ceiling price for ringer lactate injection in pack having special features shall apply to NPPA for separate ceiling price approval. (i) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (j) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (k) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (l) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (m) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (n) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (o) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1571(अ).— Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkn's k dk- vk- 1500¼v½ fnukad 30 ekpZ] 2022 vkSj dk-vk- 4591¼v½ fnukad 29.09.2022 vkn's k ds vf/kØe.k eas tgk¡ rd mldk lEcU/k uhp s dh lkj.kh ^d* es a fofufeZr iSd] uhps nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhp s dh lkj.kh ^d* ds LraHk ¼5½ eas fofufnZ"V gS] vf/kdre dher dk s mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dk s NksM+dj vf/kdre dher ds #i es a fu;r djrh gSA @ 12.1218% @ 12.1218% (1) (2) (3) (4) (5) 1 Xywdkst bta sD'ku 5% 1000 fefy xSj&dk¡p 95.10 fo'ks"k fo'ks’krkvks a lfgr 2 Xywdkst batsD'ku 5% 500 fefy xSj&dk¡p 82.27 fo'ks"k fo'ks’krkvks a lfgr 3 Xywdkst ¼,½$lksfM;e batsD'ku 5% ¼,½$0- 1000 fefy xSj&dk¡p 99.93 DyksjkbM ¼ch½ fo'ks"k fo'ks’krkvks a lfgr 9% ¼ch½ 4 Xydw kst ¼,½$lksfM;e batsD'ku 5% ¼,½$ 0- 500 fefy xSj&dk¡p 85.51 DyksjkbM ¼ch½ fo'ks"k fo'ks’krkvks a lfgr 9% ¼ch½ 5 lksfM;e DyksjkbM batsD'ku 0-9% 100 fefy xSj&dk¡p 42.05 fo'ks"k fo'ks’krkvks a lfgr 6 lksfM;e DyksjkbM batsD'ku 0-9% 250 fefy xSj&dk¡p 62.10 fo'ks"k fo'ks"krkvks a lfgr 7 lksfM;e DyksjkbM batsD'ku 0-9% 500 fefy xSj&dk¡p 87.93 fo'ks"k fo'ks’krkvks a lfgr 8 lksfM;e DyksjkbM batsD'ku 0-9% 1000 fefy xSj&dk¡p 98.49 fo'ks"k fo'ks’krkvks a lfgr[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 13 मसै स स अक्सा पैरेंि्स लललमिेड यूरोहेड के साथ टिेरी डिप बोतल मसै स स श्री कृष्णा केशव लेबोरेिरीज लललमिेड यूरोहेड के साथ ईजीपोिस बोतल मसै सच रुसोमा लेबोरेटरीि प्रा०जलजमटेड प यूरािीप मसै सच आर .के .लेबोरेटरीि प्रा०जलजमटेड यूरोहडे बाटल मसै सच यूरोलाइफ हल्े थकेयर प्रा०जलजमटेड लाइफ पोटच मसै सच टरयलकेड लाईफसाइंस प्रा०जलजमटेड यूरोहडे बाटल मसै सच पुजनस्ट्का हल्े थकेयर प्रा०जलजमटेड (नीर्े नोन पीवीसी बेग मसै सच अबैटरस हल्े थकेयर प्रा० जलजमटेड डुओ पोटच मसै सच जहग्स हल्े थकेयर (नीर्े एक्वा जिप मसै सच रूसोमा लेबोरेटरीि प्रा०जलजमटेड यूरोहडे बोटल ब्रांड नाम ड्यूजिप के साथ मसै सच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड (नीर्े यूरोहडे बोटल मसै सच सजर्न पैरेंटेरल प्रा .जलजमटेड (नीर्े “सेफ पोटच” 12.1218% के 5, 6, 7 और 8 मे दशासई गई कीमते केवल मसै सच पुजनस्ट्का हल्े थकेयर प्रा०जलजमटेड ( के 19) पर लागू होंगी. के 1, 2, 3, 4, 5, 7 और 8 मे दशासई गई कीमते केवल मैसस चजहग्स हल्े थकेयर ( के 21) पर लागू होंगी. के 2, 4 और 7 मे दशासई गई कीमते केवल मैससच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड ( के 23) पर लागू होंगी. के 2, 4, 5, 6 और 7 मे दशासई गई कीमत े केवल मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड ( के 24) पर लागू होंगी14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (5) dk- vk- 1500¼v½ fnukad 30 ekpZ] 2022 vkSj dk-vk- 4591¼v½ fnukad 29.09.2022 12.1218% (5) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐस ेसंिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप म ें इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू -च संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) ड u (1) II I ( ) II III II IV ण )त( [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 15 ORDER New Delhi, the 31st March, 2023 S.O. 1571(E).— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1500(E) dated 30.03.2022 andS.O. 4591(E) dated 29.09.2022in so far as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. No. Medicines Dosage form and Unit Ceiling price Strength (w.e.f.01.04.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 1 Glucose Injection 5% 1000ml NonGlass with 95.10 special features 2 Glucose Injection 5% 500ml Non Glass with 82.27 special features 3 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non Glass 99.93 Chloride (B) 0.9% (B) with special features 4 Glucose (A) + Sodium Injection 5% (A) + 500ml Non Glass with 85.51 Chloride (B) 0.9% (B) special features 5 Sodium Chloride Injection 0.9% 100ml Non Glass with 42.05 special features 6 Sodium Chloride Injection 0.9% 250ml Non Glass with 62.10 special features 7 Sodium Chloride Injection 0.9% 500ml Non Glass with 87.93 special features 8 Sodium Chloride Injection 0.9% 1000ml Non Glass 98.49 with special features TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s B.Braun Medical (I) Pvt Ltd. Ecoflac Plus bottle with Eurohead 2 M/s Amanta Healthcare Ltd. Steriport bottle 3 M/s Aculife Healthcare Pvt Ltd. Aculife bottle with Eurohead 4 M/s Albert David Limited Albert David bottle with Eurohead 5 M/s Denis Chem Limited Aquapulse with Eurohead 6 M/s Claris Life Sciences Limited Claris bottle with Eurohead 7 M/s Fresenius Kabi India Pvt Limited Freeflex bags 8 M/s Otsuka Pharmaceutical India Private Ltd. Unibag (previously known as Claris Otsuka Private Limited) 9 M/s Aishwarya Lifesciences LifusionEurohead bottle 10 M/s Baxter (India) Pvt. Ltd. Viaflex bags 11 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle (previously known as Claris Otsuka Private Limited) 12 M/s Fresenius Kabi India Pvt Limited Eurohead bottle 13 M/s AxaParenterals Ltd Steri Drip bottle with Eurohead 14 M/s Shree Krishna Keshav Laboratories Ltd Easyport bottle with Eurohead 15 M/s Rusoma Laboratories Pvt. Ltd. Puradrip16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 16 M/s R. K. Laboratories Pvt. Ltd. Eurohead bottle 17 M/s Eurolife Healthcare Pvt. Ltd. Life port 18 M/s RealcadeLifesciencePvt. Ltd. Euro head bottle 19 M/s Puniska Healthcare Pvt. Ltd [Note (b) below] Non –PVC bag 20 M/s Abaris Healthcare Pvt. Ltd Duo Port 21 M/s Higgs Healthcare [Note (c) below] Aqua Drip 22 M/s Rusoma Laboratories Pvt. Ltd. Eurohead Bottles with Brand name “Dewdrip” 23 M/s Puerto life Sciences Private Limited [Note (d) Euro head bottle below] 24 M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] “SAFE PORT” Note : (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) In case of M/s Puniska Healthcare Pvt. Ltd.mentioned in Sl. No. 19 of Table B, only the prices of the formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the formulations specified in Sl. No. 2, 4 & 7 of Table A are applicable. (e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable. (f) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (g) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1500(E) dated 30.03.2022 and S.O. No. 4591(E) dated 29.09.2022(plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013. (h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (i) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack alongwith documentation and demonstration. (j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (l) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (m) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (n) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 17 information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (o) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (p) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1572(अ).— , , . . , . . . . @12.1218% , , I 10509.20 38265.07 - 13(2) @ . % (4) [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 31st March, 2023 S.O. 1572(E).—In continuation of the notifications issued by National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, S.O. 1464(E) dated 02.04.2018, S.O. 1488(E) dated 29.03.2019, SO. 1217(E) dated 25.03.2020, S.O. 1334(E) dated 25.03.2021 and 1502(E) dated 30.03.2022, 5249(E) dated 11.11.2022 regarding the fixation of ceiling price of the Coronary Stents as specified in column no. (2) mentioned in the table below; after considering the Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021, it has been decided to revise the ceiling pricesof Coronary Stents as mentioned in column no. (4) in the table below, exclusive of Goods and Services Tax as applicable,and unit specified in column (3) with effect from 01.04.2023, as under: TABLE Sl. Coronary Stents Unit Ceiling Price No (Sl. No. 28 in Schedule-I of the DPCO, 2013) (in Number) (in Rs.) (1) (2) (3) (4) 1 Bare Metal Stents 1 10509.20 Drug Eluting Stents (DES) including metallic DES and Bioresorbable 38265.07 2 1 Vascular Scaffold (BVS)/ Biodegradable Stents Notes:- (a) All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of Coronary Stent, on the basis of WPI @ 12.1218% for the year 2022 over 2021 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013. (b) The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the aforesaid table. (c) As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (d) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1573(अ).— vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 4, 6, 10, 11, 14, 16, 17 18 a b[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 19 @ (12.1218%) 12.1218% (1) (2) (3) (4) (5) 6(a) 6(b) 5&,feukslys hflfyd lqIiksftVªh 500 fexzk- fjVsu'ku 1 lqIiksftVªh 21.04 1 1499 (अ) 30.03.2022 ,flM ,fuek 5&,feukslys hflfyd xksyh 400 fexzk- 1 xksyh 9.30 2 1499 (अ) 30.03.2022 ,flM 5&¶ywjksjkfly batSD'ku 250 fexzk-@5 fefy- 1 fefy- 2.90 3 1499 (अ) 30.03.2022 ,cdkohj ¼,½ $ xksyh 60 fexzk- ¼,½ $ 30 fexzk- 1 xksyh 25.00 4 1499 (अ) 30.03.2022 yfseoqMhu ¼ch½ ¼ch½ ,lhVkbylSyhflfyd bQsjoslasV@fMLijflcy@,afVªd 1 xksyh 0.22 5 1499 (अ) 30.03.2022 ,flM dksfVM xksyh 100 fexzk- ,lhVkbylSyhflfyd xksyh 100 fexzk- 1 xksyh 0.21 6 1499 (अ) 30.03.2022 ,flM ,lhVkbylSyhflfyd xksyh 150 fexzk- 1 xksyh 0.50 7 1499 (अ) 30.03.2022 ,flM ,lhVkbylSyhflfyd xksyh 325 fexzk- 1 xksyh 0.68 8 1499 (अ) 30.03.2022 ,flM ,lhVkbylSyhflfyd xksyh 350 fexzk- 1 xksyh 0.38 9 1499 (अ) 30.03.2022 ,flM ,lhVkbylSyhflfyd xksyh 75 fexzk- 1 xksyh 0.38 10 1499 (अ) 30.03.2022 ,flM vkWy&Vªkal jVs hukWbd dSIlwy 10 fexzk- 1 dSIlwy 101.84 11 1499 (अ) 30.03.2022 ,flM ,EQksVsfjflu ch batSD'ku ds fy, ikmMj 50 izfr iSd 3990.40 12 1499 (अ) 30.03.2022 ¼fyfiM½ fexzk- ,EQksVsfjflu ch batSD'ku ds fy, ikmMj 50 izfr iSd 9294.89 13 1499 (अ) 30.03.2022 ¼fyikslksey½ fexzk- ,Eihflfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 26.56 14 1499 (अ) 30.03.2022 ,aVh&Mh batSD'ku 300 ,elhth izfr iSd 2657.32 15 1499 (अ) 30.03.2022 bEequksXykscqfyu ,aVh&Mh batSD'ku 150 ,elhth izfr ok;y 2071.29 16 1499 (अ) 30.03.2022 bEequksXykscqfyu ,aVh&jscht batSD'ku 150 vkbZ;w@fefy- 1 fefy- 3453.86 17 1499 (अ) 30.03.2022 bEequksXykscqfyu ,aVh&jscht batSD'ku 300 vkbZ;w@fefy- 1 fefy- 121.76 18 1499 (अ) 30.03.2022 bEequksXykscqfyu ,aVh&VsVul 250 vkbZ;w izfr iSd 1383.49 19 1499 (अ) 30.03.2022 bEequksXykscqfyu vlsZfud VªhvkWDlkbM batSD'ku 1 fexzk-@fefy- 1 fefy- 67.59 20 1499 (अ) 30.03.2022 vVZslqusV ¼,½ $ xksyh 100 fexzk- ¼,½ $ 1 xksyh dksEch iSd 36.71 21 1499 (अ) 30.03.2022 lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½ fifjesFkkekbu ¼ch½ vVZslqusV ¼,½ $ xksyh 150 fexzk- ¼,½ $ 2 xksyh dksEch iSd 49.84 22 1499 (अ) 30.03.2022 lYQkMkWDlhu & ¼500 fexzk- $ 25 fexzk-½ ¼ch½ fifjesFkkekbu ¼ch½20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vVZslqusV ¼,½ $ xksyh 200 fexzk- ¼,½ $ 2 xksyh dksEch iSd 45.45 23 1499 (अ) 30.03.2022 lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½ fifjesFkkekbu ¼ch½ vVZslqusV ¼,½ $ xksyh 25 fexzk- ¼,½ $ 1 xksyh dksEch iSd 24.47 24 1499 (अ) 30.03.2022 lYQkMkWDlhu & ¼250 fexzk- $ 12-5 fexzk-½ ¼ch½ fifjesFkkekbu ¼ch½ ,ftFkzksekblhu dSIlwy 500 fexzk- 1 dSIlwy 20.64 25 1499 (अ) 30.03.2022 chlhth oSDlhu izfr Mkst 11.12 26 1499 (अ) 30.03.2022 cSatkfFku batSD'ku ds fy, ikmMj 12 izfr iSd 22.70 27 1499 (अ) 30.03.2022 cSutkbZyisfuflfyu yk[k ;wfuV cSatkfFku batSD'ku ds fy, ikmMj 6 izfr iSd 15.01 28 1499 (अ) 30.03.2022 cSutkbZyisfuflfyu yk[k ;wfuV 29 csutks,y isjkDlkbM Øhe 2-5% 1 xzke 2.90 1499 (अ) 30.03.2022 csutkby isfuflfyu batSD'ku ds fy, ikmMj 10 izfr iSd 9.70 30 1499 (अ) 30.03.2022 yk[k ;wfuV 31 chVkesFklksu tSy 0-05% 1 xzke 0.66 1499 (अ) 30.03.2022 32 chVkesFklksu yks'ku 0-1% 1 fefy- 1.02 1499 (अ) 30.03.2022 33 chVkesFklksu yks'ku 0-5% 1 fefy- 0.66 1499 (अ) 30.03.2022 cqMslksukbM uts y Lizs 100 ,elhth@Mkst 1 Mkst 1.13 34 1499 (अ) 30.03.2022 cqMslksukbM uts y Lizs 50 ,elhth@Mkst 1 Mkst 1.26 35 1499 (अ) 30.03.2022 cqMslksukbM bugsys'ku ¼,eMhvkbZ½ 100 1.58 36 1499 (अ) 30.03.2022 ,elhth@Mkst cqMslksukbM bugsys'ku ¼,eMhvkbZ½ 200 2.19 37 1499 (अ) 30.03.2022 ,elhth@Mkst cqMslksukbM bugsys'ku ¼MhihvkbZ½ 100 2.48 38 1499 (अ) 30.03.2022 ,elhth@Mkst cqMslksukbM bugsys'ku ¼MhihvkbZ½ 200 3.59 39 1499 (अ) 30.03.2022 ,elhth@Mkst cqMslksukbM ¼,½ $ bugsys'ku ¼,eMhvkbZ½ 100 2.34 40 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ cqMslksukbM ¼,½ $ bugsys'ku ¼,eMhvkbZ½ 200 3.33 41 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ cqMslksukbM ¼,½ $ bugsys'ku ¼,eMhvkbZ½ 400 3.80 42 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ cqMslksukbM ¼,½ $ bugsys'ku ¼MhihvkbZ½ 100 4.72 43 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ cqMslksukbM ¼,½ $ bugsys'ku ¼MhihvkbZ½ 200 6.26 44 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ cqMslksukbM ¼,½ $ bugsys'ku ¼MhihvkbZ½ 400 8.00 45 1499 (अ) 30.03.2022 QkseksZVsjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ dSfY”k;e dkWcksZusV Xksyh 500 fexzk- 1 xksyh 2.15 46 1499 (अ) 30.03.2022 dSfY'k;e XyqdksusV batSD'ku 100 fexzk-@fefy- 1 fefy- 0.68 47 1499 (अ) 30.03.2022 lsQkMªksDlhy dSIlwy 500 fexzk- 1 dSIlwy 8.90 48 1499 (अ) 30.03.2022 lsQktksfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 30.56 49 1499 (अ) 30.03.2022 lsQktksfyu batSD'ku ds fy, ikmMj 500 izfr iSd 19.37 50 1499 (अ) 30.03.2022 fexzk- lsfQDlhe dSIlwy 400 fexzk- 1 dSIlwy 36.40 51 1499 (अ) 30.03.2022 lsfVªftu dSIlwy 10 fexzk- 1 dSIlwy 2.96 52 1499 (अ) 30.03.2022 Dyksjkecqfly xksyh 2 fexzk- 1 xksyh 45.94 53 1499 (अ) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 21 Dyksjkecqfly xksyh 5 fexzk- 1 xksyh 103.25 54 1499 (अ) 30.03.2022 55 DyksjgsDlkMhu lksyq'ku 5 % ¼da'kuVªsV QkWj 1 fefy- 0.19 1499 (अ) 30.03.2022 fMyq'ku½ DyksQkftekbu dSIlwy 100 fexzk- 1 dSIlwy 4.61 56 1499 (अ) 30.03.2022 DyksQkftekbu dSIlwy 50 fexzk- 1 dSIlwy 2.70 57 1499 (अ) 30.03.2022 DyksfeQsu dSIlwy 100 fexzk- 1 dSIlwy 69.30 58 1499 (अ) 30.03.2022 DyksfeQsu dSIlwy 50 fexzk- 1 dSIlwy 38.11 59 1499 (अ) 30.03.2022 DyksDlkflfyu dSIlwy 250 fexzk- 1 dSIlwy 1.41 60 1499 (अ) 30.03.2022 DyksDlkflfyu dSIlwy 500 fexzk- 1 dSIlwy 2.37 61 1499 (अ) 30.03.2022 DyksDlkflfyu xksyh 250 fexzk- 1 xksyh 2.15 62 1499 (अ) 30.03.2022 DyksDlkflfyu batSD'ku ds fy, ikmMj 250 izfr iSd 5.52 63 1499 (अ) 30.03.2022 fexzk- 64 dksxqy's ku QSDVj IX batSD'ku ds fy, ikmMj 600 izfr iSd 15338.91 1499 (अ) 30.03.2022 vkbZ;w 65 dksxs qys'ku QSDVj VIII batSD'ku ds fy, ikmMj 250 izfr iSd 4649.89 1499 (अ) 30.03.2022 vkbZ;w 66 dksxqy's ku QSDVj VIII batSD'ku ds fy, ikmMj 500 izfr iSd 11410.50 1499 (अ) 30.03.2022 vkbZ;w dks&Vªk;eksDlktkys xksyh 800 fexzk- ¼,½ $ 160 1 xksyh 2.52 67 1499 (अ) 30.03.2022 [lYQkesFkkWDlklsy fexzk- ¼ch½ ¼,½$VªheFs kksizhe ¼ch½]] lkbDyksLiksfju batSD'ku 50 fexzk-@fefy- 1 fefy- 335.78 68 1499 (अ) 30.03.2022 Msilksu xksyh 100 fexzk- 1 xksyh 0.44 69 1499 (अ) 30.03.2022 MkSuk:fclhu I.V. batSD'ku ds fy, ikmMj izfr iSd 302.74 70 1499 (अ) 30.03.2022 20 fexzk- ¼5 fexzk-@fefy-½ MslQsjhvksDlkekbu batSD'ku ds fy, ikmMj 500 izfr iSd 200.19 71 1499 (अ) 30.03.2022 fexzk- MsDlkeFs kklksu batSD'ku 4 fexzk-@fefy- izfr iSd 11.60 72 1499 (अ) 30.03.2022 ¼2 fefy-½ 73 MsDlkVªku&40 batSD'ku 10% 1 fefy- 1.05 1499 (अ) 30.03.2022 vksjy fyD;wbZM 2 fexzk-@5 3.39 74 Mk;tsike 1 fefy- 1499 (अ) 30.03.2022 fefy- 75 fMDyksQsud dSIlwy 50 fexzk- 1 dSIlwy 0.76 1499 (अ) 30.03.2022 vksjy lksyq'ku 10 fexzk-@5 0.20 76 fMlkbDyksekbu 1 fefy- 1499 (अ) 30.03.2022 fefy- 77 fMlkbDyksekbu xksyh 10 fexzk- 1 xksyh 0.13 1499 (अ) 30.03.2022 78 MkbuksizksLVksu xksyh 0-5 fexzk- 1 xksyh 62.30 1499 (अ) 30.03.2022 MkbQFksfj;k 1631.60 79 10000 vkbZ;w izfr iSd 1499 (अ) 30.03.2022 ,VhaVksDlhu 80 MhihVh oSDlhu izfr 0-5 fefy- 17.63 1499 (अ) 30.03.2022 81 bQkohjsta dSIlwy 200 fexzk- 1 dSIlwy 29.97 1499 (अ) 30.03.2022 82 bQkohjsta dSIlwy 600 fexzk- 1 dSIlwy 78.09 1499 (अ) 30.03.2022 bFkkbZy ,Ydksgy 0.52 83 lksY;q'ku 70 izfr'kr 1 fefy- 1499 (अ) 30.03.2022 ¼Mhups jM½ 84 QsuVkukby batSD'ku 50 ,elhth@fefy- 1 fefy- 28.26 1499 (अ) 30.03.2022 Xkksyh 100 fexzk- byheus Vy 0.28 85 Qsjl lkYV ¼,½ $ 1499 (अ) 30.03.2022 vk;ju ¼,½ $ 500 ,elhth 1 xksyh Qksfyd ,flM ¼ch½ ¼ch½22 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vksjy fyD;wbZM 50 fexzk-@5 3.25 86 ¶ydw ksuktkys 1 fefy- 1499 (अ) 30.03.2022 fefy- 87 ¶ydw ksuktkys dSIlwy 100 fexzk- 1 dSIlwy 31.46 1499 (अ) 30.03.2022 88 ¶yDw lsVkbu xksyh 10 fexzk- 1 xksyh 3.10 1499 (अ) 30.03.2022 89 ¶yDw lsVkbu xksyh 20 fexzk- 1 xksyh 4.93 1499 (अ) 30.03.2022 90 ¶yDw lsVkbu xksyh 40 fexzk- 1 xksyh 6.64 1499 (अ) 30.03.2022 91 ¶yDw lsVkbu xksyh 60 fexzk- 1 xksyh 9.21 1499 (अ) 30.03.2022 92 Qksfyd ,flM dSIlwy 5 fexzk- 1 dSIlwy 7.01 1499 (अ) 30.03.2022 93 xkMkscsuVs batSD'ku 529 fexzk-@fefy- 1 fefy- 135.67 1499 (अ) 30.03.2022 izfr iSd ¼2 10.48 94 tsaVkekbflu batSD'ku 40 fexzk-@fefy- 1499 (अ) 30.03.2022 fefy-½ 95 Xywdkst batSD'ku 50 % 1 fefy- 0.60 1499 (अ) 30.03.2022 1000 fefy- 79.95 96 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % Xykl 1000 fefy- 64.54 97 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % ukWu Xykl 100 fefy- 22.44 98 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % Xykl 100 fefy- 20.31 99 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % ukWu Xykl 250 fefy- 31.01 100 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % Xykl 250 fefy- 28.01 101 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % ukWu Xykl 500 fefy- 44.01 102 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % Xykl 500 fefy- 37.97 103 Xywdkst batSD'ku 5 1499 (अ) 30.03.2022 % ukWu Xykl izfr iSd 32.15 104 Xywdkst batSD'ku 10 1499 (अ) 30.03.2022 % ¼1000 fefy½ izfr iSd ¼500 34.97 105 Xywdkst batSD'ku 10% 1499 (अ) 30.03.2022 fefy-½ Xywdkst ¼,½ $ 1000 fefy- 80.48 106 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % Xykl Xywdkst ¼,½ $ 1000 fefy- 65.03 107 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % ukWu Xykl Xywdkst ¼,½ $ 100 fefy- 22.50 108 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % Xykl Xywdkst ¼,½ $ 100 fefy- 20.33 109 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % ukWu Xykl Xywdkst ¼,½ $ 250 fefy- 31.13 110 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % Xykl Xywdkst ¼,½ $ 250 fefy- 28.12 111 batSD'ku 5 ¼,½ $ 0-9 ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ % % ukWu Xykl Xywdkst ¼,½ $ 500 fefy- 44.23 112 batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ Xykl Xywdkst ¼,½ $ 500 fefy- 38.21 113 batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 1499 (अ) 30.03.2022 lksfM;e DyksjkbM ¼ch½ ukWu Xykl 114 XywVkjkyMsgkbM lksyq'ku 2% 1 fefy- 0.07 1499 (अ) 30.03.2022 115 xzhlksQqyfou xksyh 125 fexzk- 1 xksyh 1.02 1499 (अ) 30.03.2022 116 xzhlksQqyfou xksyh 375 fexzk- 1 xksyh 5.34 1499 (अ) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 23 117 gseksMk;ylhl ¶ywM ykblsla ds vuqlkj 1 fefy- 0.04 1499 (अ) 30.03.2022 g~;qeu ukWeZy lksyq'ku QkWj bu¶;wtu 5 192.06 118 1 fefy- 1499 (अ) 30.03.2022 bEequksXykscqfyu izfr'kr g~;qeu ukWeZy lksyq'ku QkWj bu¶;wtu 10 260.03 119 1 fefy- 1499 (अ) 30.03.2022 bEequksXykscqfyu izfr'kr 120 g~;qeu ukWeZy lksyq'ku QkWj bu¶~;wtu 16.5 1 fefy- 494.49 1499 (अ) 30.03.2022 bEequksXykscqfyu izfr'kr 121 gkbMªksDyksjksFkkbtkbM xksyh 50 fexzk- 1 xksyh 0.10 1499 (अ) 30.03.2022 122 gkbMªkstu isjksDlkbM lksyq'ku 6% 1 fefy- 0.04 1499 (अ) 30.03.2022 12.31 123 हाइिोक्सोकोबालालमन इंजेक्शन 1 लमली ग्रामएमएल/ 1 लम.ली. 1499 (अ) 30.03.2022 124 gk;kslhu cqVhyczksekbM batSD'ku 20 fexzk-@fefy- 1 fefy- 12.99 1499 (अ) 30.03.2022 125 vkbZcqizksQqu dSIlwy 400 fexzk- 1 dSIlwy 1.31 1499 (अ) 30.03.2022 1 lkWQ~V 3.33 126 1499 (अ) 30.03.2022 vkbZcqizksQqu dSIlwy 200 fexzk- tsyVs kbu dSIlwy 127 befsVuhc dSIlwy 400 fexzk- 1 dSIlwy 317.98 1499 (अ) 30.03.2022 bugsy's ku 0.76 128 1499 (अ) 30.03.2022 vkbZizkVªksfi;e ¼,eMhvkbZ@MhihvkbZ½ 20 1 Mkst ,elhth@Mkst jls fijVs kWjh lkys q'ku QkWj ;wt 3.15 129 1499 (अ) 30.03.2022 vkbZizkVªksfi;e bu uscqykbtj 250 1 fefy- ,elhth@fefy- 130 vkbZlksfuftM xksyh 100 fexzk- 1 xksyh 0.84 1499 (अ) 30.03.2022 131 vkbZlksfuftM xksyh 300 fexzk- 1 xksyh 1.49 1499 (अ) 30.03.2022 tkiuht bulsQkfyfVl 868.40 132 4 ,elhth ls 6 ,elhth izfr iSd 1499 (अ) 30.03.2022 oSDlhu tkiuht bulsQkfyfVl 661.59 133 3 ,elhth rd izfr iSd 1499 (अ) 30.03.2022 oSDlhu 134 dSVkekbu batSD'ku 10 fexzk-@fefy- 1 fefy- 13.18 1499 (अ) 30.03.2022 135 yos ksuksxsZLVªsy xksyh 0-75 fexzk- 1 xksyh 28.64 1499 (अ) 30.03.2022 136 yos ksFkkbjksDlhu xksyh 37.50 ,elhth 1 xksyh 1.46 1499 (अ) 30.03.2022 137 fyXuksdsu ¼,½ $ batSD'ku 1%¼,½ $ 0.56 1499 (अ) 30.03.2022 1%200000¼5 ,elhth@fefy-½ 1 fefy- ,Mªus kykbu ¼ch½ ¼ch½ yksfiukohj ¼,½ xksyh 100 fexzk- ¼,½ $ 25 29.27 138 1 xksyh 1499 (अ) 30.03.2022 $fjVksukohj ¼ch½ fexzk- ¼ch½ izfr iSd ¼0-5 110.05 139 fetyl :cys k oSDlhu 1499 (अ) 30.03.2022 fefy-½ izfr iSd ¼0-5 63.47 140 fetyl oSDlhu oSDlhu 1499 (अ) 30.03.2022 fefy-½ 141 eys Qkyku xksyh 2 fexzk- 1 xksyh 122.13 1499 ((अ) 30.03.2022 142 eys Qkyku xksyh 5 fexzk- 1 xksyh 209.47 1499 (अ) 30.03.2022 143 eFs kksVªDs lsV batSD'ku 50 fexzk-@fefy- 1 fefy- 49.86 1499 (अ) 30.03.2022 0.10 144 लमथाईलरोसातनललतनयम पन्ैं ि 1% 1 fefy- 1499 (अ) 30.03.2022 क्लोरईड )जेंलसया वाइलेि( 27.13 145 लमथाइलथथओतनतनयम 1499 (अ) 30.03.2022 इंजेक्शन 10 लमलीग्राम/लम.ली. 1 लम.ली. क्लोराइड )मेथथलीन ब्लल ू ( 146 feMktksye xksyh 7-5 fexzk- 1 xksyh 27.94 1499 (अ) 30.03.2022 147 eksQhZu ,lvkj xksyh 30 fexzk- 1 xksyh 6.78 1499 (अ) 30.03.202224 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 148 eksQhZu xksyh 10 fexzk- 1 xksyh 6.62 1499 (अ) 30.03.2022 149 ,u&,flVkbyflLVsu lpVs 200 fexzk- 1 xzke 11.20 1499 (अ) 30.03.2022 vksjy fyD;wbZM 50 fexzk-@5 1.04 150 uos hjkikbu 1 fefy- 1499 (अ) 30.03.2022 fefy- 151 vksesizktkys xksyh 10 fexzk- 1 xksyh 5.51 1499 (अ) 30.03.2022 152 vksesizktkys dSIlwy 40 fexzk- 1 dSIlwy 6.14 1499 (अ) 30.03.2022 153 ओरल पोललओमाईललटिस 1 fefy- 127.66 1499 (अ) 30.03.2022 वेक्सीन vksjy fjgkbMªs'ku 1.11 154 ykblsla ds :i eas 1 xzke 1499 (अ) 30.03.2022 lkYVl batSD'ku 100 fexzk-¼ykblsla ds 5563.59 155 vksDlkyhIykVhu izfr iSd 1499 (अ) 30.03.2022 :i eas½ ikjk&,feukslkfyflfyd 3.54 156 xzsU;wyl ¼ykblsla ds :i eas½ 1 xzke 1499 (अ) 30.03.2022 ,flM izfr iSd ¼0-5 3.82 157 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 fefy-½ izfr iSd 5.22 158 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼1 fefy-½ izfr iSd 8.02 159 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼2 fefy-½ izfr iSd 10.84 160 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼3 fefy-½ izfr iSd 13.64 161 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼4 fefy-½ izfr iSd 16.45 162 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼5 fefy-½ izfr iSd 22.06 163 isjkflVkeksy batSD'ku 150 fexzk-@fefy- 1499 (अ) 30.03.2022 ¼7 fefy-½ 164 isfuflykekbu dSIlwy 250 fexzk- 1 dSIlwy 18.50 1499 (अ) 30.03.2022 165 ieZsFkzhu tSy 5% 1 xzke 1.82 1499 (अ) 30.03.2022 166 QsuhyQs jhu MªksIl 10% 1 fefy- 10.05 1499 (अ) 30.03.2022 167 QsuhyQs jhu MªksIl 5% 1 fefy- 4.64 1499 (अ) 30.03.2022 168 QsuhVksbu bZvkj dSIlwy 300 fexzk- 1 dSIlwy 4.74 1499 (अ) 30.03.2022 169 QsuhVksbu batSD'ku 25 fexzk-@fefy- 1 fefy- 3.12 1499 (अ) 30.03.2022 170 fiyksdkjfiu MªksIl 4% 1 fefy- 14.54 1499 (अ) 30.03.2022 171 iksVsf'k;e ijesxa usV fØLVy QkWj VkWfidy lksyq'ku 1 xzke 0.54 1499 (अ) 30.03.2022 172 ikWfoMu vk;ksMhu टरब 7-5% 1 fefy- 1.99 1499 (अ) 30.03.2022 173 ikWfoMu vk;ksMhu vksbuVesVa 10% 1 xzke 6.48 1499 (अ) 30.03.2022 174 ikWfoMu vk;ksMhu lksyq'ku 4% 1 fefy- 2.16 1499 (अ) 30.03.2022 175 izkftD;wuVys xksyh 600 fexzk 1 xksyh 43.24 1499 (अ) 30.03.2022 176 izsMfulksyksu batSD'ku 20 fexzk-@2 fefy- 1 fefy- 4.46 1499 (अ) 30.03.2022 vksjy fyD;wbZM 250 fexzk-@5 0.76 177 ikbjkftukekbM 1 fefy- 1499 (अ) 30.03.2022 fefy- 178 fjQefiflu xksyh 150 fexzk- 1 xksyh 2.00 1499 (अ) 30.03.2022 179 fjQefiflu xksyh 300 fexzk- 1 xksyh 3.65 1499 (अ) 30.03.2022 180 fjxa j ySDVVs batSD'ku 1000 fefy- izfr iSd 99.30 1499 (अ) 30.03.2022 181 fjxa j ySDVVs batSD'ku 100 fefy- izfr iSd 26.00 1499 (अ) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 25 182 fjxa j ySDVVs batSD'ku 250 fefy- izfr iSd 44.33 1499 (अ) 30.03.2022 183 fjxa j ySDVVs batSD'ku 500 fefy- izfr iSd 56.49 1499 (अ) 30.03.2022 184 fjVksukohj dSIlwy 100 fexzk- 1 dSIlwy 35.13 1499 (अ) 30.03.2022 185 lsycqVkeksy dSIlwy 4 fexzk- 1 dSIlwy 0.74 1499 (अ) 30.03.2022 186 flYoj lYQkMkbftu Øhe 1% 1 xzke 0.62 1499 (अ) 30.03.2022 LuSd osukse ,aVhlsje 693.70 187 1499 (अ) 30.03.2022 ykbvksfQykftM batSD'ku ds fy, ikmMj 10 fefy- iSd ikWyhosysVa LuSd osukse ,aVhlsje 538.70 188 izfr iSd ¼10 1499 (अ) 30.03.2022 lksyqcy@fyD;wbM batSD'ku fefy-½ ikWyhosysVa 1000 fefy- 73.87 189 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 Xykl 1000 fefy- 58.26 190 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 ukWu Xykl 100 fefy- 21.84 191 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 Xykl 100 fefy- 19.67 192 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 ukWu Xykl 250 fefy- 29.46 193 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 Xykl 250 fefy- 26.44 194 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 ukWu Xykl 500 fefy- 40.96 195 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 Xykl 500 fefy- 34.86 196 lksfM;e DyksjkbM batSD'ku 0-9% 1499 (अ) 30.03.2022 ukWu Xykl 197 lksfM;e ukbZVªsV batSD'ku 30 fexzk-@fefy- 1 fefy- 32.34 1499 (अ) 30.03.2022 lksfM;e 32.14 198 batSD'ku 10 fexzk-@fefy- 1 fefy- 1499 (अ) 30.03.2022 ukbVªksi:lkbM 199 LVªIsVksfdukl batSD'ku 7]50]000 vkbZ;w izfr iSd 1567.32 1499 (अ) 30.03.2022 200 lfDluhy dksfyu batSD'ku 50 fexzk-@fefy- 1 fefy- 6.02 1499 (अ) 30.03.2022 201 lqekVªhIVu xksyh 25 fexzk- 1 xksyh 41.44 1499 (अ) 30.03.2022 202 lqekVªhIVu xksyh 50 fexzk- 1 xksyh 64.15 1499 (अ) 30.03.2022 lLis'a ku QkWj buVªkVªkpys izfr iSd eas 83.27 203 1499 (अ) 30.03.2022 ljQsDVkaV buLVkby's ku ¼ykblsla ds :i izfr fefy- eas½ QksLQksfyfiM~l 204 VkØkfsyeql xksyh 0.5 fexzk- 1 xksyh 23.32 1499 (अ) 30.03.2022 205 VkØkfsyeql xksyh 1 fexzk- 1 xksyh 42.83 1499 (अ) 30.03.2022 206 VkØkfsyeql xksyh 2 fexzk- 1 xksyh 84.60 1499 (अ) 30.03.2022 207 प्रत्येक 0.5 लमली. डोसेस मे: डडप्थरेरया 23.33 1499 (अ) 30.03.2022 िोक्साइड ≤5 एलएफ ≥(2आईय)ू प्रत्येक 0.5 टी डी वैजक्ट्सन िेट्नस िोक्साइड ≥5 एलएफ ≥(40 लमलीपकै . आईयू) 208 प्रत्येक 0.5 लमली. डोसेस मे: डडप्थरेरया 219.24 1499 (अ) 30.03.2022 िोक्साइड ≤ 5 एलएफ )≥ 2 आईयू( प्रत्येक 5 लमली . टी डी वैजक्ट्सन िेट्नस िोक्साइड ≥ 5 एलएफ )≥ 40 पकै आईयू( 209 प्रत्येक 0.5 लमली. डोसेस मे: डडप्थरेरया 20.00 1499 (अ) 30.03.2022 प्रत्येक 0.5 टी डी वैजक्ट्सन िोक्साइड ≤ 25 एलएफ )≥ 30 लमलीपकै . आईयू( िेट्नस िोक्साइड ≥ 5 एलएफ26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] )≥ 40 आईय(ू 210 Ves kstksyksekbM xksyh 100 fexzk- 1 xksyh 1925.47 1499 (अ) 30.03.2022 211 Ves kstksyksekbM xksyh 20 fexzk- 1 xksyh 466.49 1499 (अ) 30.03.2022 212 Ves kstksyksekbM xksyh 250 fexzk- 1 xksyh 4765.73 1499 (अ) 30.03.2022 batSD'ku ds fy, ikmMj 0-5 50.71 213 FkhvksisuVkWu izfr iSd 1499 (अ) 30.03.2022 xzke 214 FkhvksisuVkWu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 61.52 1499 (अ) 30.03.2022 215 fVeksyksy MªksIl 0-25% 1 fefy- 6.43 1499 (अ) 30.03.2022 batSD'ku 50 fexzk-@fefy- ¼20 1.54 216 VªkekMksy 1 fefy- 1499 (अ) 30.03.2022 fefy- iSd½ 217 VªkekMksy xksyh 100 fexzk- 1 xksyh 24.48 1499 (अ) 30.03.2022 218 VªkekMksy xksyh 50 fexzk- 1 xksyh 10.03 1499 (अ) 30.03.2022 219 osjkikfey batSD'ku 2-5 fexzk-@fefy- 1 fefy- 1.45 1499 (अ) 30.03.2022 220 fouOykLVhu batSD'ku 1 fexzk-@fefy- 1 fefy- 25.54 1499 (अ) 30.03.2022 221 foVkfeu , dSIlwy 50000 vkbZ;w 1 dSIlwy 0.68 1499 (अ) 30.03.2022 222 okjQfju xksyh 1 fexzk- 1 xksyh 3.00 1499 (अ) 30.03.2022 223 okjQfju xksyh 2 fexzk- 1 xksyh 3.31 1499 (अ) 30.03.2022 224 okjQfju xksyh 3 fexzk- 1 xksyh 3.89 1499 (अ) 30.03.2022 225 okjQfju xksyh 5 fexzk- 1 xksyh 2.92 1499 (अ) 30.03.2022 izfr iSd 2.89 226 okVj QkWj batSD'ku batSD'ku 1499 (अ) 30.03.2022 ¼10 fefy-½ izfr iSd ¼5 2.79 227 okVj QkWj batSD'ku batSD'ku 1499 (अ) 30.03.2022 fefy-½ izfr iSd ¼500 57.39 228 okVj QkWj batSD'ku batSD'ku 1499 (अ) 30.03.2022 fefy-½ izfr iSd 100.73 229 okVj QkWj batSD'ku batSD'ku 1499 (अ) 30.03.2022 ¼1000 fefy-½ 230 ftMksoqMkbu dSIlwy 300 fexzk- 1 dSIlwy 2.56 1499 (अ) 30.03.2022 231 ftMksoqMkbu xksyh 300 fexzk- 1 xksyh 17.74 1499 (अ) 30.03.2022 232 ftad lYQsV fMLizsflcy xksyh 20 fexzk- 1 xksyh 3.91 1499 (अ) 30.03.2022 233 tksyfiMse dSIlwy 5 fexzk- 1 dSIlwy 9.14 1499 (अ) 30.03.2022 - ( 12.1218% ) 11(3) (5) a b मे[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 27 12.1218 (5) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप में इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू च-संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) (ञ) u II I II III II IV ड [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1573(E).— In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 1 5-aminosalicylic Suppository 500 mg 1 Suppository 21.04 1499 (E) 30.03.2022 Acid Retention Enema 2 5-aminosalicylic Tablet 400 mg 1 Tablet 9.30 1499 (E) 30.03.2022 Acid 3 5-Fluorouracil Injection 250 mg/5 ml 1 ml 2.90 1499 (E) 30.03.2022 4 Abacavir (A) + Tablet 60 mg(A) + 30 1 Tablet 25.00 1499 (E) 30.03.2022 Lamivudine (B) mg(B) 5 Acetylsalicylic acid Effervescent/ 1 Tablet 0.22 1499 (E) 30.03.2022 Dispersible/ Enteric coated Tablet 100 mg 6 Acetylsalicylic acid Tablet 100 mg 1 Tablet 0.21 1499 (E) 30.03.2022 7 Acetylsalicylic acid Tablet 150 mg 1 Tablet 0.50 1499 (E) 30.03.2022 8 Acetylsalicylic acid Tablet 325mg 1 Tablet 0.68 1499 (E) 30.03.2022 9 Acetylsalicylic acid Tablet 350mg 1 Tablet 0.38 1499 (E) 30.03.2022 10 Acetylsalicylic acid Tablet 75 mg 1 Tablet 0.38 1499 (E) 30.03.2022 11 All-trans Retinoic Capsule 10 mg 1 Capsule 101.84 1499 (E) 30.03.2022 Acid 12 Amphotericin B Powder for Injection 50 Each Pack 3990.40 1499 (E) 30.03.2022 (Lipid) mg 13 Amphotericin B Powder for Injection 50 Each Pack 9294.89 1499 (E) 30.03.2022 (Liposomal) mg 14 Ampicillin Powder for Injection 1 Each Pack 26.56 1499 (E) 30.03.2022 gm 15 Anti-D Injection 300mcg Each Pack 2657.32 1499 (E) 30.03.2022 immunoglobulin 16 Anti-D Injection 150mcg Each Vial 2071.29 1499 (E) 30.03.2022 Immunoglobulin 17 Anti-rabies Injection 150 IU/ml 1 ml 3453.86 1499 (E) 30.03.2022 immunoglobulin 18 Anti-rabies Injection 300 IU/ml 1 ml 121.76 1499 (E) 30.03.2022 immunoglobulin 19 Anti-tetanus 250IU Each Pack 1383.49 1499 (E) 30.03.2022 immunoglobulin 20 Arsenic Trioxide Injection 1mg/ml 1 ml 67.59 1499 (E) 30.03.2022 21 Artesunate (A) + Tablet 100 mg(A) + 1 Combi pack 36.71 1499 (E) 30.03.2022 Sulphadoxine - Tablet (750 mg+ 37.5 Pyrimethamine (B) mg) (B) 22 Artesunate (A) + Tablet 150 mg(A) + 2 Combi pack 49.84 1499 (E) 30.03.2022 Sulphadoxine - Tablet (500 mg+ 25 mg) Pyrimethamine (B) (B) 23 Artesunate (A) + Tablet 200 mg(A) + 2 Combi pack 45.45 1499 (E) 30.03.2022 Sulphadoxine - Tablet (750 mg+ 37.5 Pyrimethamine (B) mg) (B) 24 Artesunate (A) + Tablet 25 mg(A) + 1 Combi pack 24.47 1499 (E) 30.03.2022 Sulphadoxine - Tablet (250 mg+ 12.5 Pyrimethamine (B) mg) (B)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 29 Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 25 Azithromycin Capsule 500 mg 1 Capsule 20.64 1499 (E) 30.03.2022 26 BCG vaccine Each Dose 11.12 1499 (E) 30.03.2022 27 Benzathine Powder for Injection 12 Each Pack 22.70 1499 (E) 30.03.2022 benzylpenicillin lac units 28 Benzathine Powder for Injection 6 Each Pack 15.01 1499 (E) 30.03.2022 benzylpenicillin lac units 29 Benzoyl Peroxide Cream 2.5% 1 gm 2.90 1499 (E) 30.03.2022 30 Benzyl penicillin Powder for Injection 10 Each Pack 9.70 1499 (E) 30.03.2022 Lac Units 31 Betamethasone Gel 0.05% 1 gm 0.66 1499 (E) 30.03.2022 32 Betamethasone Lotion 0.1% 1 ml 1.02 1499 (E) 30.03.2022 33 Betamethasone Lotion 0.5% 1 ml 0.66 1499 (E) 30.03.2022 34 Budesonide Nasal Spray 100 1 Dose 1.13 1499 (E) 30.03.2022 mcg/dose 35 Budesonide Nasal Spray 50 1 Dose 1.26 1499 (E) 30.03.2022 mcg/dose 36 Budesonide Inhalation (MDI) 100 Per Metered 1.58 1499 (E) 30.03.2022 mcg/dose Dose 37 Budesonide Inhalation (MDI) 200 Per metered 2.19 1499 (E) 30.03.2022 mcg/dose Dose 38 Budesonide Inhalation (DPI) 100 Per Dose 2.48 1499 (E) 30.03.2022 mcg/dose 39 Budesonide Inhalation (DPI) 200 Per Dose 3.59 1499 (E) 30.03.2022 mcg/dose 40 Budesonide (A)+ Inhalation (MDI) 100 Per Metered 2.34 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) Dose 41 Budesonide (A)+ Inhalation (MDI) 200 Per Metered 3.33 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) Dose 42 Budesonide (A)+ Inhalation (MDI) 400 Per Metered 3.80 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) Dose 43 Budesonide (A)+ Inhalation (DPI) 100 Per Dose 4.72 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) 44 Budesonide (A)+ Inhalation (DPI) 200 Per Dose 6.26 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) 45 Budesonide (A)+ Inhalation (DPI) 400 Per Dose 8.00 1499 (E) 30.03.2022 Formoterol (B) mcg (A) + 6 mcg (B) 46 Calcium Carbonate Tablet 500mg 1 Tablet 2.15 1499 (E) 30.03.2022 47 Calcium gluconate Injection 100 mg/ml 1 ml 0.68 1499 (E) 30.03.2022 48 Cefadroxil Capsule 500 mg 1 Capsule 8.90 1499 (E) 30.03.2022 49 Cefazolin Powder for Injection 1 Each Pack 30.56 1499 (E) 30.03.2022 gm 50 Cefazolin Powder for Injection 500 Each Pack 19.37 1499 (E) 30.03.2022 mg 51 Cefixime Capsule 400 mg 1 Capsule 36.40 1499 (E) 30.03.2022 52 Cetirizine Capsule 10 mg 1 Capsule 2.96 1499 (E) 30.03.2022 53 Chlorambucil Tablet 2 mg 1 Tablet 45.94 1499 (E) 30.03.2022 54 Chlorambucil Tablet 5 mg 1 Tablet 103.25 1499 (E) 30.03.2022 55 Chlorhexidine Solution 5% 1 ml 0.19 1499 (E) 30.03.2022 (Concentrate for dilution) 56 Clofazimine Capsule 100 mg 1 Capsule 4.61 1499 (E) 30.03.2022 57 Clofazimine Capsule 50 mg 1 Capsule 2.70 1499 (E) 30.03.2022 58 Clomiphene Capsule 100 mg 1 Capsule 69.30 1499 (E) 30.03.2022 59 Clomiphene Capsule 50 mg 1 Capsule 38.11 1499 (E) 30.03.202230 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 60 Cloxacillin Capsule 250mg 1 Capsule 1.41 1499 (E) 30.03.2022 61 Cloxacillin Capsule 500mg 1 Capsule 2.37 1499 (E) 30.03.2022 62 Cloxacillin Tablet 250mg 1 Tablet 2.15 1499 (E) 30.03.2022 63 Cloxacillin Powder for Each Pack 5.52 1499 (E) 30.03.2022 Injection250mg 64 Coagulation factor Powder for Injection 600 Each Pack 15338.91 1499 (E) 30.03.2022 IX IU 65 Coagulation factor Powder for Injection 250 Each pack 4649.89 1499 (E) 30.03.2022 VIII IU 66 Coagulation factor Powder for Injection 500 Each Pack 11410.50 1499 (E) 30.03.2022 VIII IU 67 Co-trimoxazole Tablet 800 mg(A)+160 1 Tablet 2.52 1499 (E) 30.03.2022 (Sulphamethoxazole mg(B) (A)+Trimethoprim (B)] 68 Cyclosporine Injection 50 mg/ml 1 ml 335.78 1499 (E) 30.03.2022 69 Dapsone Tablet 100 mg 1 Tablet 0.44 1499 (E) 30.03.2022 70 Daunarubicin Powder for I.V. Injection Each pack 302.74 1499 (E) 30.03.2022 20 mg (5 mg/ml) 71 Desferrioxamine Powder for Injection Each pack 200.19 1499 (E) 30.03.2022 500mg 72 Dexamethasone Injection 4 mg/ml Each Pack (2 11.60 1499 (E) 30.03.2022 ml) 73 Dextran-40 Injection 10% 1 ml 1.05 1499 (E) 30.03.2022 74 Diazepam Oral Liquid 2 mg/5ml 1 ml 3.39 1499 (E) 30.03.2022 75 Diclofenac Capsule 50 mg 1 Capsule 0.76 1499 (E) 30.03.2022 76 Dicyclomine Oral Solution 10mg/5ml 1 ml 0.20 1499 (E) 30.03.2022 77 Dicyclomine Tablet 10mg 1 Tablet 0.13 1499 (E) 30.03.2022 78 Dinoprostone Tablet 0.5mg 1 Tablet 62.30 1499 (E) 30.03.2022 79 Diphtheria antitoxin 10000 IU Each Pack 1631.60 1499 (E) 30.03.2022 80 DPT vaccine Per 0.5 ml 17.63 1499 (E) 30.03.2022 81 Efavirenz Capsule 200 mg 1 Capsule 29.97 1499 (E) 30.03.2022 82 Efavirenz Capsule 600 mg 1 Capsule 78.09 1499 (E) 30.03.2022 83 Ethyl Alcohol Solution 70% 1 ml 0.52 1499 (E) 30.03.2022 (Denatured) 84 Fentanyl Injection 50mcg/ml 1 ml 28.26 1499 (E) 30.03.2022 85 Ferrous Salt (A) + Tablet 100mg elemental 1 Tablet 0.28 1499 (E) 30.03.2022 Folic Acid (B) iron (A) + 500mcg (B) 86 Fluconazole Oral Liquid 50mg/5ml 1 ml 3.25 1499 (E) 30.03.2022 87 Fluconazole Capsule 100 mg 1 Capsule 31.46 1499 (E) 30.03.2022 88 Fluoxetine Tablet 10 mg 1 Tablet 3.10 1499 (E) 30.03.2022 89 Fluoxetine Tablet 20 mg 1 Tablet 4.93 1499 (E) 30.03.2022 90 Fluoxetine Tablet 40 mg 1 Tablet 6.64 1499 (E) 30.03.2022 91 Fluoxetine Tablet 60 mg 1 Tablet 9.21 1499 (E) 30.03.2022 92 Folic Acid Capsule 5 mg 1 Capsule 7.01 1499 (E) 30.03.2022 93 Gadobenate Injection 529 mg/ml 1 ml 135.67 1499 (E) 30.03.2022 94 Gentamicin Injection 40 mg/ml Each Pack (2 10.48 1499 (E) 30.03.2022 ml) 95 Glucose Injection 50% 1 ml 0.60 1499 (E) 30.03.2022 96 Glucose Injection 5% 1000ml Glass 79.95 1499 (E) 30.03.2022 97 Glucose Injection 5% 1000ml Non- 64.54 1499 (E) 30.03.2022 Glass 98 Glucose Injection 5% 100ml Glass 22.44 1499 (E) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 31 Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 99 Glucose Injection 5% 100ml Non- 20.31 1499 (E) 30.03.2022 Glass 100 Glucose Injection 5% 250ml Glass 31.01 1499 (E) 30.03.2022 101 Glucose Injection 5% 250ml Non- 28.01 1499 (E) 30.03.2022 Glass 102 Glucose Injection 5% 500ml Glass 44.01 1499 (E) 30.03.2022 103 Glucose Injection 5% 500ml Non- 37.97 1499 (E) 30.03.2022 Glass 104 Glucose Injection 10% Each Pack 32.15 1499 (E) 30.03.2022 (1000 ml) 105 Glucose Injection 10% Each Pack 34.97 1499 (E) 30.03.2022 (500 ml) 106 Glucose (A) + Injection 5% (A) + 0.9% 1000ml Glass 80.48 1499 (E) 30.03.2022 Sodium Chloride (B) (B) 107 Glucose (A) + Injection 5% (A) + 0.9% 1000ml Non- 65.03 1499 (E) 30.03.2022 Sodium Chloride (B) Glass (B) 108 Glucose (A) + Injection 5% (A) + 0.9% 100ml Glass 22.50 1499 (E) 30.03.2022 Sodium Chloride (B) (B) 109 Glucose (A) + Injection 5% (A) + 0.9% 100ml Non- 20.33 1499 (E) 30.03.2022 Sodium Chloride (B) Glass (B) 110 Glucose (A) + Injection 5% (A) + 0.9% 250ml Glass 31.13 1499 (E) 30.03.2022 Sodium Chloride (B) (B) 111 Glucose (A) + Injection 5% (A) + 0.9% 250ml Non- 28.12 1499 (E) 30.03.2022 Sodium Chloride (B) Glass (B) 112 Glucose (A) + Injection 5% (A) + 0.9% 500ml Glass 44.23 1499 (E) 30.03.2022 Sodium Chloride (B) (B) 113 Glucose (A) + Injection 5% (A) + 0.9% 500ml Non- 38.21 1499 (E) 30.03.2022 Sodium Chloride (B) Glass (B) 114 Glutaraldehyde Solution 2% 1 ml 0.07 1499 (E) 30.03.2022 115 Griseofulvin Tablet 125mg 1 Tablet 1.02 1499 (E) 30.03.2022 116 Griseofulvin Tablet 375 mg 1 Tablet 5.34 1499 (E) 30.03.2022 117 Haemodialysis fluid As license 1 ml 0.04 1499 (E) 30.03.2022 118 Human Normal Solution for infusion 5% 1 ml 192.06 1499 (E) 30.03.2022 Immunoglobulin 119 Human Normal Solution for infusion 1 ml 260.03 1499 (E) 30.03.2022 Immunoglobulin 10% 120 Human Normal Solution for infusion 1 ml 494.49 1499 (E) 30.03.2022 Immunoglobulin 16.5% 121 Hydrochlorothiazide Tablet 50 mg 1 Tablet 0.10 1499 (E) 30.03.2022 122 Hydrogen peroxide Solution 6% 1 ml 0.04 1499 (E) 30.03.2022 123 Hydroxocobalamin Injection 1 mg/ml 1 ML 12.31 1499 (E) 30.03.2022 124 Hyoscine Injection 20 mg/ml 1 ml 12.99 1499 (E) 30.03.2022 butylbromide 125 Ibuprofen Capsule 400 mg 1 Capsule 1.31 1499 (E) 30.03.2022 126 Ibuprofen Capsule 200 mg 1 soft gelatin 3.33 1499 (E) 30.03.2022 capsule32 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 127 Imatinib Capsule 400 mg 1 Capsule 317.98 1499 (E) 30.03.2022 128 Ipratropium Inhalation (MDI/DPI) 20 1 Dose 0.76 1499 (E) 30.03.2022 mcg/dose 129 Ipratropium Respirator solution for 1 ml 3.15 1499 (E) 30.03.2022 use in Nebulizer 250 mcg/ml 130 Isoniazid Tablet 100mg 1 Tablet 0.84 1499 (E) 30.03.2022 131 Isoniazid Tablet 300mg 1 Tablet 1.49 1499 (E) 30.03.2022 132 Japanese 4mcg to 6mcg Each Pack 868.40 1499 (E) 30.03.2022 Encephalitis Vaccine 133 Japanese up to 3mcg Each Pack 661.59 1499 (E) 30.03.2022 Encephalitis Vaccine 134 Ketamine Injection 10 mg/ml 1 ml 13.18 1499 (E) 30.03.2022 135 Levonorgestrel Tablet 0.75 mg 1 Tablet 28.64 1499 (E) 30.03.2022 136 Levothyroxine Tablet 37.50 mcg 1 Tablet 1.46 1499 (E) 30.03.2022 137 Lignocaine (A) + Injection 1% (A) + 1 ml 0.56 1499 (E) 30.03.2022 Adrenaline (B) 1:200000 (5 mcg/ml) (B) 138 Lopinavir (A) + Tablet 100 mg(A) + 25 1 Tablet 29.27 1499 (E) 30.03.2022 Ritonavir (B) mg(B) 139 Measles Rubbela Each Pack 110.05 1499 (E) 30.03.2022 Vaccine (0.5ml) 140 Measles vaccine Vaccine Each Pack 63.47 1499 (E) 30.03.2022 (0.5ml) 141 Melphalan Tablet 2 mg 1 Tablet 122.13 1499 (E) 30.03.2022 142 Melphalan Tablet 5 mg 1 Tablet 209.47 1499 (E) 30.03.2022 143 Methotrexate Injection 50 mg/ml 1 ml 49.86 1499 (E) 30.03.2022 144 Methylrosanilinium Paint 1% 1 ml 0.10 1499 (E) 30.03.2022 chloride (Gentian Violet) 145 Methylthioninium Injection 10mg/ml 1 ML 27.13 1499 (E) 30.03.2022 chloride (Methylene blue) 146 Midazolam Tablet 7.5mg 1 Tablet 27.94 1499 (E) 30.03.2022 147 Morphine SR Tablet 30 mg 1 Tablet 6.78 1499 (E) 30.03.2022 148 Morphine Tablet 10 mg 1 Tablet 6.62 1499 (E) 30.03.2022 149 N-acetylcysteine Sachet 200mg 1 gm 11.20 1499 (E) 30.03.2022 150 Nevirapine Oral Liquid 50 mg/5ml 1 ml 1.04 1499 (E) 30.03.2022 151 Omeprazole Tablet 10 mg 1 Tablet 5.51 1499 (E) 30.03.2022 152 Omeprazole Capsule 40 mg 1 Capsule 6.14 1499 (E) 30.03.2022 153 Oral poliomyelitis 1 ml 127.66 1499 (E) 30.03.2022 vaccine 154 Oral Rehydration As Licensed 1 gm 1.11 1499 (E) 30.03.2022 Salts 155 Oxaliplatin Injection 100mg(as Each Pack 5563.59 1499 (E) 30.03.2022 licensed) 156 Para-aminosalicylic Granules (As licensed) 1 gm 3.54 1499 (E) 30.03.2022 acid 157 Paracetamol Injection 150 mg/ml Each Pack ( 3.82 1499 (E) 30.03.2022 0.5 ml) 158 Paracetamol Injection 150 mg/ml Each Pack (1 5.22 1499 (E) 30.03.2022 ml) 159 Paracetamol Injection 150 mg/ml Each Pack (2 8.02 1499 (E) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 33 Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) ml) 160 Paracetamol Injection 150 mg/ml Each Pack (3 10.84 1499 (E) 30.03.2022 ml) 161 Paracetamol Injection 150 mg/ml Each Pack (4 13.64 1499 (E) 30.03.2022 ml) 162 Paracetamol Injection 150 mg/ml Each Pack (5 16.45 1499 (E) 30.03.2022 ml) 163 Paracetamol Injection 150 mg/ml Each Pack (7 22.06 1499 (E) 30.03.2022 ml) 164 Penicillamine Capsule 250 mg 1 Capsule 18.50 1499 (E) 30.03.2022 165 Permethrin Gel 5% 1 gm 1.82 1499 (E) 30.03.2022 166 Phenylephrine Drop 10% 1 ml 10.05 1499 (E) 30.03.2022 167 Phenylephrine Drops 5% 1 ml 4.64 1499 (E) 30.03.2022 168 Phenytoin ERCapsule 300 mg 1 Capsule 4.74 1499 (E) 30.03.2022 169 Phenytoin injection 25 mg/ml 1 ml 3.12 1499 (E) 30.03.2022 170 Pilocarpine Drops 4% 1 ml 14.54 1499 (E) 30.03.2022 171 Potassium Crystals for topical 1 gm 0.54 1499 (E) 30.03.2022 permanganate solution 172 Povidone iodine Scrub 7.5% 1 ml 1.99 1499 (E) 30.03.2022 173 Povidone iodine Ointment 10% 1 gm 6.48 1499 (E) 30.03.2022 174 Povidone iodine Solution 4% 1 ml 2.16 1499 (E) 30.03.2022 175 Praziquantel Tablet 600 mg 1 tablet 43.24 1499 (E) 30.03.2022 176 Prednisolone Injection 20 mg/2ml 1 ml 4.46 1499 (E) 30.03.2022 177 Pyrazinamide Oral Liquid 250 mg/5ml 1 ml 0.76 1499 (E) 30.03.2022 178 Rifampicin Tablet 150 mg 1 Tablet 2.00 1499 (E) 30.03.2022 179 Rifampicin Tablet 300 mg 1 Tablet 3.65 1499 (E) 30.03.2022 180 Ringer Lactate Injection 1000ml Each Pack 99.30 1499 (E) 30.03.2022 181 Ringer Lactate Injection 100ml Each Pack 26.00 1499 (E) 30.03.2022 182 Ringer Lactate Injection 250ml Each Pack 44.33 1499 (E) 30.03.2022 183 Ringer Lactate Injection 500ml Each Pack 56.49 1499 (E) 30.03.2022 184 Ritonavir Capsule 100 mg 1 Capsule 35.13 1499 (E) 30.03.2022 185 Salbutamol Capsule 4 mg 1 Capsule 0.74 1499 (E) 30.03.2022 186 Silver Cream 1% 1 gm 0.62 1499 (E) 30.03.2022 Sulphadiazine 187 Snake venom Powder for Injection 10 ml Pack 693.70 1499 (E) 30.03.2022 antiserum- Lyophilized polyvalent 188 Snake Venom Injection Each Pack 538.70 1499 (E) 30.03.2022 Antiserum-Soluble/ (10 ML) Liquid Polyvalent 189 Sodium Chloride Injection 0.9% 1000ml Glass 73.87 1499 (E) 30.03.2022 190 Sodium Chloride Injection 0.9% 1000ml Non- 58.26 1499 (E) 30.03.2022 Glass 191 Sodium Chloride Injection 0.9% 100ml Glass 21.84 1499 (E) 30.03.2022 192 Sodium Chloride Injection 0.9% 100ml Non- 19.67 1499 (E) 30.03.2022 Glass 193 Sodium Chloride Injection 0.9% 250ml Glass 29.46 1499 (E) 30.03.2022 194 Sodium Chloride Injection 0.9% 250ml Non- 26.44 1499 (E) 30.03.2022 Glass 195 Sodium Chloride Injection 0.9% 500ml Glass 40.96 1499 (E) 30.03.2022 196 Sodium Chloride Injection 0.9% 500ml Non- 34.86 1499 (E) 30.03.2022 Glass34 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 197 Sodium nitrite Injection 30 mg/ml 1 ml 32.34 1499 (E) 30.03.2022 198 Sodium Injection 10 mg/ml 1 ml 32.14 1499 (E) 30.03.2022 Nitroprusside 199 Streptokinase Injection 7,50,000 IU Each Pack 1567.32 1499 (E) 30.03.2022 200 Succinyl Choline Injection 50 mg/ml 1 ml 6.02 1499 (E) 30.03.2022 201 Sumatriptan Tablet 25mg 1 Tablet 41.44 1499 (E) 30.03.2022 202 Sumatriptan Tablet 50mg 1 Tablet 64.15 1499 (E) 30.03.2022 203 Surfactant Suspension for Per mg of 83.27 1499 (E) 30.03.2022 intratracheal instillation Phospholipids (As liensed) in the pack 204 Tacrolimus Tablet 0.5 mg 1 Tablet 23.32 1499 (E) 30.03.2022 205 Tacrolimus Tablet 1 mg 1 Tablet 42.83 1499 (E) 30.03.2022 206 Tacrolimus Tablet 2 mg 1 Tablet 84.60 1499 (E) 30.03.2022 207 TD Vaccine Each dose of 0.5ml Each 0.5ml 23.33 1499 (E) 30.03.2022 contains: Diphtheria Pack Toxoid ≤5Lf (≥ 2IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) 208 TD Vaccine Each dose of 0.5ml Each 5ml 219.24 1499 (E) 30.03.2022 contains: Diphtheria Pack Toxoid ≤5Lf (≥ 2IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) 209 TD Vaccine Each dose of 0.5ml Each 0.5ml 20.00 1499 (E) 30.03.2022 contains: Diphtheria Pack Toxoid ≤25Lf (≥ 30IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) 210 Temozolomide Tablet 100 mg 1 Tablet 1925.47 1499 (E) 30.03.2022 211 Temozolomide Tablet 20 mg 1 Tablet 466.49 1499 (E) 30.03.2022 212 Temozolomide Tablet 250 mg 1 Tablet 4765.73 1499 (E) 30.03.2022 213 Thiopentone Powder for Injection 0.5 Each Pack 50.71 1499 (E) 30.03.2022 gm 214 Thiopentone Powder for Injection 1 Each Pack 61.52 1499 (E) 30.03.2022 gm 215 Timolol Drops 0.25% 1 ml 6.43 1499 (E) 30.03.2022 216 Tramadol Injection 50 mg/ml (20 1 ml 1.54 1499 (E) 30.03.2022 ml Pack) 217 Tramadol Tablet 100 mg 1 Tablet 24.48 1499 (E) 30.03.2022 218 Tramadol Tablet 50 mg 1 Tablet 10.03 1499 (E) 30.03.2022 219 Verapamil Injection 2.5 mg/ml 1 ml 1.45 1499 (E) 30.03.2022 220 Vinblastine Injection 1mg/ml 1 ml 25.54 1499 (E) 30.03.2022 221 Vitamin A Capsule 50000 IU 1 Capsule 0.68 1499 (E) 30.03.2022 222 Warfarin Tablet 1 mg 1 Tablet 3.00 1499 (E) 30.03.2022 223 Warfarin Tablet 2 mg 1 Tablet 3.31 1499 (E) 30.03.2022 224 Warfarin Tablet 3 mg 1 Tablet 3.89 1499 (E) 30.03.2022 225 Warfarin Tablet 5 mg 1 Tablet 2.92 1499 (E) 30.03.2022 226 Water for Injection Injection Each Pack 2.89 1499 (E) 30.03.2022 (10 ml) 227 Water for Injection Injection Each Pack (5 2.79 1499 (E) 30.03.2022 ml) 228 Water for Injection Injection Per 500 ml 57.39 1499 (E) 30.03.2022 Pack 229 Water for Injection Injection Per 1000 ml 100.73 1499 (E) 30.03.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 35 Sl. Medicines Dosage form and Unit Ceiling Existing S.O. No. & Date No Strength price (wef 1.4.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) Pack 230 Zidovudine Capsule 300 mg 1 Capsule 2.56 1499 (E) 30.03.2022 231 Zidovudine Tablet 300 mg 1 Tablet 17.74 1499 (E) 30.03.2022 232 Zinc sulphate Dispersible Tablet 20mg 1 Tablet 3.91 1499 (E) 30.03.2022 233 Zolpidem Capsule 5 mg 1 Capsule 9.14 1499 (E) 30.03.2022 Notes: - a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the manufacturer shall approach NPPA for specific price approval for its formulations. d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. e) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. and Date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI @ 12.1218% for year 2022over 2021in accordance with paragraph 16(2) of DPCO, 2013. f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013. k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled36 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1574(अ).— , नवम्बर 4, 6, 10, 11, 14, 16, 17 18 a b @ (12.1218%) 12.1218% (1) (2) (3) (4) (5) 6(a 6(b 1 6-मकैपटॉप्यूटरन गोली 50 जमलीग्राम 1 गोली 5.25 11.01.2023 2 अबाकवीर गोली 300 जमलीग्राम 1 गोली 48.59 19.12.2022 3 अबाकवीर (ए) + गोली 600 जमलीग्राम (ए) 1 गोली 72.31 19.12.2022 लाजमवुडाइन (बी) +300 जमलीग्राम (बी) 4 एजसटािोलामाइड गोली 250 जमलीग्राम 1 गोली 4.05 06.01.2023 5 पाउडर फोर इंिेक्ट्िन 0.5 एजक्ट्टनोमाइजसन डी 1 वाइल 331.00 24.02.2023 जमलीग्राम 6 ऐसीक्ट्लोजवर गोली 400 जमलीग्राम 1 गोली 13.65 06.01.2023 7 ऐसीक्ट्लोजवर गोली 200 जमलीग्राम 1 गोली 7.61 06.01.2023 8 पाउडर फोर इंिेक्ट्िन 250 ऐसीक्ट्लोजवर 1 वाईल 426.37 11.01.2023 जमलीग्राम 9 पाउडर फोर इंिेक्ट्िन 500 ऐसीक्ट्लोजवर 1 वाईल 528.41 11.01.2023 जमलीग्राम 10 ऐसीक्ट्लोजवर गोली 800 जमलीग्राम 1 गोली 37.66 11.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 37 11 ऐसीक्ट्लोजवर ओइंटमेंट 3% 1 ग्राम 11.67 24.02.2023 12 इंिेक्ट्िन 3 एडेनोसाइन 1 जम.ली. 92.84 11.01.2023 जमलीग्राम/जम.ली. 13 एिेनालाईन इंिेक्ट्िन1जमलीग्राम/जम.ली. 1 जम.ली. 12.23 24.02.2023 14 एलोप्यूटरनॉल गोली 300 जमलीग्राम 1 गोली 5.62 19.12.2022 15 एलोप्यूटरनॉल गोली 100 जमलीग्राम 1 गोली 1.89 06.01.2023 16 इंिेक्ट्िन 0.5 अलप्रोस्ट्टैजडल 1 जम.ली. 6106.41 24.02.2023 जमलीग्राम/जम.ली. 17 ऐजमयोडैरोन गोली 200 जमलीग्राम 1 गोली 11.51 06.01.2023 18 ऐजमयोडैरोन गोली 100 जमलीग्राम 1 गोली 6.14 06.01.2023 19 इंिेक्ट्िन 50 ऐजमयोडैरोन 1 जम.ली. 21.13 11.01.2023 जमलीग्राम/जम.ली. 20 ऐजमटरजप्टलाइन गोली 50 जमलीग्राम 1 गोली 5.98 19.12.2022 21 ऐजमटरजप्टलाइन गोली 75 जमलीग्राम 1 गोली 5.44 06.01.2023 22 ऐजमटरजप्टलाइन गोली 25 जमलीग्राम 1 गोली 2.48 06.01.2023 23 ऐजमटरजप्टलाइन गोली 10 जमलीग्राम 1 गोली 2.38 11.01.2023 24 अम्लोजडजपन गोली 2.5 जमलीग्राम 1 गोली 1.79 06.01.2023 25 अम्लोजडजपन गोली 5 जमलीग्राम 1 गोली 2.50 19.12.2022 26 अम्लोजडजपन गोली 10 जमलीग्राम 1 गोली 5.44 06.01.2023 27 एमोजक्ट्सजसजलन कैप्सूल 250 जमलीग्राम 1 कैप्सूल 2.44 11.01.2023 28 एमोजक्ट्सजसजलन कैप्सूल 500 जमलीग्राम 1 कैप्सूल 7.35 02.02.2023 29 पाउडर फोर इंिेक्ट्िन 1 एमोजक्ट्सजसजलन (ए) ग्राम (ए) +200 जमलीग्राम 1 वाईल 140.64 06.01.2023 +क्ट्लैवुलाजनक एजसड बी)) (बी) 30 पाउडर फोर इंिेक्ट्िन 500 एमोजक्ट्सजसजलन (ए) + जमलीग्राम (ए) + 100 1 वाईल 101.33 11.01.2023 क्ट्लैवुलाजनक एजसड (बी) जमलीग्राम (बी) 31 िाई जसरप 125 जमलीग्राम एमोजक्ट्सजसजलन (ए) + (ए) + 31.25 1 जम.ली. 2.05 11.01.2023 क्ट्लैवुलाजनक एजसड (बी) (बी)/5जम.ली.(पी) 32 एमोजक्ट्सजसजलन (ए) गोली 500 जमलीग्राम (ए) 1 गोली 18.29 06.01.2023 +क्ट्लैवुलाजनक एजसड (बी) + 125 जमलीग्राम (बी) 33 ओरल जलदक्वड 200 एमोजक्ट्सजसजलन (ए) + जमलीग्राम (ए) + 28.5 1 जम.ली. 2.01 02.02.2023 क्ट्लैवुलाजनक एजसड (बी) जमलीग्राम (बी)/5 जम.ली.(पी) 34 पाउडर फोर इंिेक्ट्िन 500 एम्पीजसलीन 1 वाईल 14.25 06.01.2023 जमलीग्राम 35 आटेमेडर (ए) + ल्यूमेफैंटरन गोली 40 जमलीग्राम (ए) + 1 गोली 18.04 11.01.2023 (बी) 240 जमलीग्राम (बी) 36 आटेमेडर (ए) + ल्यूमफैंटरन गोली 80 जमलीग्राम (ए) + 1 गोली 25.50 19.12.2022 (बी) 480 जमलीग्राम (बी)38 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 37 आटेमेडर (ए) + ल्यूमफैंटरन गोली 20 जमलीग्राम (ए) 1 गोली 12.64 19.12.2022 (बी) + 120 जमलीग्राम (बी) 38 पाउडर फोर इंिेक्ट्िन 60 आर्टचसुनेट 1 वाईल 244.71 11.01.2023 जमलीग्राम 39 पाउडर फोर इंिेक्ट्िन 120 आर्टचसुनेट 1 वाईल 454.40 11.01.2023 जमलीग्राम 40 कोम्बी पैक (ए + बी) 1 आटेसुनेट (ए) + गोली 50 जमलीग्राम (ए) + 1 कोम्बी सल्फैडॉजक्ट्सन - 22.54 11.01.2023 1 गोली (500 जमलीग्राम + पैक पाइटरमेथामाइन (बी) 25 जमलीग्राम) (बी) 41 गोली 300 जमलीग्राम (ए) एटाजानवीर (ए) + + गोली 100 जमलीग्राम 1 गोली 99.82 06.01.2023 टरटोनवीर (बी) (बी) 42 एटोरवास्ट्टेटटन गोली 40 जमलीग्राम 1 गोली 19.29 06.01.2023 43 एटोरवास्ट्टेटटन गोली 20 जमलीग्राम 1 गोली 12.55 06.01.2023 44 एटोरवास्ट्टेटटन गोली 10 जमलीग्राम 1 गोली 4.94 06.01.2023 45 एटोरवास्ट्टेटटन गोली 80 जमलीग्राम 1 गोली 40.57 19.12.2022 46 एरोजपन िोप 1% 1 जम.ली. 3.93 24.02.2023 47 एरोजपन ओइंट्मेंट 1% 1 ग्राम 4.70 24.02.2023 48 इंिेक्ट्िन 0.6 एरोजपन 1 जम.ली. 4.57 24.02.2023 जमलीग्राम/जम.ली. 49 अजैजथयोप्राइन गोली 50 जमलीग्राम 1 गोली 11.25 06.01.2023 50 पाउडर फोर इंिेक्ट्िन 500 एजजथ्रोमाइजसन 1 वाईल 204.71 11.01.2023 जमलीग्राम 51 एजजथ्रोमाइजसन गोली 250 जमलीग्राम 1 गोली 11.64 02.02.2023 52 एजजथ्रोमाइजसन गोली 500 जमलीग्राम 1 गोली 23.56 02.02.2023 53 ओरल जलदक्वड 200 एजजथ्रोमाइजसन 1 जम.ली. 3.40 02.02.2023 जमलीग्राम/5 जम(पी) .ली. 54 बैक्ट्लोफेन गोली 20 जमलीग्राम 1 गोली 16.28 19.12.2022 55 बैक्ट्लोफेन गोली 10 जमलीग्राम 1 गोली 11.89 06.01.2023 56 बैक्ट्लोफेन गोली 5 जमलीग्राम 1 गोली 6.36 19.12.2022 57 बेंडामुस्ट्टाइन इंिेक्ट्िन 100 जमलीग्राम / 1 वाईल 4946.53 11.01.2023 हाइिोक्ट्लोराइड वाईल 58 बेंजोइल पेरोक्ट्साइड िेल 2.5 % 1 ग्राम 3.62 24.02.2023 59 बेंजोइल पेरोक्ट्साइड िेल 5 % 1 ग्राम 7.97 24.02.2023 60 बेटामेथासोन वैलेरेट क्रीम 0.05% 1 ग्राम 0.67 24.02.2023 61 बेटामेथासोन वैलेरेट क्रीम 0.1% 1 ग्राम 1.04 24.02.2023 62 बाइकलुटामाइड गोली 50 जमलीग्राम 1 गोली 43.30 19.12.2022 63 जबसकॉडल गोली 5 जमलीग्राम 1 गोली 1.16 06.01.2023 64 1 जबसकॉडल सपोजसटरी 5 जमलीग्राम 9.97 02.02.2023 सपोजसटरी 65 पाउडर फोर इंिेक्ट्िन ब्लोमाइजसन 1 वाईल 677.37 11.01.2023 15units[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 39 66 पाउडर फोर इंिेक्ट्िन 2 बोटेजोजमब 1 वाईल 5260.20 11.01.2023 जमलीग्राम 67 गोली (सब(ललंगुअल- 0.4 बुप्रेनॉर्फचन 1 गोली 9.42 06.01.2023 जमलीग्राम 68 गोली (ललंगुअल-सब) 2 बुप्रेनॉर्फचन नालॉक्ट्सोन+ (ए) जमलीग्राम + (ए) 0.5 1 गोली 36.97 06.01.2023 (बी) जमलीग्राम (बी) 69 गोली (ललंगुअल-सब) 0.4 बुप्रेनॉर्फचन नालॉक्ट्सोन+ (ए) जमलीग्राम (ए) + 0.1 1 गोली 11.81 06.01.2023 (बी) जमलीग्राम (बी( 70 ओरल जलदक्वड 20 कैफीन 1 जम.ली. 245.67 11.01.2023 जमलीग्राम/जम.ली. 71 कैजल्ियम फोजलनेट गोली 15 जमलीग्राम 1 गोली 47.53 24.02.2023 72 कैपेजसटाबाइन गोली 500 जमलीग्राम 1 गोली 112.71 19.12.2022 73 मोडीफाइड टरलीि – गोली काबाचमेिापाइन 1 गोली 2.39 19.12.2022 200 जमलीग्राम 74 मोडीफाइड टरलीि– गोली काबाचमेिापाइन 1 गोली 4.66 19.12.2022 400 जमलीग्राम 75 काबाचमेिापाइन गोली 400 जमलीग्राम 1 गोली 3.55 19.12.2022 76 काबचमेजपाइन गोली 200 जमलीग्राम 1 गोली 1.56 06.01.2023 77 ओरल जलदक्वड 100 काबचमेजपाइन 1 जम.ली. 0.31 11.01.2023 जमलीग्राम/5जम.ली. (पी) 78 काबचमेजपाइन गोली 100 जमलीग्राम 1 गोली 1.06 02.02.2023 79 कार्बचमाजोल गोली 10 जमलीग्राम 1 गोली 4.26 06.01.2023 80 कार्बचमाजोल गोली 5 जमलीग्राम 1 गोली 2.18 06.01.2023 81 कार्बचमाजोल गोली 20 जमलीग्राम 1 गोली 13.86 11.01.2023 82 इंिेक्ट्िन 10 काबोप्लैटटन 1 जम.ली. 59.06 24.02.2023 जमलीग्राम/जम.ली. 83 काबोजक्ट्सजमथाइल सेलुलोि िोप 0.5% 1 जम.ली. 12.29 02.02.2023 84 काबोजक्ट्सजमथाइल सेलुलोि िोप 1% 1 जम.ली. 16.58 02.02.2023 85 सेफैिोजसल गोली 500 जमलीग्राम 1 गोली 4.47 19.12.2022 86 ओरल जलदक्वड 125 सेफैिोजसल 1 जम.ली. 0.68 11.01.2023 जमलीग्राम/5जम.ली. (पी) 87 सेदफजक्ट्सम गोली 400 जमलीग्राम 1 गोली 22.09 19.12.2022 88 सेदफजक्ट्सम गोली 200 जमलीग्राम 1 गोली 9.77 06.01.2023 89 ओरल जलदक्वड 50 सेदफजक्ट्सम 1 जम.ली. 1.62 02.02.2023 जमलीग्राम/5 जम.ली. (पी) 90 ओरल जलदक्वड 100 सेदफजक्ट्सम 1 जम.ली. 2.38 02.02.2023 जमलीग्राम/5जम.ली.(पी) 91 पाउडर फोर इंिेक्ट्िन 250 सेफोटाजक्ट्सम 1 वाईल 17.71 06.01.2023 जमलीग्राम40 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 92 पाउडर फोर इंिेक्ट्िन 500 सेफोटाजक्ट्सम 1 वाईल 24.37 06.01.2023 जमलीग्राम 93 पाउडर फोर इंिेक्ट्िन सेफोटाजक्ट्सम 1 वाईल 39.96 06.01.2023 1000 जमलीग्राम 94 पाउडर फोर इंिेक्ट्िन सेफ्टाजजडाइम 1 वाईल 227.01 06.01.2023 1000 जमलीग्राम 95 पाउडर फोर इंिेक्ट्िन 250 सेफ्टाजजडाइम 1 वाईल 79.06 02.02.2023 जमलीग्राम 96 पाउडर फोर इंिेक्ट्िन 500 सेजफ्रयाक्ट्सोन 1 वाईल 50.27 06.01.2023 जमलीग्राम 97 पाउडर फोर इंिेक्ट्िन 250 सेजफ्रयाक्ट्सोन 1 वाईल 28.34 06.01.2023 जमलीग्राम 98 पाउडर फोर इंिेक्ट्िन सेजफ्रयाक्ट्सोन 1 वाईल 62.38 06.01.2023 1000 जमलीग्राम 99 पाउडर फोर इंिेक्ट्िन सेजफ्रयाक्ट्सोन 1 वाईल 138.11 06.01.2023 2000 जमलीग्राम 100 ओरल जलदक्वड 125 सेफ्यूरोजक्ट्सम 1 जम.ली. 5.28 19.12.2022 जमलीग्राम / 5 जम.ली. (पी) 101 सेटीटरजजन गोली 10 जमलीग्राम 1 गोली 1.88 11.01.2023 102 ओरल जलदक्वड 5 सेटीटरजजन 1 जम.ली. 0.66 02.02.2023 जमलीग्राम/5 जम(पी).ली. 103 क्ट्लोरोदक्वन गोली 150 जमलीग्राम 1 गोली 1.16 11.01.2023 104 ओरल जलदक्वड 50 क्ट्लोरोदक्वन 1 जम.ली. 0.33 11.01.2023 जमलीग्राम/5जम.ली. 105 कॉलेकैजल्सफेरॉल गोली 1000 आईयू 1 गोली 4.30 19.12.2022 106 ओरल जलदक्वड 400 आईयू कॉलेकैजल्सफेरॉल 1 जम.ली. 2.61 11.01.2023 /जम.ली. 107 सॉजलड ओरल डोज फॉमच कॉलेकैजल्सफेरॉल 1 गोली 22.50 02.02.2023 60000 आईयू गोली 108 जसप्रोफ्लोक्ट्साजसन गोली 250 जमलीग्राम 1 गोली 2.19 06.01.2023 109 जसप्रोफ्लोक्ट्साजसन गोली 500 जमलीग्राम 1 गोली 4.24 06.01.2023 110 जसप्रोफ्लोक्ट्साजसन िॉप 0.3 % 1 जम.ली. 1.53 11.01.2023 111 इंिेक्ट्िन 200 जसप्रोफ्लोक्ट्साजसन 1 जम.ली. 0.20 11.01.2023 जमलीग्राम/100जम.ली. 112 जसप्रोफ्लोक्ट्साजसन ओइंटमेंट 0.3% 1 ग्राम 1.28 24.02.2023 113 इंिेक्ट्िन 1 जसस्ट्प्लैटटन 1 जम.ली. 7.08 24.02.2023 जमलीग्राम/जम.ली. 114 क्ट्लैटरथ्रोमाइजसन गोली 250 जमलीग्राम 1 गोली 23.89 06.01.2023 115 क्ट्लैटरथ्रोमाइजसन गोली 500 जमलीग्राम 1 गोली 39.83 06.01.2023 116 ओरल जलदक्वड 125 क्ट्लैटरथ्रोमाइजसन 1 जम.ली. 4.60 11.01.2023 जमलीग्राम/5जम.ली. (पी) 117 लक्ट्लंडामाइजसन कैप्सूल 150 जमलीग्राम 1 कैप्सूल 16.35 19.12.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 41 118 लक्ट्लंडामाइजसन कैप्सूल 300 जमलीग्राम 1 कैप्सूल 28.36 19.12.2022 119 लक्ट्लंडामाइजसन गोली 300 जमलीग्राम 1 गोली 18.97 11.01.2023 120 क्ट्लोबाजम गोली 5 जमलीग्राम 1 गोली 5.72 06.01.2023 121 क्ट्लोबाजम गोली 10 जमलीग्राम 1 गोली 9.84 06.01.2023 122 क्ट्लोमीफेनेजसरेट गोली 100 जमलीग्राम 1 गोली 13.94 11.01.2023 123 क्ट्लोमीफेनेजसरेट गोली 50 जमलीग्राम 1 गोली 8.83 11.01.2023 124 क्ट्लोनाजेपम गोली 0.25 जमलीग्राम 1 गोली 2.01 06.01.2023 125 क्ट्लोनाजेपम गोली 0.5 जमलीग्राम 1 गोली 3.45 06.01.2023 126 क्ट्लोनाजेपम गोली 1 जमलीग्राम 1 गोली 4.76 06.01.2023 127 क्ट्लोजपडोग्रेल गोली 75 जमलीग्राम 1 गोली 6.66 06.01.2023 128 क्ट्लोजपडोग्रेल गोली 150 जमलीग्राम 1 गोली 20.48 11.01.2023 129 क्ट्लोजापाइन गोली 25 जमलीग्राम 1 गोली 2.78 06.01.2023 130 क्ट्लोजापाइन गोली 50 जमलीग्राम 1 गोली 5.19 06.01.2023 131 क्ट्लोजापाइन गोली 100 जमलीग्राम 1 गोली 8.45 06.01.2023 132 कोल्सीजसन गोली 0.5 जमलीग्राम 1 गोली 3.26 02.02.2023 133 पाउडर फोर इंिेक्ट्िन 500 साईक्ट्लोफॉस्ट्फोमाईड 1 वाईल 73.48 11.01.2023 जमलीग्राम 134 साइक्ट्लोसेरीन कैप्सूल250 जमलीग्राम 1 कैप्सूल 59.18 19.12.2022 135 साइक्ट्लोस्ट्पोटरन कैप्सूल 25 जमलीग्राम 1 कैप्सूल 28.04 11.01.2023 136 ओरल जलदक्वड 100 साइक्ट्लोस्ट्पोटरन 1 जम.ली. 80.58 11.01.2023 जमलीग्राम/जम.ली. (पी) 137 साइक्ट्लोस्ट्पोटरन कैप्सूल 50 जमलीग्राम 1 कैप्सूल 55.10 24.02.2023 138 साइक्ट्लोस्ट्पोटरन कैप्सूल 100जमलीग्राम 1 कैप्सूल 103.10 24.02.2023 139 इंिेक्ट्िन 1000 साइटोजसनएराजबनोसाइड 1 वाईल 1130.26 11.01.2023 जमलीग्राम/वाईल 140 इंिेक्ट्िन 100 जमलीग्राम / साइटोजसनएराजबनोसाइड 1 वाईल 139.58 02.02.2023 वाईल 141 इंिेक्ट्िन 500 जमलीग्राम/ साइटोजसनएराजबनोसाइड 1 वाईल 536.30 02.02.2023 वाईल 142 पाउडर फोर इंिेक्ट्िन 200 डकारबाजीन 1 वाईल 381.72 06.01.2023 जमलीग्राम 143 पाउडर फोर इंिेक्ट्िन 500 डकारबाजीन 1 वाईल 518.79 11.01.2023 जमलीग्राम 144 डेकलाटसवीर गोली 60 जमलीग्राम 1 गोली 199.95 19.12.2022 145 िारुनवीर गोली 600 जमलीग्राम 1 गोली 154.42 19.12.2022 146 डेक्ट्सामेथासोन गोली 0.5 जमलीग्राम 1 गोली 0.22 02.02.2023 147 डायिेपाम गोली 5 जमलीग्राम 1 गोली 1.62 11.01.2023 148 इंिेक्ट्िन 5 डायिेपाम 1 जम.ली. 5.53 11.01.2023 जमलीग्राम/जम.ली. 149 डाईक्ट्लोफेनाक गोली 50 जमलीग्राम 1 गोली 2.05 06.01.2023 150 डाईक्ट्लोफेनाक इंिेक्ट्िन 25 1 जम.ली. 1.69 11.01.202342 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] जमलीग्राम/जम.ली. 151 डायथाइलकाबाचमाजीन (डी गोली 100 जमलीग्राम 1 गोली 1.67 19.12.2022 ई सी) 152 डायथाइलकाबाचमाजजन गोली 50 जमलीग्राम 1 गोली 0.56 24.02.2023 (डीईसी) 153 डायथाइलकाबाचमाजजन ओरल जलदक्वड 120 1 जम.ली. 0.48 24.02.2023 (डीईसी) जमलीग्राम/ 5 जम.ली.(पी) 154 जडिोजक्ट्सन गोली 0.25जमलीग्राम 1 गोली 1.33 06.01.2023 155 जडजल्टयाजेम गोली 60 जमलीग्राम 1 गोली 5.46 06.01.2023 156 डाइनोप्रोस्ट्टोन िेल 0.5 जमलीग्राम 1 ग्राम 84.71 24.02.2023 157 पाउडर फोर इंिक्ट्े िन 20 डॉसीटेक्ट्सेल 1 वाईल 2868.23 06.01.2023 जमलीग्राम 158 पाउडर फोर इंिेक्ट्िन 80 डॉसीटेक्ट्सेल 1 वाईल 10333.12 11.01.2023 जमलीग्राम 159 डॉlलूटेग्रेजवर गोली 50 जमलीग्राम 1 गोली 112.78 19.12.2022 160 डोमपटरडोन गोली 10 जमलीग्राम 1 गोली 2.30 11.01.2023 161 ओरल जलदक्वड 1 डोमपटरडोन 1 जम.ली. 1.24 11.01.2023 जमलीग्राम/जम.ली. 162 डोनेपेजजल गोली 10 जमलीग्राम 1 गोली 17.45 06.01.2023 163 डोनेपेजजल गोली 5 जमलीग्राम 1 गोली 12.10 06.01.2023 164 इंिेक्ट्िन 40 डोपामाइन 1 जम.ली. 4.76 11.01.2023 जमलीग्राम/जम.ली. 165 डॉक्ट्सीसाइजक्ट्लन कैप्सूल 100 जमलीग्राम 1 कैप्सूल 3.08 02.02.2023 166 डी- पेजनजसलमाइन कैप्सूल 250 जमलीग्राम 1 कैप्सूल 15.65 11.01.2023 167 इफावरेन्ि गोली 600 जमलीग्राम 1 गोली 70.59 11.01.2023 168 एनालाजप्रल गोली 5 जमलीग्राम 1 गोली 3.70 06.01.2023 169 एनालाजप्रल गोली 2.5 जमलीग्राम 1 गोली 2.18 06.01.2023 170 एंटेकावीर गोली 1 जमलीग्राम 1 गोली 130.22 19.12.2022 171 एंटेकावीर गोली 0.5 जमलीग्राम 1 गोली 84.43 11.01.2023 172 इंिेक्ट्िन 2000 एटरथ्रोपोइटीन 1 जम.ली. 549.55 24.02.2023 आईयू/जम.ली. 173 इंिेक्ट्िन 10000 आईयू एटरथ्रोपोइटीन 1 जम.ली. 1969.00 24.02.2023 /जम.ली. 174 एजस्ट्सटालोप्राम गोली 5 जमलीग्राम 1 गोली 5.02 06.01.2023 175 एजस्ट्सटालोप्राम गोली 10 जमलीग्राम 1 गोली 9.00 06.01.2023 176 एजस्ट्सटालोप्राम गोली 20 जमलीग्राम 1 गोली 14.36 06.01.2023 177 एथेमब्युटोल गोली 600जमलीग्राम 1 गोली 4.08 06.01.2023 178 एथेमब्युटोल गोली 800 जमलीग्राम 1 गोली 4.95 06.01.2023 179 एथेमब्युटोल गोली 400 जमलीग्राम 1 गोली 2.61 06.01.2023 180 एजथजनलएस्ट्राजडयोल (ए) + गोली 0.03 जमलीग्राम (ए) 1 गोली 3.17 06.01.2023 लेवोनोगेस्ट्रेल (बी) + गोली 0.15 जमलीग्राम[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 43 (बी) 181 एजथओनामाइड गोली 250 जमलीग्राम 1 गोली 14.81 19.12.2022 182 एटोपोसाइड कैप्सूल 50 जमलीग्राम 1 कैप्सूल 56.63 11.01.2023 183 इंिेक्ट्िन 20 एटोपोसाइड 1 जम.ली. 34.51 11.01.2023 जमलीग्राम/जम.ली. 184 दफल्ग्राजस्ट्टम इंिेक्ट्िन 300 एमसीिी 1 वाइल 1159.91 24.02.2023 185 फ्लुकोनाजोल गोली 400 जमलीग्राम 1 गोली 29.74 19.12.2022 186 फ्लूकोनाजोल गोली 200 जमलीग्राम 1 गोली 17.45 06.01.2023 187 फ्लूकोनाजोल गोली 100 जमलीग्राम 1 गोली 7.62 06.01.2023 188 फ्लुकोनाजोल गोली 150 जमलीग्राम 1 गोली 12.06 11.01.2023 189 फ्लुकोनाजोल गोली 50 जमलीग्राम 1 गोली 9.67 02.02.2023 190 फ्लुनाटरजजन गोली 5 जमलीग्राम 1 गोली 2.47 19.12.2022 191 फ्लुनाटरजजन गोली 10 जमलीग्राम 1 गोली 4.82 19.12.2022 192 फ्लुक्ट्सोटाइन कैप्सूल 20 जमलीग्राम 1 कैप्सूल 3.99 19.12.2022 193 फ्लुक्ट्सोटाइन कैप्सूल 60 जमलीग्राम 1 कैप्सूल 11.10 19.12.2022 194 फ्लुक्ट्सोटाइन कैप्सूल 40 जमलीग्राम 1 कैप्सूल 6.49 19.12.2022 195 फ्लुक्ट्सोटाइन कैप्सूल 10 जमलीग्राम 1 कैप्सूल 3.31 19.12.2022 196 इंिेक्ट्िन 25 फ्लूफेनजीन 1 जम.ली. 55.26 24.02.2023 जमलीग्राम/जम.ली. 197 फोजलक एजसड गोली 5 जमलीग्राम 1 गोली 1.51 11.01.2023 198 फ़्यूरोसेमाइड गोली 40 जमलीग्राम 1 गोली 0.90 02.02.2023 199 इंिेक्ट्िन 10 फ़्यूरोसेमाइड 1 जम.ली. 2.99 24.02.2023 जमलीग्राम/जम.ली. 200 फ्यूजसजडक एजसड क्रीम 2 % 1 ग्राम 9.83 24.02.2023 201 जिदफटटजनब गोली 250 जमलीग्राम 1 गोली 237.12 02.02.2023 202 पाउडर फोर इंिेक्ट्िन िेमजसटाबाइन 1 वाईल 5592.24 06.01.2023 1000 जमलीग्राम 203 पाउडर फोर इंिेक्ट्िन 200 िेमजसटाबाइन 1 वाईल 1299.72 06.01.2023 जमलीग्राम 204 इंिेक्ट्िन 10 िेंटामाइजसन 1 जम.ली. 2.41 24.02.2023 जमलीग्राम/जम.ली. 205 जग्लमेपाइराइड गोली 2 जमलीग्राम 1 गोली 5.79 06.01.2023 206 जग्लमेपाइराइड गोली 1 जमलीग्राम 1 गोली 3.70 06.01.2023 207 ग्लूकोि इंिेक्ट्िन 25% 1 जम.ली. 0.20 24.02.2023 208 इंिेक्ट्िन 5 जग्लसरील टरजनरेट 1 जम.ली. 6.18 11.01.2023 जमलीग्राम/जम.ली. 209 इंिेक्ट्िन 0.2 ग्लाइकोपीरोलेट 1 जम.ली. 14.53 11.01.2023 जमलीग्राम/जम.ली. 210 जग्रसोफुजल्वन गोली 250 जमलीग्राम 1 गोली 1.77 06.01.2023 211 हलै ोपेरीडोल गोली 1.5 जमलीग्राम 1 गोली 1.56 06.01.202344 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 212 हलै ोपेरीडोल गोली 5 जमलीग्राम 1 गोली 3.56 19.12.2022 213 हलै ोपेरीडोल गोली 10 जमलीग्राम 1 गोली 4.77 19.12.2022 214 ओरल जलदक्वड 2 हलै ोपेरीडोल 1 जम.ली. 2.24 11.01.2023 जमलीग्राम/5जम.ली. 215 हालोथाने जलक़ुड फोर इनहले ेिन 1 जम.ली. 6.09 24.02.2023 216 इंिेक्ट्िन 1000 आईयू/ हपे ाटरन 1 जम.ली. 21.21 19.12.2022 जम.ली. 217 इंिेक्ट्िन 5000 आईयू / हपे ाटरन 1 जम.ली. 59.96 19.12.2022 जम.ली. 218 होमेरोजपन िोप 2% 1 जम.ली. 6.40 02.02.2023 blesa 52 fexzk- 219 gkeksZu fjfyftax vkbZ;wMh 1 vkbZ;wMh 4103.29 29.03.2023 yos ksuksxsZLVªsy 'kkfey gS 220 ह्यूमन कोटरओजनक इंिेक्ट्िन 5000 आईयू 1 वाइल 417.45 24.02.2023 गोनाडोरोजपन 221 हाइिोक्ट्लोरोजथयाजिड गोली 25 जमलीग्राम 1 गोली 1.74 11.01.2023 222 हाइिोक्ट्लोरोजथयाजिड गोली 12.5 जमलीग्राम 1 गोली 1.04 11.01.2023 223 पाउडर फोर इंिेक्ट्िन 100 हाइिोकार्टचसोन 1 वाईल 44.79 06.01.2023 जमलीग्राम 224 हाइिोकार्टचसोन गोली 10 जमलीग्राम 1 गोली 6.70 24.02.2023 225 पाउडर फोर इंिेक्ट्िन 20 हाइिोकार्टचसोन 1 वाइल 65.60 24.02.2023 0जमलीग्राम 226 हाइिोकार्टचसोन गोली 5 जमलीग्राम 1 गोली 3.11 24.02.2023 227 हाइिोकार्टचसोन गोली 20 जमलीग्राम 1 गोली 14.88 24.02.2023 228 हायिोक्ट्सीप्रोपायल इंिेक्ट्िन 2% 1 जम.ली. 29.20 24.02.2023 जमथायलसेलुलॉि 229 हाइिोक्ट्सीक्ट्लोरोक्वीन गोली 400 जमलीग्राम 1 गोली 13.80 19.12.2022 230 हाइिोक्ट्सीक्ट्लोरोक्वीन गोली 200 जमलीग्राम 1 गोली 6.35 06.01.2023 231 हाइिोक्ट्सीयूटरया कैप्सूल 500 जमलीग्राम 1 कैप्सूल 12.12 06.01.2023 232 आइबुप्रोफेन गोली 200 जमलीग्राम 1 गोली 0.70 06.01.2023 233 आइबुप्रोफेन गोली 400 जमलीग्राम 1 गोली 1.19 11.01.2023 234 ओरल जलदक्वड 100 आइबुप्रोफेन 1 जम.ली. 0.22 02.02.2023 जमलीग्राम / 5 जम.ली.(पी) 235 इमैटटजनब गोली 100 जमलीग्राम 1 गोली 69.75 06.01.2023 236 इमैटटजनब गोली 400 जमलीग्राम 1 गोली 199.61 11.01.2023 237 इंसुजलन इंटरमीजडएट एलक्ट्टंग इंिेक्ट्िन 40 आई/जम.ली. 1 जम.ली. 16.98 24.02.2023 (एनपीएर्) 238 इंिेक्ट्िन 20 आयरन सुक्रोि 1 जम.ली. 57.40 24.02.2023 जमलीग्राम/जम.ली. 239 आइसोफ्लुरेन जलक़ुड फोर इनहले ेिन 1 जम.ली. 9.65 11.01.2023 240 आइसोसॉरबाइड जडजनरेट गोली 5 जमलीग्राम 1 गोली 0.81 19.12.2022 241 आइसोसॉरबाइड जडजनरेट गोली 10जमलीग्राम 1 गोली 0.80 24.02.2023 242 इस्ट्पघुला ग्रेनुलेस/ हस्ट्कपाउडर / 1 ग्राम 0.94 24.02.2023 243 इराकोनािोल ओरल जलदक्वड 10 1 जम.ली. 4.94 19.12.2022[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 45 जमलीग्राम / जम.ली. 244 vkbZ;wMh daVsfauxa dkWij ykblsla ds :i eas 1 vkbZ;wMh 280.99 24.02.2023 245 इंिेक्ट्िन 50 केटामाइन 1 जम.ली. 12.12 02.02.2023 जमलीग्राम/जम.ली. 246 इंिेक्ट्िन 5 लेबेटालोल 1 जम.ली. 49.98 11.01.2023 जमलीग्राम/जम.ली. 247 ओरल जलदक्वड 10 ग्राम लैक्ट्टुलोि 1 जम.ली. 1.23 11.01.2023 /15जम.ली. 248 लैमीवुडीन गोली 100 जमलीग्राम 1 गोली 10.40 19.12.2022 249 लैमीवुडीन गोली 150 जमलीग्राम 1 गोली 10.86 19.12.2022 250 पाउडर फोर इंिेक्ट्िन एल- ऐस्ट्पैरिाइनेस 1 वाईल 1034.81 06.01.2023 5000 केयू 251 पाउडर फोर इंिेक्ट्िन एल- ऐस्ट्पैरिाइनेस 1 वाईल 1707.64 06.01.2023 10000 केयू 252 लेजनलेडोमाइड कैप्सूल 5 जमलीग्राम 1 कैप्सूल 67.25 19.12.2022 253 लेजनलेडोमाइड कैप्सूल 25 जमलीग्राम 1 कैप्सूल 292.25 11.01.2023 254 लेरोजोल गोली 2.5 जमलीग्राम 1 गोली 29.31 19.12.2022 255 पाउडर फोर इंिेक्ट्िन ल्यूप्रोलाइड एसीटेट 1 वाईल 17080.55 11.01.2023 22.5 जमलीग्राम 256 पाउडर फोर इंिेक्ट्िन ल्यूप्रोलाइड एसीटेट 1 वाईल 9293.96 11.01.2023 11.25 जमलीग्राम 257 पाउडर फोर इंिेक्ट्िन ल्यूप्रोलाइड एसीटेट 1 वाईल 3112.50 11.01.2023 3.75 जमलीग्राम 258 लेवेटटरासेटम गोली 250 जमलीग्राम 1 गोली 6.30 06.01.2023 259 लेवेटटरासेटम गोली 500 जमलीग्राम 1 गोली 12.98 06.01.2023 260 मोडीफाइड टरलीि गोली लेवेटटरासेटम 1 गोली 18.29 19.12.2022 750 जमलीग्राम 261 लेवेटटरासेटम गोली 750 जमलीग्राम 1 गोली 19.34 06.01.2023 262 ओरल जलदक्वड 100 लेवेटटरासेटम 1 जम.ली. 3.96 11.01.2023 जमलीग्राम/जम.ली. (पी) 263 इंिेक्ट्िन 100 जमलीग्राम/ लेवेटटरासेटम 1 जम.ली. 23.01 02.02.2023 जम.ली. 264 मोडीफाईड टरलीि –गोली लेवोडोपा (ए) + कार्बचडोपा 200 जमलीग्राम (ए) + 50 1 गोली 4.73 11.01.2023 (बी) जमलीग्राम (बी) 265 लेवोडोपा (ए) + कार्बचडोपा गोली 100 जमलीग्राम (ए) 1 गोली 2.57 19.12.2022 (बी) + 25 जमलीग्राम (बी) 266 लेवोडोपा (ए) + कार्बचडोपा गोली 100 जमलीग्राम (ए) 1 गोली 1.76 19.12.2022 (बी) + 10 जमलीग्राम (बी) 267 लेवोडोपा (ए) + कार्बचडोपा गोली 250 जमलीग्राम (ए) 1 गोली 4.41 19.12.2022 (बी) +25 जमलीग्राम (बी) 268 लेवोडोपा (ए) + कार्बचडोपा मोडीफाइड टरलीि –गोली 1 गोली 2.79 24.02.2023 (बी) 100 जमलीग्राम (ए) + 2546 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] जमलीग्राम (बी) 269 जलवोफ़्लॉक्ट्साजसन गोली 250 जमलीग्राम 1 गोली 4.76 06.01.2023 270 जलवोफ़्लॉक्ट्साजसन गोली 500 जमलीग्राम 1 गोली 8.80 06.01.2023 271 जलवोफ़्लॉक्ट्साजसन गोली 750 जमलीग्राम 1 गोली 12.44 06.01.2023 272 लेवोथायरोजक्ट्सन गोली 50 एमसीिी 1 गोली 1.03 19.12.2022 273 लेवोथायरोजक्ट्सन गोली 75 एमसीिी 1 गोली 1.43 19.12.2022 274 लेवोथायरोजक्ट्सन गोली 88 एमसीिी 1 गोली 1.64 19.12.2022 275 लेवोथायरोजक्ट्सन गोली 112 एमसीिी 1 गोली 1.65 19.12.2022 276 लेवोथायरोजक्ट्सन गोली 25 एमसीिी 1 गोली 1.44 19.12.2022 277 लेवोथायरोजक्ट्सन गोली 62.5 एमसीिी 1 गोली 1.61 11.01.2023 278 लेवोथायरोजक्ट्सन गोली 12.5 एमसीिी 1 गोली 1.48 24.02.2023 279 लेवोथायरोजक्ट्सन गोली 100 एमसीिी 1 गोली 1.32 24.02.2023 280 लेवोथायरोजक्ट्सन गोली 125 एमसीिी 1 गोली 1.69 24.02.2023 281 1 जलग्नोकेन टोजपकल फोम च2-5 % 1.13 24.02.2023 ग्राम/जम.ली. 282 जलग्नोकेन इंिेक्ट्िन 2% 1 जम.ली. 1.04 24.02.2023 283 जलनेजोजलड गोली 600 जमलीग्राम 1 गोली 35.66 19.12.2022 284 जलजथयम गोली 300 जमलीग्राम 1 गोली 1.62 11.01.2023 285 लोपेरामाइड गोली 2 जमलीग्राम 1 गोली 2.27 19.12.2022 286 लोजपनवीर (ए) + टरटोनवीर गोली 200 जमलीग्राम (ए) 1 गोली 47.96 11.01.2023 (बी) + 50 जमलीग्राम (बी) 287 लोरािेपेम गोली 1 जमलीग्राम 1 गोली 2.30 19.12.2022 288 लोरािेपेम गोली 2 जमलीग्राम 1 गोली 2.81 19.12.2022 289 इंिेक्ट्िन 500 मैगनीजियम सल्फेट 1 जम.ली. 4.86 24.02.2023 जमलीग्राम/जम.ली. 290 मैजनटोल इंिेक्ट्िन 20 % 1 जम.ली. 0.34 11.01.2023 291 मेबेंडािोल गोली 100 जमलीग्राम 1 गोली 2.90 19.12.2022 292 ओरल जलदक्वड 100 मेबेंडािोल 1 जम.ली. 0.84 11.01.2023 जमलीग्राम/5जम.ली. (पी) 293 मेिोक्ट्सीप्रोिेस्ट्टेरोन एसीटेट गोली 10 जमलीग्राम 1 गोली 6.24 11.01.2023 294 इंिेक्ट्िन 150 जमलीग्राम मेिोक्ट्सीप्रोिेस्ट्टेरोन एसीटेट 1 जम.ली. 289.74 11.01.2023 /जम.ली. 295 ओरल जलदक्वड 100 मेफानाजमक एजसड 1 जम.ली. 0.56 19.12.2022 जमलीग्राम / 5 जम.ली. (पी) 296 मेफ्लोक्वाइन गोली 250 जमलीग्राम 1 गोली 52.15 06.01.2023 297 मेग्लुमाइन डायरीजोएट इंिेक्ट्िन 60% डब्ल्यू वी / 1 जम.ली. 9.47 24.02.2023 298 मेग्लुमाइन डायरीजोएट इंिेक्ट्िन 76% डब्ल्यू वी / 1 जम.ली. 10.20 24.02.2023 299 इंिेक्ट्िन 100 मेस्ना 1 जम.ली. 15.50 19.12.2022 जमलीग्राम/जम.ली. 300 मेटफोर्मचन गोली 1000 जमलीग्राम 1 गोली 3.48 19.12.2022 301 मेटफोर्मचन गोली 500 जमलीग्राम 1 गोली 2.01 06.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 47 302 मोडीफाइड टरलीि गोली मेटफोर्मचन 1 गोली 4.04 06.01.2023 1000 जमलीग्राम 303 मेथोरेक्ट्सेट गोली 10 जमलीग्राम 1 गोली 13.28 06.01.2023 304 मेथोरेक्ट्सेट गोली 2.5 जमलीग्राम 1 गोली 5.31 06.01.2023 305 जमथाइलिोमेटरन गोली 0.125 जमलीग्राम 1 गोली 8.93 11.01.2023 306 इंिेक्ट्िन 0.2 जमथाइलिोमेटरन 1 जम.ली. 14.94 02.02.2023 जमलीग्राम/जम.ली. 307 मेटोक्ट्लोप्रमाइड गोली 10 जमलीग्राम 1 गोली 1.34 06.01.2023 308 इंिेक्ट्िन 5 मेटोक्ट्लोप्रमाइड जमलीग्राम/जम.ली. (लेस िने 1 जम.ली. 2.66 24.02.2023 10 जम.ली. पैक) 309 मेटोप्रोलोल गोली 25 जमलीग्राम 1 गोली 4.20 06.01.2023 310 मेटोप्रोलोल गोली 50 जमलीग्राम 1 गोली 5.84 06.01.2023 311 मोडीफाईड टरलीि गोली मेटोप्रोलोल 1 गोली 14.99 11.01.2023 100 जमलीग्राम 312 मेटोप्रोलोल गोली 100 जमलीग्राम 1 गोली 11.13 11.01.2023 313 मेरोजनडािोल गोली 200 जमलीग्राम 1 गोली 0.81 06.01.2023 314 मेरोजनडािोल गोली 400 जमलीग्राम 1 गोली 1.52 06.01.2023 315 इंिेक्ट्िन 500 मेरोजनडािोल 1 जम.ली. 0.21 11.01.2023 जमलीग्राम/100जम.ली. 316 ओरल जलदक्वड 200 मेरोजनडािोल 1 जम.ली. 0.51 11.01.2023 जमलीग्राम/5जम.ली. (पी) 317 नैिल स्ट्प्रै 1.25 जमलीग्राम जमडाजोलम 1 जम.ली. 216.80 11.01.2023 / अक़ुएसन 318 नैिल स्ट्प्रै 0.5 जमलीग्राम / जमडाजोलम 1 जम.ली. 79.93 11.01.2023 अक़ुएसन 319 इंिेक्ट्िन 1 जमलीग्राम/ जमडाजोलम 1 जम.ली. 5.92 24.02.2023 जम.ली. 320 इंिेक्ट्िन 5 जमलीग्राम/ जमडाजोलम 1 जम.ली. 10.87 24.02.2023 जम.ली. 321 जमफेजप्रस्ट्टोन गोली 200 जमलीग्राम 1 गोली 350.89 11.01.2023 322 जमसोप्रोस्ट्टोल गोली 200 एमसीिी 1 गोली 18.97 19.12.2022 323 जमसोप्रोस्ट्टोल गोली 100mcg 1 गोली 9.92 11.01.2023 324 मोंटेलुकास्ट्ट गोली 4 जमलीग्राम 1 गोली 10.03 19.12.2022 325 गोली 5 जमलीग्राम (र्बाने मोंटेलुकास्ट्ट 1 गोली 11.71 19.12.2022 योग्य सजहत गोली) 326 मोंटेलुकास्ट्ट गोली 10 जमलीग्राम 1 गोली 16.43 19.12.2022 327 इंिेक्ट्िन मॉर्फचन 1 जम.ली. 19.59 24.02.2023 10जमलीग्राम/जम.ली. 328 इंिेक्ट्िन मॉर्फचन 1 जम.ली. 14.93 24.02.2023 15जमलीग्राम/जम.ली. 329 मोक्ट्सीफ्लोक्ट्साजसन गोली 400 जमलीग्राम 1 गोली 25.82 06.01.202348 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 330 मायकोफेनोलेट मोफेटटल गोली 500 जमलीग्राम 1 गोली 73.87 19.12.2022 331 मायकोफेनोलेट मोफेटटल गोली 250 जमलीग्राम 1 गोली 49.60 02.02.2023 332 इंिेक्ट्िन 200 एनएजसटाइलजसस्ट्टीन- 1 जम.ली. 23.63 11.01.2023 जमलीग्राम/जम.ली. 333 इंिेक्ट्िन 0.4 नालोक्ट्सोन 1 जम.ली. 92.72 11.01.2023 जमलीग्राम/जम.ली. 334 नैटामाइजसन िोप 5% 1 जम.ली. 23.37 02.02.2023 335 इंिेक्ट्िन 0.5 जनओजस्ट्टग्माइन 1 जम.ली. 5.01 11.01.2023 जमलीग्राम/जम.ली. 336 जनओजस्ट्टग्माइन गोली 15 जमलीग्राम 1 गोली 4.58 24.02.2023 337 नेजवरेपीन गोली 200 जमलीग्राम 1 गोली 15.79 19.12.2022 338 जनफेजडजपन गोली 10 जमलीग्राम 1 गोली 1.53 24.02.2023 339 नाइरोफ्यूरन्टाइन गोली 100 जमलीग्राम 1 गोली 8.10 06.01.2023 340 इंिेक्ट्िन 2 जमलीग्राम/ नॉरएिेनालाईन 1 जम.ली. 20.17 24.02.2023 जम.ली. 341 नोरेजथस्ट्टरोन गोली 5 जमलीग्राम 1 गोली 5.39 06.01.2023 342 ओमेप्राजोल कैप्सूल 20 जमलीग्राम 1 कैप्सूल 2.87 02.02.2023 343 ओंडान्सेरॉन गोली 4 जमलीग्राम 1 गोली 5.13 11.01.2023 344 ओरल जलदक्वड 2 ओंडान्सेरॉन 1 जम.ली. 1.25 11.01.2023 जमलीग्राम/5जम.ली. (पी) 345 इंिेक्ट्िन 2 ओंडान्सेरॉन 1 जम.ली. 5.96 02.02.2023 जमलीग्राम/जम.ली. 346 इंिेक्ट्िन 5 ऑजक्ट्सजप्लजप्टन जमलीग्राम/जम.ली. in 10 1 वाईल 2233.82 11.01.2023 जम.ली. वाईल 347 ऑक्ट्सीटोजसन इंिेक्ट्िन 5 आईयू/जम.ली. 1 जम.ली. 17.83 02.02.2023 348 पैंटोप्राजोल इंिेक्ट्िन 40 जमलीग्राम 1 वाईल 50.45 06.01.2023 349 पेराजसटामोल गोली 650 जमलीग्राम 1 गोली 2.00 06.01.2023 350 ओरल जलदक्वड 125 पेराजसटामोल 1 जम.ली. 0.37 11.01.2023 जमलीग्राम/5 जम.ली. (पी) 351 ओरल जलदक्वड 250 पेराजसटामोल 1 जम.ली. 0.67 11.01.2023 जमलीग्राम/5 जम.ली. (पी) 352 ओरल जलदक्वड 120 पेराजसटामोल 1 जम.ली. 0.60 11.01.2023 जमलीग्राम/5 जम.ली. (पी) 353 पेराजसटामोल गोली 500 जमलीग्राम 1 गोली 0.89 02.02.2023 354 1 पेराजसटामोल सपोजसटरी 80 जमलीग्राम 6.66 02.02.2023 सपोजसटरी 355 1 पेराजसटामोल सपोजसटरी 170 जमलीग्राम 7.94 02.02.2023 सपोजसटरी 356 फेनोबार्बचटोन गोली 30 जमलीग्राम 1 गोली 1.31 06.01.2023 357 फेनोबार्बचटोन गोली 60 जमलीग्राम 1 गोली 1.89 11.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 49 358 इंिेक्ट्िन 200 फेनोबार्बचटोन 1 जम.ली. 22.14 11.01.2023 जमलीग्राम/जम.ली. 359 ओरल जलदक्वड 20 फेनोबार्बचटोन 1 जम.ली. 0.49 24.02.2023 जमलीग्राम/5जम.ली. (पी) 360 फेनीटोइन गोली 300 जमलीग्राम 1 गोली 5.48 06.01.2023 361 इंिेक्ट्िन 50 दफनाइटोइन 1 जम.ली. 5.95 11.01.2023 जमलीग्राम/जम.ली. 362 फाइटोमेनाजडयोन (जवटाजमन इंिेक्ट्िन 10 1 जम.ली. 53.08 24.02.2023 K1) जमलीग्राम/जम.ली. 363 जपलोकार्पचन िोप 2 % 1 जम.ली. 10.83 24.02.2023 364 पाउडर फोर इंिेक्ट्िन जपपेराजसजलन (ए) + 1000 जमलीग्राम (ए)+125 1 वाईल 99.65 06.01.2023 टाजोबैक्ट्टम (बी) जमलीग्राम (बी) 365 पाउडर फोर इंिेक्ट्िन जपपेराजसजलन (ए) + 2000 जमलीग्राम (ए) 1 वाईल 191.53 06.01.2023 टाजोबैक्ट्टम (बी) +250 जमलीग्राम (बी) 366 पाउडर फोर इंिेक्ट्िन जपपेराजसजलन (ए) + 4000 जमलीग्राम (ए) 1 वाईल 399.38 06.01.2023 टाजोबैक्ट्टम (बी) +500 जमलीग्राम (बी) 367 ओरल जलदक्वड 500 पोटेजियम क्ट्लोराइड 1 जम.ली. 0.30 11.01.2023 जमलीग्राम/5जम.ली. 368 इंिेक्ट्िन 150 पोटेजियम क्ट्लोराइड 1 जम.ली. 2.39 24.02.2023 जमलीग्राम/जम.ली. 369 पोवीडोन आयोडीन सोलूिन 5% 1 जम.ली. 0.43 24.02.2023 370 पोवीडोन आयोडीन सोलूिन 7.5% 1 जम.ली. 0.81 24.02.2023 371 पोवीडोन आयोडीन सोलूिन 10% 1 जम.ली. 0.96 24.02.2023 372 प्रैजलडॉजक्ट्सम क्ट्लोराइड इंिेक्ट्िन 25 1 जम.ली. 4.56 11.01.2023 (2-पीएएम) जमलीग्राम/जम.ली. 373 प्रेडजनसोलोन गोली 40जमलीग्राम 1 गोली 3.40 11.01.2023 374 ओरल जलदक्वड 5 प्रेडजनसोलोन 1 जम.ली. 0.49 11.01.2023 जमलीग्राम/5जम.ली. (पी) 375 ओरल जलदक्वड 15 प्रेडजनसोलोन 1 जम.ली. 0.86 11.01.2023 जमलीग्राम/5जम.ली.(पी) 376 प्रेडजनसोलोन गोली 10 जमलीग्राम 1 गोली 1.19 02.02.2023 377 प्रेडजनसोलोन गोली 5 जमलीग्राम 1 गोली 0.68 02.02.2023 378 प्रेडजनसोलोन गोली 20 जमलीग्राम 1 गोली 2.39 02.02.2023 379 प्रेडजनसोलोन िोप 1% 1 जम.ली. 5.76 24.02.2023 380 प्राइमाक्वीन गोली 7.5 जमलीग्राम 1 गोली 2.37 06.01.2023 381 प्राइमाक्वीन गोली 15 जमलीग्राम 1 गोली 5.13 02.02.2023 382 प्रोपरकाइन आई िॉप 0.5% 1 जम.ली. 10.24 11.01.2023 383 इंिेक्ट्िन 10 प्रोपोफोल 1 जम.ली. 6.50 24.02.2023 जमलीग्राम/जम.ली.50 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 384 प्रोप्रानोलोल गोली 40 जमलीग्राम 1 गोली 3.21 06.01.2023 385 प्रोप्रानोलोल गोली 10 जमलीग्राम 1 गोली 1.31 06.01.2023 386 प्रोप्रानोलोल गोली 20 जमलीग्राम 1 गोली 3.19 11.01.2023 387 इंिेक्ट्िन 10 प्रोटामाइन सल्फेट 1 जम.ली. 9.77 24.02.2023 जमलीग्राम/जम.ली. 388 पायराजीनामाईड गोली 1000 जमलीग्राम 1 गोली 10.52 06.01.2023 389 पायराजीनामाईड गोली 500 जमलीग्राम 1 गोली 4.88 06.01.2023 390 पायराजीनामाईड गोली 750 जमलीग्राम 1 गोली 7.20 06.01.2023 391 पायराजीनामाईड गोली 1500 जमलीग्राम 1 गोली 11.80 24.02.2023 392 पाइटरडोजक्ट्सन गोली 100 जमलीग्राम 1 गोली 5.97 02.02.2023 393 दक्वजनन गोली 300 जमलीग्राम 1 गोली 5.65 06.01.2023 394 रेबीि वैक्ट्सीन एि लाइसेंस 1 वाइल 378.69 24.02.2023 395 राल्टेग्रेजवर गोली 400 जमलीग्राम 1 गोली 147.78 19.12.2022 396 राजमजप्रल गोली 2.5 जमलीग्राम 1 गोली 5.21 19.12.2022 397 राजमजप्रल गोली 5 जमलीग्राम 1 गोली 8.18 19.12.2022 398 टरबावायटरन कैप्सूल 200 जमलीग्राम 1 कैप्सूल 26.49 11.01.2023 399 टरफैजम्पजसन कैप्सूल 600 जमलीग्राम 1 कैप्सूल 11.35 19.12.2022 400 टरफैजम्पजसन कैप्सूल 450 जमलीग्राम 1 कैप्सूल 5.67 06.01.2023 401 टरफैजम्पजसन कैप्सूल 150 जमलीग्राम 1 कैप्सूल 2.28 11.01.2023 402 टरफैजम्पजसन कैप्सूल 300 जमलीग्राम 1 कैप्सूल 4.60 11.01.2023 403 ओरल जलदक्वड 100 टरफैजम्पजसन 1 जम.ली. 0.47 24.02.2023 जमलीग्राम/5जम.ली.(पी) 404 टरसपेरीडोन गोली 1 जमलीग्राम 1 गोली 3.02 06.01.2023 405 टरसपेरीडोन गोली 2 जमलीग्राम 1 गोली 4.48 19.12.2022 406 टरसपेरीडोन गोली 4 जमलीग्राम 1 गोली 7.35 19.12.2022 407 ओरल जलदक्वड 1 टरसपेरीडोन 1 जम.ली. 2.20 11.01.2023 जमलीग्राम/जम.ली. 408 टरटोनवीर गोली 100 जमलीग्राम 1 गोली 29.20 02.02.2023 409 इंिेक्ट्िन 10 टरजट्क्ट्समैब 1 जम.ली. 761.76 02.02.2023 जमलीग्राम/जम.ली. 410 सैल्बुटामोल गोली 4 जमलीग्राम 1 गोली 0.21 06.01.2023 411 सैल्बुटामोल गोली 2 जमलीग्राम 1 गोली 0.17 06.01.2023 412 ओरल जलदक्वड 2 सैल्बुटामोल 1 जम.ली. 0.17 11.01.2023 जमलीग्राम/5जम.ली. 413 इनहले ेिन सैल्बुटामोल (एमडीआई(*डीपीआई/ 1 एमडीआई 0.49 02.02.2023 100 एमसीिी / डोि 414 रेजस्ट्परेटर सॉल्यूिन सॉल्यूिन फोर ) सैल्बुटामोल 1 जम.ली. 0.68 02.02.2023 नेब्युलाइजर 5 जमलीग्राम / जम.ली.)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 51 415 सैजलजसजलक एजसड ओइंटमेंट 3-6% (6%) 1 ग्राम 2.01 24.02.2023 416 इंिेक्ट्िन (एि पर आईपी) - सोजडयम बाइकाबोनेट 1 जम.ली. 1.34 02.02.2023 8.4% 417 सोजडयम वैल्प्रोएट गोली 300 जमलीग्राम 1 गोली 4.46 19.12.2022 418 ओरल जलदक्वड 200 सोजडयम वैल्प्रोएट 1 जम.ली. 0.65 02.02.2023 जमलीग्राम/5 जम.ली. (पी) 419 सोजडयम वैल्प्रोएट गोली 200 जमलीग्राम 1 गोली 3.58 24.02.2023 420 मोडीफाइड टरलीि – गोली सोजडयम वैल्प्रोएट 1 गोली 9.28 24.02.2023 500 जमलीग्राम 421 सोजडयम वैल्प्रोएट गोली 500 जमलीग्राम 1 गोली 8.11 24.02.2023 422 मोडीफाइड टरलीि – गोली सोजडयम वैल्प्रोएट 1 गोली 6.09 24.02.2023 300 जमलीग्राम 423 इंिेक्ट्िन सोजडयम वैल्प्रोएट 1 जम.ली. 6.74 24.02.2023 100जमलीग्राम/जम.ली. 424 सोफोसबुवीर गोली 400 जमलीग्राम 1 गोली 525.08 19.12.2022 425 स्ट्पैरोनोलाक्ट्टोंन गोली 50 जमलीग्राम 1 गोली 4.37 11.01.2023 426 स्ट्पैरोनोलाक्ट्टोंन गोली 25 जमलीग्राम 1 गोली 2.18 02.02.2023 427 इंिेक्ट्िन 15,00,000 स्ट्रेप्टोदकनेि 1 वाईल 1877.23 11.01.2023 आईयू 428 पाउडर फोर इंिेक्ट्िन 750 स्ट्रेप्टोमाइजसन 1 वाईल 10.10 11.01.2023 जमलीग्राम 429 पाउडर फोर इंिेक्ट्िन स्ट्रेप्टोमाइजसन 1 वाईल 10.86 11.01.2023 1000 जमलीग्राम 430 सल्फासालाजजन गोली 500 जमलीग्राम 1 गोली 4.72 06.01.2023 431 टैक्रोजलमस कैप्सूल 0.5 जमलीग्राम 1 कैप्सूल 20.66 19.12.2022 432 टैक्रोजलमस कैप्सूल 1 जमलीग्राम 1 कैप्सूल 40.62 19.12.2022 433 टैक्रोजलमस कैप्सूल 2 जमलीग्राम 1 कैप्सूल 84.33 19.12.2022 434 टामोक्ट्सीफेन गोली 20 जमलीग्राम 1 गोली 2.94 06.01.2023 435 टामोक्ट्सीफेन गोली 10 जमलीग्राम 1 गोली 2.20 06.01.2023 436 टेजल्मसटचन गोली 20 जमलीग्राम 1 गोली 3.87 06.01.2023 437 टेजल्मसटचन गोली 40 जमलीग्राम 1 गोली 6.76 19.12.2022 438 टेजल्मसटचन गोली 80 जमलीग्राम 1 गोली 10.40 06.01.2023 439 टेमोजोलोमाइड कैप्सूल 20 जमलीग्राम 1 कैप्सूल 441.31 19.12.2022 440 टेमोजोलोमाइड कैप्सूल 250 जमलीग्राम 1 कैप्सूल 4303.77 19.12.2022 441 टेमोजोलोमाइड कैप्सूल 100 जमलीग्राम 1 कैप्सूल 1508.62 11.01.2023 442 इंिेक्ट्िन 40 जमलीग्राम / टेनेक्ट्टेप्लेस 1 वाईल 50386.90 11.01.2023 वाईल 443 टेनेक्ट्टेप्लेस इंिेक्ट्िन 30 जमलीग्राम / 1 वाईल 36907.98 11.01.202352 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] वाईल 444 टेनोफोजवर अलाफेनामाइड गोली 25 जमलीग्राम 1 गोली 48.87 06.01.2023 फ्यूमरेट (टीएएफ) 445 टेनोफोजवर जडसोप्रोक्ट्सील गोली 300 जमलीग्राम (ए) फ्यूमरेट लैजमवुडाइन + (ए) 1 गोली 45.57 11.01.2023 + 300 जमलीग्राम (बी) (बी) 446 टेनोफोजवर जडसोप्रॉजक्ट्सल गोली 300 जमलीग्राम (ए) फ्यूमरेट) + लैजमवुडाइन (बी) + 300 जमलीग्राम (बी) + 1 गोली 102.83 11.01.2023 + एफाजवरेंज (सी) 600 जमलीग्राम (सी) 447 टेनोफोजवर जडसप्रॉजक्ट्सल गोली 300 जमलीग्राम 1 गोली 45.83 11.01.2023 फ्यूमरेट *(टी डी एफ) 448 थैजलडोमाइड कैप्सूल 50 जमलीग्राम 1 कैप्सूल 31.15 06.01.2023 449 थैजलडोमाइड कैप्सूल 100 जमलीग्राम 1 कैप्सूल 62.01 06.01.2023 450 जथयाजमन गोली 100 जमलीग्राम 1 गोली 4.46 11.01.2023 451 इंिेक्ट्िन 100 जथयाजमन 1 जम.ली. 22.59 24.02.2023 जमलीग्राम/जम.ली. 452 टटमोलोल िॉप 0.5 % 1 जम.ली. 13.39 11.01.2023 453 इनहले ेिन (एमडीआई) 9 टटयोरोजपयम 1 एमडीआई 2.78 24.02.2023 एमसीिी / डोि 454 इनहले ेिन (डीपीआई( 18 टटयोरोजपयम 1 डीपीआई 10.70 24.02.2023 एमसीिी डोि / 455 इंिेक्ट्िन 50 रामाडोल जमलीग्राम/जम.ली. (अप टू 2 1 जम.ली. 11.78 02.02.2023 जम.ली. पैक) 456 इंिेक्ट्िन 100 रेनेक्ट्जाजमक एजसड 1 जम.ली. 13.71 11.01.2023 जमलीग्राम/जम.ली. 457 रेनेक्ट्जाजमक एजसड गोली 500 जमलीग्राम 1 गोली 18.54 11.01.2023 458 इंिेक्ट्िन 440 रस्ट्टुज़ुमाब 1 वाईल 54722.18 11.01.2023 जमलीग्राम/50जम.ली. 459 राइहजे क्ट्सफेजनडाइल गोली 2 जमलीग्राम 1 गोली 1.36 24.02.2023 460 रॉजपकैमाइड आई िॉप 1 % 1 जम.ली. 9.42 11.01.2023 461 वेलगैन्सीक्ट्लोजवर गोली 450 जमलीग्राम 1 गोली 400.71 19.12.2022 462 पाउडर फोर इंिेक्ट्िन 500 वैनकॉमायजसन 1 वाईल 317.61 11.01.2023 जमलीग्राम 463 पाउडर फोर इंिेक्ट्िन वैनकॉमायजसन 1 वाईल 470.23 11.01.2023 1000 जमलीग्राम 464 पाउडर फोर इंिेक्ट्िन 250 वैनकॉमायजसन 1 वाईल 251.24 11.01.2023 जमलीग्राम 465 पाउडर फोर इंिेक्ट्िन 10 प्रत्येक वेकुरोजनयम 117.35 19.12.2022 जमलीग्राम वाईल 466 पाउडर फोर इंिेक्ट्िन 4 प्रत्येक वेकुरोजनयम 74.40 19.12.2022 जमलीग्राम वाईल 467 वेरापाजमल गोली 80 जमलीग्राम 1 गोली 1.59 02.02.2023 468 वेरापाजमल गोली 40 जमलीग्राम 1 गोली 0.86 02.02.2023 469 जवजन्क्रस्ट्टाईन इंिेक्ट्िन 1 1 जम.ली. 57.51 02.02.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 53 जमलीग्राम/जम.ली. 470 िाइलोमेटाजोजलन नेिल िोप 0.05 % 1 जम.ली. 4.19 02.02.2023 471 िाइलोमेटाजोजलन नेिल िोप 0.1% 1 जम.ली. 5.12 02.02.2023 472 जजडोवुडाइन (ए) + गोली 300 जमलीग्राम (ए) लेजमवुडाइन (बी) + + 150 जमलीग्राम (बी) + 1 गोली 21.13 02.02.2023 नेजवरापीन (सी) 200 जमलीग्राम (सी) 473 जिडोवुडाइन (ए) + गोली 300 जमलीग्राम (ए) 1 गोली 21.09 06.01.2023 लेजमवुडाइन (बी) +150 जमलीग्राम (बी) 474 पाउडर फोर इंिेक्ट्िन 4 जोलेिोजनक एजसड 1 वाईल 2391.91 11.01.2023 जमलीग्राम 475 जोल्पीडेम गोली 5 जमलीग्राम 1 गोली 6.21 06.01.2023 476 जोल्पीडेम गोली 10 जमलीग्राम 1 गोली 8.51 19.12.2022 - ( 12.1218% ) 11(3) (5) एस.ओ. द्वारा अधिसूधित उपरोक्त के 6 ए और बी 12.1218 (5) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-।। के रूप में इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4)54 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (1( u II I II III II IV ड [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1574(E).— In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 1 6-Mercaptopurine Tablet 50mg 1 Tablet 5.25 194(E) 11.01.2023 2 Abacavir Tablet 300 mg 1 Tablet 48.59 5938(E) 19.12.2022 3 Abacavir (A) Tablet 600mg (A) +300mg 72.31 5938(E) 19.12.2022 +Lamivudine(B) (B) 1 Tablet 4 Acetazolamide Tablet 250mg 1 Tablet 4.05 87(E) 06.01.2023 5 Actinomycin D Powder for Injection 0.5mg 1 Vial 331.00 879(E) 24.02.2023 6 Acyclovir Tablet 400mg 1 Tablet 13.65 87(E) 06.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 55 Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 7 Acyclovir Tablet 200mg 1 Tablet 7.61 87(E) 06.01.2023 8 Acyclovir Powder for Injection 250 mg 1 Vial 426.37 194(E) 11.01.2023 9 Acyclovir Powder for Injection 500 mg 1 Vial 528.41 194(E) 11.01.2023 10 Acyclovir Tablet 800mg 1 Tablet 37.66 195(E) 11.01.2023 11 Acyclovir Ointment 3% 1 GM 11.67 879(E) 24.02.2023 12 Adenosine Injection 3mg/mL 1 ML 92.84 194(E) 11.01.2023 13 Adrenaline Injection1mg/mL 1 ML 12.23 879(E) 24.02.2023 14 Allopurinol Tablet 300mg 1 Tablet 5.62 5938(E) 19.12.2022 15 Allopurinol Tablet 100mg 1 Tablet 1.89 87(E) 06.01.2023 16 Alprostadil Injection 0.5mg/mL 1 ML 6106.41 879(E) 24.02.2023 17 Amiodarone Tablet 200mg 1 Tablet 11.51 87(E) 06.01.2023 18 Amiodarone Tablet 100mg 1 Tablet 6.14 87(E) 06.01.2023 19 Amiodarone Injection 50mg/mL 1 ML 21.13 194(E) 11.01.2023 20 Amitriptyline Tablet 50mg 1 Tablet 5.98 5938(E) 19.12.2022 21 Amitriptyline Tablet 75mg 1 Tablet 5.44 89(E) 06.01.2023 22 Amitriptyline Tablet 25mg 1 Tablet 2.48 89(E) 06.01.2023 23 Amitriptyline Tablet 10mg 1 Tablet 2.38 194(E) 11.01.2023 24 Amlodipine Tablet 2.5mg 1 Tablet 1.79 89(E) 06.01.2023 25 Amlodipine Tablet 5mg 1 Tablet 2.50 5938(E) 19.12.2022 26 Amlodipine Tablet 10mg 1 Tablet 5.44 89(E) 06.01.2023 27 Amoxicillin Capsule 250mg 1 Capsule 2.44 194(E) 11.01.2023 28 Amoxicillin Capsule 500mg 1 Capsule 7.35 484(E) 02.02.2023 29 Amoxicillin (A) + Powder for Injection 1 g (A) 140.64 87(E) 06.01.2023 Clavulanic acid (B) +200mg (B) 1 Vial 30 Amoxicillin (A) + Powder for Injection 500mg 101.33 194(E) 11.01.2023 Clavulanic acid (B) (A) + 100mg (B) 1 Vial 31 Amoxicillin (A) + Dry Syrup 125mg (A) + 31.25 2.05 194(E) 11.01.2023 Clavulanic acid (B) (B)/5mL(p) 1 ML 32 Amoxicillin (A) Tablet 500 mg (A) + 125 mg 18.29 87(E) 06.01.2023 +Clavulanic acid (B) (B) 1 Tablet 33 Amoxicillin (A) Oral liquid 200 mg (A) + 2.01 484(E) 02.02.2023 +Clavulanic acid (B) 28.5mg(B)/5 mL(p) 1 ML 34 Ampicillin Powder for Injection 500 mg 1 Vial 14.25 87(E) 06.01.2023 35 Artemether (A) + Tablet 40 mg (A) + 240 mg 18.04 194(E) 11.01.2023 Lumefantrine(B) (B) 1 Tablet 36 Artemether (A) 25.50 5938(E) 19.12.2022 +Lumefantrine(B) Tablet 80mg(A)+480mg(B) 1 Tablet 37 Artemether (A) Tablet 20 mg (A) + 120 mg 12.64 5938(E) 19.12.2022 +Lumefantrine(B) (B) 1 Tablet 38 Artesunate Powder for Injection 60 mg 1 Vial 244.71 194(E) 11.01.2023 39 Artesunate Powder for Injection 120mg 1 Vial 454.40 194(E) 11.01.2023 40 Artesunate (A) + Combi pack (A+B) 1 Tablet Sulphadoxine - 50mg (A) + 1Tablet (500mg 1 Combi 22.54 194(E) 11.01.2023 Pyrimethamine (B) + 25mg) (B) Pack 41 Atazanavir (A) Tablet 300mg(A) + Tablet 99.82 87(E) 06.01.2023 +Ritonavir(B) 100mg(B) 1 Tablet 42 Atorvastatin Tablet 40mg 1 Tablet 19.29 89(E) 06.01.2023 43 Atorvastatin Tablet 20mg 1 Tablet 12.55 89(E) 06.01.2023 44 Atorvastatin Tablet 10mg 1 Tablet 4.94 89(E) 06.01.2023 45 Atorvastatin Tablet 80mg 1 Tablet 40.57 5939(E) 19.12.2022 46 Atropine Drops 1% 1 ML 3.93 879(E) 24.02.2023 47 Atropine Ointment 1% 1 GM 4.70 879(E) 24.02.2023 48 Atropine Injection 0.6mg/mL 1 ML 4.57 879(E) 24.02.2023 49 Azathioprine Tablet 50mg 1 Tablet 11.25 87(E) 06.01.2023 50 Azithromycin Powder for Injection 500mg 1 Vial 204.71 194(E) 11.01.202356 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 51 Azithromycin Tablet 250mg 1 Tablet 11.64 484(E) 02.02.2023 52 Azithromycin Tablet 500mg 1 Tablet 23.56 484(E) 02.02.2023 53 Azithromycin Oral liquid 200 mg/5 mL (p) 1 ML 3.40 484(E) 02.02.2023 54 Baclofen Tablet 20mg 1 Tablet 16.28 5938(E) 19.12.2022 55 Baclofen Tablet 10mg 1 Tablet 11.89 89(E) 06.01.2023 56 Baclofen Tablet 5mg 1 Tablet 6.36 5938(E) 19.12.2022 57 Bendamustine 4946.53 195(E) 11.01.2023 hydrochloride Injection 100 mg/vial 1 Vial 58 Benzoyl peroxide Gel 2.5 % 1 GM 3.62 879(E) 24.02.2023 59 Benzoyl peroxide Gel 5 % 1 GM 7.97 879(E) 24.02.2023 60 Betamethasone 0.67 879(E) 24.02.2023 valerate Cream 0.05% 1 GM 61 Betamethasone 1.04 879(E) 24.02.2023 valerate Cream 0.1% 1 GM 62 Bicalutamide Tablet 50mg 1 Tablet 43.30 5938(E) 19.12.2022 63 Bisacodyl Tablet 5mg 1 Tablet 1.16 87(E) 06.01.2023 64 1 9.97 484(E) 02.02.2023 Bisacodyl Suppository 5mg Suppository 65 Bleomycin Powder for Injection 15units 1 Vial 677.37 194(E) 11.01.2023 66 Bortezomib Powder for Injection 2mg 1 Vial 5260.20 194(E) 11.01.2023 67 Buprenorphine Tablet (Sub-lingual)0.4mg 1 Tablet 9.42 88(E) 06.01.2023 68 Buprenorphine (A) Tablet (Sub-lingual) 36.97 88(E) 06.01.2023 +Naloxone (B) 2mg(A)+0.5mg(B) 1 Tablet 69 Buprenorphine (A) Tablet (Sub-lingual) 11.81 88(E) 06.01.2023 +Naloxone (B) 0.4mg(A)+0.1mg(B) 1 Tablet 70 Caffeine Oral liquid 20 mg/mL 1 ML 245.67 194(E) 11.01.2023 71 Calcium folinate Tablet 15mg 1 Tablet 47.53 879(E) 24.02.2023 72 Capecitabine Tablet 500mg 1 Tablet 112.71 5938(E) 19.12.2022 73 Modified Release – Tablet 2.39 5938(E) 19.12.2022 Carbamazepine 200mg 1 Tablet 74 Modified Release – Tablet 4.66 5938(E) 19.12.2022 Carbamazepine 400mg 1 Tablet 75 Carbamazepine Tablet 400mg 1 Tablet 3.55 5938(E) 19.12.2022 76 Carbamazepine Tablet 200mg 1 Tablet 1.56 87(E) 06.01.2023 77 Carbamazepine Oral liquid 100mg/5mL(p) 1 ML 0.31 194(E) 11.01.2023 78 Carbamazepine Tablet 100mg 1 Tablet 1.06 484(E) 02.02.2023 79 Carbimazole Tablet 10mg 1 Tablet 4.26 87(E) 06.01.2023 80 Carbimazole Tablet 5mg 1 Tablet 2.18 87(E) 06.01.2023 81 Carbimazole Tablet 20mg 1 Tablet 13.86 195(E) 11.01.2023 82 Carboplatin Injection 10mg/mL 1 ML 59.06 879(E) 24.02.2023 83 Carboxymethyl 12.29 484(E) 02.02.2023 cellulose Drops 0.5% 1 ML 84 Carboxymethyl 16.58 484(E) 02.02.2023 cellulose Drops 1% 1 ML 85 Cefadroxil Tablet 500mg 1 Tablet 4.47 5938(E) 19.12.2022 86 Cefadroxil Oral liquid 125mg/5mL(p) 1 ML 0.68 194(E) 11.01.2023 87 Cefixime Tablet 400mg 1 Tablet 22.09 5938(E) 19.12.2022 88 Cefixime Tablet 200mg 1 Tablet 9.77 87(E) 06.01.2023 89 Cefixime Oral liquid 50 mg/5 mL (p) 1 ML 1.62 484(E) 02.02.2023 90 Cefixime Oral liquid 100mg/5mL(p) 1 ML 2.38 484(E) 02.02.2023 91 Cefotaxime Powder for Injection 250 mg 1 Vial 17.71 87(E) 06.01.2023 92 Cefotaxime Powder for Injection 500 mg 1 Vial 24.37 87(E) 06.01.2023 93 Cefotaxime Powder for Injection 1000mg 1 Vial 39.96 87(E) 06.01.2023 94 Ceftazidime Powder for Injection 1000mg 1 Vial 227.01 87(E) 06.01.2023 95 Ceftazidime Powder for Injection 250 mg 1 Vial 79.06 484(E) 02.02.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 57 Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 96 Ceftriaxone Powder for Injection 500 mg 1 Vial 50.27 87(E) 06.01.2023 97 Ceftriaxone Powder for Injection 250 mg 1 Vial 28.34 87(E) 06.01.2023 98 Ceftriaxone Powder for Injection 1000mg 1 Vial 62.38 87(E) 06.01.2023 99 Ceftriaxone Powder for Injection 2000mg 1 Vial 138.11 87(E) 06.01.2023 100 Cefuroxime Oralliquid 125mg/5mL(p) 1 ML 5.28 5939(E) 19.12.2022 101 Cetirizine Tablet 10mg 1 Tablet 1.88 194(E) 11.01.2023 102 Cetirizine Oral liquid 5mg/5mL(p) 1 ML 0.66 484(E) 02.02.2023 103 Chloroquine Tablet 150 mg 1 Tablet 1.16 194(E) 11.01.2023 104 Chloroquine Oral liquid 50mg/5mL 1 ML 0.33 194(E) 11.01.2023 105 Cholecalciferol Tablet 1000 IU 1 Tablet 4.30 5938(E) 19.12.2022 106 Cholecalciferol Oral liquid 400 IU/mL 1 ML 2.61 194(E) 11.01.2023 107 Solid oral dosage form 60000 22.50 484(E) 02.02.2023 Cholecalciferol IU Tablets 1 Tablet 108 Ciprofloxacin Tablet 250mg 1 tablet 2.19 87(E) 06.01.2023 109 Ciprofloxacin Tablet 500mg 1 tablet 4.24 87(E) 06.01.2023 110 Ciprofloxacin Drops 0.3 % 1 ML 1.53 194(E) 11.01.2023 111 Ciprofloxacin Injection 200mg/100mL 1 ML 0.20 194(E) 11.01.2023 112 Ciprofloxacin Ointment 0.3% 1 GM 1.28 879(E) 24.02.2023 113 Cisplatin Injection 1mg/mL 1 ML 7.08 879(E) 24.02.2023 114 Clarithromycin Tablet 250mg 1 Tablet 23.89 89(E) 06.01.2023 115 Clarithromycin Tablet 500mg 1 Tablet 39.83 89(E) 06.01.2023 116 Clarithromycin Oral liquid 125mg/5mL(p) 1 ML 4.60 194(E) 11.01.2023 117 Clindamycin Capsule 150mg 1 Capsule 16.35 5938(E) 19.12.2022 118 Clindamycin Capsule 300mg 1 Capsule 28.36 5938(E) 19.12.2022 119 Clindamycin Tablet 300mg 1 Tablet 18.97 194(E) 11.01.2023 120 Clobazam Tablet 5mg 1 Tablet 5.72 89(E) 06.01.2023 121 Clobazam Tablet 10mg 1 Tablet 9.84 89(E) 06.01.2023 122 Clomiphenecitrate Tablet 100 mg 1 Tablet 13.94 194(E) 11.01.2023 123 Clomiphenecitrate Tablet 50mg 1 Tablet 8.83 194(E) 11.01.2023 124 Clonazepam Tablet 0.25mg 1 Tablet 2.01 87(E) 06.01.2023 125 Clonazepam Tablet 0.5mg 1 Tablet 3.45 87(E) 06.01.2023 126 Clonazepam Tablet 1mg 1 Tablet 4.76 87(E) 06.01.2023 127 Clopidogrel Tablet 75mg 1 Tablet 6.66 87(E) 06.01.2023 128 Clopidogrel Tablet 150 mg 1 Tablet 20.48 195(E) 11.01.2023 129 Clozapine Tablet 25mg 1 Tablet 2.78 87(E) 06.01.2023 130 Clozapine Tablet 50mg 1 Tablet 5.19 87(E) 06.01.2023 131 Clozapine Tablet 100 mg 1 Tablet 8.45 87(E) 06.01.2023 132 Colchicine Tablet 0.5mg 1 Tablet 3.26 484(E) 02.02.2023 133 Cyclophosphamide Powder for Injection 500mg 1 Vial 73.48 194(E) 11.01.2023 134 Cycloserine Capsule250mg 1 Capsule 59.18 5938(E) 19.12.2022 135 Cyclosporine Capsule 25 mg 1 Capsule 28.04 194(E) 11.01.2023 136 Cyclosporine Oral liquid 100mg/mL(p) 1 ML 80.58 194(E) 11.01.2023 137 Cyclosporine Capsule 50 mg 1 Capsule 55.10 879(E) 24.02.2023 138 Cyclosporine Capsule 100mg 1 Capsule 103.10 879(E) 24.02.2023 139 Cytosine arabinoside Injection 1000mg/vial 1 Vial 1130.26 194(E) 11.01.2023 140 Cytosine arabinoside Injection 100mg/vial 1 Vial 139.58 484(E) 02.02.2023 141 Cytosine arabinoside Injection 500mg/vial 1 Vial 536.30 484(E) 02.02.2023 142 Dacarbazine Powder for Injection 200mg 1 Vial 381.72 87(E) 06.01.2023 143 Dacarbazine Powder for Injection 500mg 1 Vial 518.79 194(E) 11.01.2023 144 Daclatasvir Tablet 60mg 1 Tablet 199.95 5939(E) 19.12.2022 145 Darunavir Tablet 600mg 1 Tablet 154.42 5938(E) 19.12.2022 146 Dexamethasone Tablet 0.5mg 1 Tablet 0.22 484(E) 02.02.2023 147 Diazepam Tablet 5 mg 1 Tablet 1.62 194(E) 11.01.2023 148 Diazepam Injection 5mg/mL 1 ML 5.53 194(E) 11.01.2023 149 Diclofenac Tablet 50mg 1 Tablet 2.05 87(E) 06.01.202358 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 150 Diclofenac Injection 25mg/mL 1 ML 1.69 194(E) 11.01.2023 151 Diethylcarbamazine 1.67 5938(E) 19.12.2022 (DEC) Tablet 100mg 1 Tablet 152 Diethylcarbamazine 0.56 879(E) 24.02.2023 (DEC) Tablet 50mg 1 Tablet 153 Diethylcarbamazine 0.48 879(E) 24.02.2023 (DEC) Oral liquid 120mg/5mL(p) 1 ML 154 Digoxin Tablet 0.25mg 1 Tablet 1.33 87(E) 06.01.2023 155 Diltiazem Tablet 60mg 1 Tablet 5.46 87(E) 06.01.2023 156 Dinoprostone Gel 0.5mg 1 GM 84.71 879(E) 24.02.2023 157 Docetaxel Powder for Injection 20mg 1 Vial 2868.23 87(E) 06.01.2023 158 Docetaxel Powder for Injection 80mg 1 Vial 10333.12 194(E) 11.01.2023 159 Dolutegravir Tablet 50mg 1 Tablet 112.78 5939(E) 19.12.2022 160 Domperidone Tablet 10mg 1 Tablet 2.30 183(E) 11.01.2023 161 Domperidone Oral Liquid 1mg/mL 1 ML 1.24 194(E) 11.01.2023 162 Donepezil Tablet 10mg 1 Tablet 17.45 89(E) 06.01.2023 163 Donepezil Tablet 5mg 1 Tablet 12.10 89(E) 06.01.2023 164 Dopamine Injection 40mg/mL 1 ML 4.76 194(E) 11.01.2023 165 Doxycycline Capsule 100mg 1 Capsule 3.08 484(E) 02.02.2023 166 D-Penicillamine Capsule 250 mg 1 Capsule 15.65 194(E) 11.01.2023 167 Efavirenz Tablet 600mg 1 Tablet 70.59 194(E) 11.01.2023 168 Enalapril Tablet 5mg 1 Tablet 3.70 87(E) 06.01.2023 169 Enalapril Tablet 2.5mg 1 Tablet 2.18 87(E) 06.01.2023 170 Entecavir Tablet 1mg 1 Tablet 130.22 5938(E) 19.12.2022 171 Entecavir Tablet 0.5mg 1 Tablet 84.43 195(E) 11.01.2023 172 Erythropoietin Injection 2000IU/mL 1 ML 549.55 879(E) 24.02.2023 173 Erythropoietin Injection 10000 IU/mL 1 ML 1969.00 879(E) 24.02.2023 174 Escitalopram Tablet 5mg 1 Tablet 5.02 87(E) 06.01.2023 175 Escitalopram Tablet 10mg 1 Tablet 9.00 87(E) 06.01.2023 176 Escitalopram Tablet 20mg 1 Tablet 14.36 87(E) 06.01.2023 177 Ethambutol Tablet 600mg 1 Tablet 4.08 87(E) 06.01.2023 178 Ethambutol Tablet 800mg 1 Tablet 4.95 87(E) 06.01.2023 179 Ethambutol Tablet 400mg 1 Tablet 2.61 87(E) 06.01.2023 180 Ethinylestradiol (A)+ Tablet 0.03mg(A) + Tablet 3.17 87(E) 06.01.2023 Levonorgestrel (B) 0.15mg(B) 1 Tablet 181 Ethionamide Tablet 250mg 1 Tablet 14.81 5938(E) 19.12.2022 182 Etoposide Capsule 50mg 1 Capsule 56.63 194(E) 11.01.2023 183 Etoposide Injection 20mg/mL 1 ML 34.51 194(E) 11.01.2023 184 Filgrastim Injection 300mcg 1 Vial 1159.91 879(E) 24.02.2023 185 Fluconazole Tablet 400mg 1 Tablet 29.74 5938(E) 19.12.2022 186 Fluconazole Tablet 200mg 1 Tablet 17.45 87(E) 06.01.2023 187 Fluconazole Tablet 100mg 1 Tablet 7.62 87(E) 06.01.2023 188 Fluconazole Tablet 150mg 1 Tablet 12.06 194(E) 11.01.2023 189 Fluconazole Tablet 50mg 1 Tablet 9.67 485(E) 02.02.2023 190 Flunarizine Tablet 5mg 1 Tablet 2.47 5938(E) 19.12.2022 191 Flunarizine Tablet 10mg 1 Tablet 4.82 5938(E) 19.12.2022 192 Fluoxetine Capsule 20 mg 1 Capsule 3.99 5938(E) 19.12.2022 193 Fluoxetine Capsule 60 mg 1 Capsule 11.10 5938(E) 19.12.2022 194 Fluoxetine Capsule 40 mg 1 Capsule 6.49 5938(E) 19.12.2022 195 Fluoxetine Capsule 10 mg 1 Capsule 3.31 5938(E) 19.12.2022 196 Fluphenazine Injection 25mg/mL 1 ML 55.26 879(E) 24.02.2023 197 Folic Acid Tablet 5 mg 1 Tablet 1.51 194(E) 11.01.2023 198 Furosemide Tablet 40mg 1 Tablet 0.90 484(E) 02.02.2023 199 Furosemide Injection 10mg/mL 1 ML 2.99 879(E) 24.02.2023 200 Fusidic acid Cream 2 % 1 GM 9.83 879(E) 24.02.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 59 Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 201 Gefitinib Tablet 250mg 1 Tablet 237.12 484(E) 02.02.2023 202 Gemcitabine Powder for Injection 1000mg 1 Vial 5592.24 87(E) 06.01.2023 203 Gemcitabine Powder for Injection 200 mg 1 Vial 1299.72 87(E) 06.01.2023 204 Gentamicin Injection 10mg/mL 1 ML 2.41 879(E) 24.02.2023 205 Glimepiride Tablet 2mg 1 Tablet 5.79 89(E) 06.01.2023 206 Glimepiride Tablet 1mg 1 Tablet 3.70 89(E) 06.01.2023 207 Glucose Injection 25% 1 ML 0.20 879(E) 24.02.2023 208 Glyceryl trinitrate Injection 5mg/mL 1 ML 6.18 194(E) 11.01.2023 209 Glycopyrrolate Injection 0.2mg/mL 1 ML 14.53 194(E) 11.01.2023 210 Griseofulvin Tablet 250mg 1 Tablet 1.77 87(E) 06.01.2023 211 Haloperidol Tablet 1.5mg 1 Tablet 1.56 89(E) 06.01.2023 212 Haloperidol Tablet 5mg 1 Tablet 3.56 5938(E) 19.12.2022 213 Haloperidol Tablet 10mg 1 Tablet 4.77 5938(E) 19.12.2022 214 Haloperidol Oral liquid 2mg/5mL 1 ML 2.24 194(E) 11.01.2023 215 Halothane Liquid for inhalation 1 ML 6.09 879(E) 24.02.2023 216 Heparin Injection 1000IU/mL 1 ML 21.21 5938(E) 19.12.2022 217 Heparin Injection 5000IU/mL 1 ML 59.96 5938(E) 19.12.2022 218 Homatropine Drops 2% 1 ML 6.40 484(E) 02.02.2023 219 Hormone Releasing Contains 52 mg of 4103.29 1520(E) 29.03.2023 IUD Levonorgestrel 1 IUD 220 Human chorionic 417.45 879(E) 24.02.2023 gonadotropin Injection 5000 IU 1 Vial 221 Hydrochlorothiazide Tablet 25 mg 1 Tablet 1.74 194(E) 11.01.2023 222 Hydrochlorothiazide Tablet 12.5mg 1 Tablet 1.04 194(E) 11.01.2023 223 Hydrocortisone Powder for Injection 100mg 1 Vial 44.79 87(E) 06.01.2023 224 Hydrocortisone Tablet 10mg 1 Tablet 6.70 879(E) 24.02.2023 225 Hydrocortisone Powder for Injection 200mg 1 Vial 65.60 879(E) 24.02.2023 226 Hydrocortisone Tablet 5mg 1 Tablet 3.11 879(E) 24.02.2023 227 Hydrocortisone Tablet 20mg 1 Tablet 14.88 880(E) 24.02.2023 228 Hydroxy propylmethyl 29.20 879(E) 24.02.2023 cellulose Injection 2% 1 ML 229 Hydroxychloroquine Tablet 400mg 1 Tablet 13.80 5938(E) 19.12.2022 230 Hydroxychloroquine Tablet 200mg 1 Tablet 6.35 87(E) 06.01.2023 231 Hydroxyurea Capsule 500mg 1 Capsule 12.12 87(E) 06.01.2023 232 Ibuprofen Tablet 200mg 1 Tablet 0.70 87(E) 06.01.2023 233 Ibuprofen Tablet 400mg 1 Tablet 1.19 194(E) 11.01.2023 234 Ibuprofen Oral liquid 100mg/5mL(p) 1 ML 0.22 484(E) 02.02.2023 235 Imatinib Tablet 100mg 1 Tablet 69.75 87(E) 06.01.2023 236 Imatinib Tablet 400mg 1 Tablet 199.61 194(E) 11.01.2023 237 Insulin Intermediate 16.98 879(E) 24.02.2023 Acting (NPH) Injection 40IU/mL 1 ML 238 Iron sucrose Injection 20mg/mL 1 ML 57.40 879(E) 24.02.2023 239 Isoflurane Liquid for inhalation 1 ML 9.65 194(E) 11.01.2023 240 Isosorbide dinitrate Tablet 5mg 1 Tablet 0.81 5938(E) 19.12.2022 241 Isosorbide dinitrate Tablet 10mg 1 Tablet 0.80 879(E) 24.02.2023 242 Ispaghula Granules/Husk/Powder 1 GM 0.94 879(E) 24.02.2023 243 Itraconazole Oralliquid 10mg/mL 1 ML 4.94 5939(E) 19.12.2022 244 IUD containing 280.99 879(E) 24.02.2023 Copper As licensed 1 IUD 245 Ketamine Injection 50mg/mL 1 ML 12.12 484(E) 02.02.2023 246 Labetalol Injection 5mg/mL 1 ML 49.98 194(E) 11.01.2023 247 Lactulose Oral liquid 10 g/15mL 1 ML 1.23 194(E) 11.01.2023 248 Lamivudine Tablet 100mg 1 Tablet 10.40 5939(E) 19.12.2022 249 Lamivudine Tablet 150mg 1 Tablet 10.86 5939(E) 19.12.202260 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 250 Powder for Injection 5000 1034.81 87(E) 06.01.2023 L-Asparaginase KU 1 Vial 251 Powder for Injection 1707.64 87(E) 06.01.2023 L-Asparaginase 10000KU 1 Vial 252 Lenalidomide Capsule 5mg 1 Capsule 67.25 5939(E) 19.12.2022 253 Lenalidomide Capsule 25 mg 1 Capsule 292.25 195(E) 11.01.2023 254 Letrozole Tablet 2.5mg 1 Tablet 29.31 5938(E) 19.12.2022 255 Leuprolide acetate Powder for injection 22.5 mg 1 Vial 17080.55 195(E) 11.01.2023 256 Leuprolide acetate Powder for injection 11.25mg 1 Vial 9293.96 195(E) 11.01.2023 257 Leuprolide acetate Powder for injection 3.75 mg 1 Vial 3112.50 195(E) 11.01.2023 258 Levetiracetam Tablet 250mg 1 Tablet 6.30 89(E) 06.01.2023 259 Levetiracetam Tablet 500mg 1 Tablet 12.98 89(E) 06.01.2023 260 Modified Release Tablet 18.29 5938(E) 19.12.2022 Levetiracetam 750mg 1 Tablet 261 Levetiracetam Tablet 750mg 1 Tablet 19.34 89(E) 06.01.2023 262 Levetiracetam Oral liquid 100 mg/mL (p) 1 ML 3.96 194(E) 11.01.2023 263 Levetiracetam Injection 100mg/mL 1 ML 23.01 484(E) 02.02.2023 264 Levodopa (A) + Modified Release–Tablet 4.73 194(E) 11.01.2023 Carbidopa (B) 200mg (A) + 50mg (B) 1 Tablet 265 Levodopa (A) Tablet 100 mg (A) + 25 mg 2.57 5938(E) 19.12.2022 +Carbidopa(B) (B) 1 Tablet 266 Levodopa (A) Tablet 100 mg (A) + 10 mg 1.76 5938(E) 19.12.2022 +Carbidopa(B) (B) 1 Tablet 267 Levodopa (A) 4.41 5938(E) 19.12.2022 +Carbidopa(B) Tablet 250mg(A) +25mg(B) 1 Tablet 268 Levodopa (A) Modified Release–Tablet 100 2.79 879(E) 24.02.2023 +Carbidopa(B) mg (A) + 25 mg (B) 1 Tablet 269 Levofloxacin Tablet 250mg 1 Tablet 4.76 89(E) 06.01.2023 270 Levofloxacin Tablet 500mg 1 Tablet 8.80 89(E) 06.01.2023 271 Levofloxacin Tablet 750mg 1 Tablet 12.44 89(E) 06.01.2023 272 Levothyroxine Tablet 50mcg 1 Tablet 1.03 5938(E) 19.12.2022 273 Levothyroxine Tablet 75mcg 1 Tablet 1.43 5938(E) 19.12.2022 274 Levothyroxine Tablet 88 mcg 1 Tablet 1.64 5938(E) 19.12.2022 275 Levothyroxine Tablet 112 mcg 1 Tablet 1.65 5938(E) 19.12.2022 276 Levothyroxine Tablet 25 mcg 1 Tablet 1.44 5938(E) 19.12.2022 277 Levothyroxine Tablet 62.5mcg 1 Tablet 1.61 194(E) 11.01.2023 278 Levothyroxine Tablet 12.5mcg 1 Tablet 1.48 879(E) 24.02.2023 279 Levothyroxine Tablet 100mcg 1 Tablet 1.32 879(E) 24.02.2023 280 Levothyroxine Tablet 125mcg 1 Tablet 1.69 879(E) 24.02.2023 281 Lignocaine Topical forms 2-5 % 1 GM/ML 1.13 879(E) 24.02.2023 282 Lignocaine Injection 2% 1 ML 1.04 879(E) 24.02.2023 283 Linezolid Tablet 600mg 1 Tablet 35.66 5938(E) 19.12.2022 284 Lithium Tablet 300mg 1 Tablet 1.62 194(E) 11.01.2023 285 Loperamide Tablet 2mg 1 Tablet 2.27 5938(E) 19.12.2022 286 Lopinavir (A) + Tablet 200 mg (A) + 50mg 47.96 194(E) 11.01.2023 Ritonavir(B) (B) 1 Tablet 287 Lorazepam Tablet 1 mg 1 Tablet 2.30 5938(E) 19.12.2022 288 Lorazepam Tablet 2 mg 1 Tablet 2.81 5938(E) 19.12.2022 289 Magnesium sulphate Injection 500mg/mL 1 ML 4.86 879(E) 24.02.2023 290 Mannitol Injection 20 % 1 ML 0.34 194(E) 11.01.2023 291 Mebendazole Tablet 100 mg 1 Tablet 2.90 5938(E) 19.12.2022 292 Mebendazole Oral liquid 100mg/5mL(p) 1 ML 0.84 194(E) 11.01.2023 293 Medroxyprogesterone 6.24 194(E) 11.01.2023 acetate Tablet 10 mg 1 Tablet 294 Medroxyprogesterone Injection 150mg/mL 1 ML 289.74 195(E) 11.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 61 Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) acetate 295 Mefenamicacid Oral liquid 100mg/5mL(p) 1 ML 0.56 5938(E) 19.12.2022 296 Mefloquine Tablet 250 mg 1 Tablet 52.15 87(E) 06.01.2023 297 Meglumine diatrizoate Injection 60%w/v 1 ML 9.47 879(E) 24.02.2023 298 Meglumine diatrizoate Injection 76%w/v 1 ML 10.20 879(E) 24.02.2023 299 Mesna Injection 100mg/mL 1 ML 15.50 5938(E) 19.12.2022 300 Metformin Tablet 1000mg 1 Tablet 3.48 5938(E) 19.12.2022 301 Metformin Tablet 500mg 1 Tablet 2.01 89(E) 06.01.2023 302 Modified release Tablet 4.04 89(E) 06.01.2023 Metformin 1000mg 1 Tablet 303 Methotrexate Tablet 10mg 1 tablet 13.28 87(E) 06.01.2023 304 Methotrexate Tablet 2.5mg 1 tablet 5.31 87(E) 06.01.2023 305 Methylergometrine Tablet 0.125mg 1 Tablet 8.93 194(E) 11.01.2023 306 Methylergometrine Injection 0.2mg/mL 1 ML 14.94 484(E) 02.02.2023 307 Metoclopramide Tablet 10mg 1 Tablet 1.34 87(E) 06.01.2023 308 Injection 5mg/mL (Less than 2.66 879(E) 24.02.2023 Metoclopramide 10ML Pack) 1 ML 309 Metoprolol Tablet 25mg 1 Tablet 4.20 87(E) 06.01.2023 310 Metoprolol Tablet 50mg 1 Tablet 5.84 87(E) 06.01.2023 311 Modified Release Tablet 100 14.99 195(E) 11.01.2023 Metoprolol mg 1 Tablet 312 Metoprolol Tablet 100 mg 1 Tablet 11.13 195(E) 11.01.2023 313 Metronidazole Tablet 200mg 1 Tablet 0.81 87(E) 06.01.2023 314 Metronidazole Tablet 400mg 1 Tablet 1.52 87(E) 06.01.2023 315 Metronidazole Injection 500mg/100mL 1 ML 0.21 194(E) 11.01.2023 316 Metronidazole Oral liquid 200mg/5mL(p) 1 ML 0.51 194(E) 11.01.2023 317 Nasal Spray 1.25mg/ 216.80 195(E) 11.01.2023 Midazolam actuation 1 ML 318 Midazolam Nasal Spray 0.5 mg/actuation 1 ML 79.93 195(E) 11.01.2023 319 Midazolam Injection 1mg/mL 1 ML 5.92 879(E) 24.02.2023 320 Midazolam Injection 5mg/mL 1 ML 10.87 879(E) 24.02.2023 321 Mifepristone Tablet 200mg 1 Tablet 350.89 194(E) 11.01.2023 322 Misoprostol Tablet 200mcg 1 Tablet 18.97 5938(E) 19.12.2022 323 Misoprostol Tablet 100mcg 1 Tablet 9.92 194(E) 11.01.2023 324 Montelukast Tablet 4 mg 1 Tablet 10.03 5939(E) 19.12.2022 325 Tablet 5 mg (including 11.71 5939(E) 19.12.2022 Montelukast chewable Tablet s) 1 Tablet 326 Montelukast Tablet 10 mg 1 Tablet 16.43 5939(E) 19.12.2022 327 Morphine Injection 10mg/mL 1 ML 19.59 879(E) 24.02.2023 328 Morphine Injection 15mg/mL 1 ML 14.93 879(E) 24.02.2023 329 Moxifloxacin Tablet 400mg 1 Tablet 25.82 89(E) 06.01.2023 330 Mycophenolatemofetil Tablet 500mg 1 Tablet 73.87 5938(E) 19.12.2022 331 Mycophenolate 49.60 484(E) 02.02.2023 mofetil Tablet 250mg 1 Tablet 332 N-acetylcysteine Injection 200 mg/mL 1 ML 23.63 194(E) 11.01.2023 333 Naloxone Injection 0.4mg/mL 1 ML 92.72 194(E) 11.01.2023 334 Natamycin Drops 5% 1 ML 23.37 484(E) 02.02.2023 335 Neostigmine Injection 0.5mg/mL 1 ML 5.01 194(E) 11.01.2023 336 Neostigmine Tablet 15mg 1 Tablet 4.58 879(E) 24.02.2023 337 Nevirapine Tablet 200 mg 1 Tablet 15.79 5938(E) 19.12.2022 338 Nifedipine Tablet 10mg 1 Tablet 1.53 879(E) 24.02.2023 339 Nitrofurantoin Tablet 100 mg 1 Tablet 8.10 87(E) 06.01.2023 340 Noradrenaline Injection 2mg/mL 1 ML 20.17 879(E) 24.02.2023 341 Norethisterone Tablet 5mg 1 Tablet 5.39 87(E) 06.01.2023 342 Omeprazole Capsule 20 mg 1 Capsule 2.87 484(E) 02.02.202362 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 343 Ondansetron Tablet 4 mg 1 Tablet 5.13 194(E) 11.01.2023 344 Ondansetron Oral liquid 2mg/5mL(p) 1 ML 1.25 194(E) 11.01.2023 345 Ondansetron Injection 2mg/mL 1 ML 5.96 484(E) 02.02.2023 346 Injection 5 mg/mL in 10 mL 2233.82 194(E) 11.01.2023 Oxaliplatin vial 1 Vial 347 Oxytocin Injection 5 IU/mL 1 ML 17.83 484(E) 02.02.2023 348 Pantoprazole Injection 40mg 1 Vial 50.45 87(E) 06.01.2023 349 Paracetamol Tablet 650mg 1 Tablet 2.00 89(E) 06.01.2023 350 Paracetamol Oral Liquid 125 mg/5 mL (p) 1 ML 0.37 194(E) 11.01.2023 351 Paracetamol Oral Liquid 250 mg/5 mL (p) 1 ML 0.67 194(E) 11.01.2023 352 Paracetamol Oral liquid 120 mg/5 mL (p) 1 ML 0.60 194(E) 11.01.2023 353 Paracetamol Tablet 500mg 1 Tablet 0.89 484(E) 02.02.2023 354 1 6.66 484(E) 02.02.2023 Paracetamol Suppository 80mg Suppository 355 1 7.94 484(E) 02.02.2023 Paracetamol Suppository 170mg Suppository 356 Phenobarbitone Tablet 30mg 1 Tablet 1.31 87(E) 06.01.2023 357 Phenobarbitone Tablet 60mg 1 Tablet 1.89 194(E) 11.01.2023 358 Phenobarbitone Injection 200mg/mL 1 ML 22.14 194(E) 11.01.2023 359 Phenobarbitone Oral liquid 20mg/5mL (p) 1 ML 0.49 879(E) 24.02.2023 360 Phenytoin Tablet 300mg 1 Tablet 5.48 87(E) 06.01.2023 361 Phenytoin Injection 50mg/mL 1 ML 5.95 194(E) 11.01.2023 362 Phytomenadione 53.08 879(E) 24.02.2023 (Vitamin K1) Injection 10mg/mL 1 ML 363 Pilocarpine Drops 2 % 1 ML 10.83 879(E) 24.02.2023 364 Piperacillin (A) Powder for Injection 99.65 87(E) 06.01.2023 +Tazobactam(B) 1000mg(A)+125mg(B) 1 Vial 365 Piperacillin (A) Powder for Injection 191.53 87(E) 06.01.2023 +Tazobactam(B) 2000mg(A)+250mg(B) 1 Vial 366 Piperacillin (A) Powder for Injection 399.38 87(E) 06.01.2023 +Tazobactam(B) 4000mg(A)+500mg(B) 1 Vial 367 Potassium chloride Oral liquid 500mg/5mL 1 ML 0.30 194(E) 11.01.2023 368 Potassium chloride Injection 150mg/mL 1 ML 2.39 879(E) 24.02.2023 369 Povidone iodine Solution 5% 1 ML 0.43 879(E) 24.02.2023 370 Povidone iodine Solution 7.5% 1 ML 0.81 879(E) 24.02.2023 371 Povidone iodine Solution 10% ( 1 ML 0.96 879(E) 24.02.2023 372 Pralidoxime chloride 4.56 194(E) 11.01.2023 (2-PAM) Injection 25mg/mL 1 ML 373 Prednisolone Tablet 40mg 1 Tablet 3.40 194(E) 11.01.2023 374 Prednisolone Oral liquid 5mg/5mL(p) 1 ML 0.49 194(E) 11.01.2023 375 Prednisolone Oral liquid 15mg/5mL(p) 1 ML 0.86 194(E) 11.01.2023 376 Prednisolone Tablet 10mg 1 Tablet 1.19 484(E) 02.02.2023 377 Prednisolone Tablet 5mg 1 Tablet 0.68 484(E) 02.02.2023 378 Prednisolone Tablet 20mg 1 Tablet 2.39 484(E) 02.02.2023 379 Prednisolone Drops 1% 1 ML 5.76 879(E) 24.02.2023 380 Primaquine Tablet 7.5mg 1 Tablet 2.37 87(E) 06.01.2023 381 Primaquine Tablet 15mg 1 Tablet 5.13 484(E) 02.02.2023 382 Proparacaine Eye Drops0.5% 1 ML 10.24 194(E) 11.01.2023 383 Propofol Injection 10mg/mL 1 ML 6.50 879(E) 24.02.2023 384 Propranolol Tablet 40mg 1 Tablet 3.21 87(E) 06.01.2023 385 Propranolol Tablet 10mg 1 Tablet 1.31 87(E) 06.01.2023 386 Propranolol Tablet 20mg 1 Tablet 3.19 195(E) 11.01.2023 387 Protamine Sulphate Injection 10mg/mL 1 ML 9.77 879(E) 24.02.2023 388 Pyrazinamide Tablet 1000mg 1 Tablet 10.52 87(E) 06.01.2023 389 Pyrazinamide Tablet 500mg 1 Tablet 4.88 87(E) 06.01.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 63 Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 390 Pyrazinamide Tablet 750mg 1 Tablet 7.20 87(E) 06.01.2023 391 Pyrazinamide Tablet 1500mg 1 Tablet 11.80 879(E) 24.02.2023 392 Pyridoxine Tablet 100 mg 1 Tablet 5.97 484(E) 02.02.2023 393 Quinine Tablet 300 mg 1 Tablet 5.65 87(E) 06.01.2023 394 Rabies vaccine As licensed 1 Vial 378.69 879(E) 24.02.2023 395 Raltegravir Tablet 400mg 1 Tablet 147.78 5938(E) 19.12.2022 396 Ramipril Tablet 2.5 mg 1 Tablet 5.21 5938(E) 19.12.2022 397 Ramipril Tablet 5mg 1 Tablet 8.18 5938(E) 19.12.2022 398 Ribavirin Capsule 200 mg 1 Capsule 26.49 194(E) 11.01.2023 399 Rifampicin Capsule 600mg 1 Capsule 11.35 5938(E) 19.12.2022 400 Rifampicin Capsule 450mg 1 Capsule 5.67 87(E) 06.01.2023 401 Rifampicin Capsule 150mg 1 Capsule 2.28 194(E) 11.01.2023 402 Rifampicin Capsule 300mg 1 Capsule 4.60 194(E) 11.01.2023 403 Rifampicin Oral liquid 100mg/5mL(p) 1 ML 0.47 879(E) 24.02.2023 404 Risperidone Tablet 1 mg 1 Tablet 3.02 89(E) 06.01.2023 405 Risperidone Tablet 2 mg 1 Tablet 4.48 5938(E) 19.12.2022 406 Risperidone Tablet 4 mg 1 Tablet 7.35 5938(E) 19.12.2022 407 Risperidone Oral liquid 1mg/mL 1 ML 2.20 194(E) 11.01.2023 408 Ritonavir Tablet 100mg 1 Tablet 29.20 484(E) 02.02.2023 409 Rituximab Injection 10mg/mL 1 ML 761.76 484(E) 02.02.2023 410 Salbutamol Tablet 4 mg 1 Tablet 0.21 87(E) 06.01.2023 411 Salbutamol Tablet 2 mg 1 Tablet 0.17 87(E) 06.01.2023 412 Salbutamol Oral liquid 2mg/5mL 1 ML 0.17 194(E) 11.01.2023 413 Inhalation (MDI/DPI) 0.49 484(E) 02.02.2023 Salbutamol 100mcg/dose 1 Dose 414 Respirator Solution (Solution 0.68 484(E) 02.02.2023 Salbutamol for Nebulizer 5mg/mL) 1 ML 415 Salicylic acid Ointment 3-6% (6%) 1 GM 2.01 879(E) 24.02.2023 416 Sodium bicarbonate Injection (as per IP) - 8.4% 1 ML 1.34 484(E) 02.02.2023 417 Sodium Valproate Tablet 300mg 1 Tablet 4.46 5938(E) 19.12.2022 418 Sodium Valproate Oral liquid 200mg/5mL(p) 1 ML 0.65 484(E) 02.02.2023 419 Sodium Valproate Tablet 200mg 1 Tablet 3.58 879(E) 24.02.2023 420 Modified Release – Tablet 9.28 879(E) 24.02.2023 Sodium Valproate 500mg 1 Tablet 421 Sodium Valproate Tablet 500mg 1 Tablet 8.11 879(E) 24.02.2023 422 Modified Release – Tablet 6.09 879(E) 24.02.2023 Sodium Valproate 300mg 1 Tablet 423 Sodium Valproate Injection 100mg/mL 1 ML 6.74 879(E) 24.02.2023 424 Sofosbuvir Tablet 400mg 1 Tablet 525.08 5938(E) 19.12.2022 425 Spironolactone Tablet 50mg 1 Tablet 4.37 194(E) 11.01.2023 426 Spironolactone Tablet 25mg 1 Tablet 2.18 484(E) 02.02.2023 427 Streptokinase Injection 15,00,000IU 1 Vial 1877.23 194(E) 11.01.2023 428 Streptomycin Powder for Injection 750 mg 1 Vial 10.10 194(E) 11.01.2023 429 Streptomycin Powder for Injection 1000mg 1 Vial 10.86 194(E) 11.01.2023 430 Sulfasalazine Tablet 500 mg 1 Tablet 4.72 87(E) 06.01.2023 431 Tacrolimus Capsule 0.5mg 1 Capusle 20.66 5938(E) 19.12.2022 432 Tacrolimus Capsule 1mg 1 Capusle 40.62 5938(E) 19.12.2022 433 Tacrolimus Capsule 2mg 1 Capusle 84.33 5938(E) 19.12.2022 434 Tamoxifen Tablet 20mg 1 Tablet 2.94 87(E) 06.01.2023 435 Tamoxifen Tablet 10mg 1 Tablet 2.20 87(E) 06.01.2023 436 Telmisartan Tablet 20mg 1 Tablet 3.87 89(E) 06.01.2023 437 Telmisartan Tablet 40mg 1 Tablet 6.76 5938(E) 19.12.2022 438 Telmisartan Tablet 80mg 1 Tablet 10.40 89(E) 06.01.2023 439 Temozolomide Capsule 20 mg 1 Capsule 441.31 5938(E) 19.12.2022 440 Temozolomide Capsule 250mg 1 Capsule 4303.77 5938(E) 19.12.202264 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Strength Unit Ceiling price Existing S.O. No. & No (wef 1.4.2023 Date with WPI @ 12.1218%) (1) (2) (3) (4) (5) 6(a) 6(b) 441 Temozolomide Capsule 100mg 1 Capsule 1508.62 194(E) 11.01.2023 442 Tenecteplase Injection 40mg/vial 1 Vial 50386.90 195(E) 11.01.2023 443 Tenecteplase Injection 30mg/vial 1 Vial 36907.98 195(E) 11.01.2023 444 Tenofovir Alafenamide 48.87 88(E) 06.01.2023 Fumarate (TAF) Tablet 25mg 1 Tablet 445 Tenofovir Disproxil Fumarate (A) + Tablet 300mg (A) + 45.57 194(E) 11.01.2023 Lamivudine (B) 300mg(B) 1 Tablet 446 Tenofovir Disproxil Fumarate (A) 102.83 194(E) 11.01.2023 +Lamivudine (B)+ Tablet 300mg(A)+ 300mg (B) Efavirenz(C) + 600mg(C) 1 Tablet 447 Tenofovir Disproxil 45.83 194(E) 11.01.2023 Fumarate (TDF)* Tablet 300mg 1 Tablet 448 Thalidomide Capsule 50 mg 1 Capsule 31.15 87(E) 06.01.2023 449 Thalidomide Capsule 100mg 1 Capsule 62.01 87(E) 06.01.2023 450 Thiamine Tablet 100 mg 1 Tablet 4.46 194(E) 11.01.2023 451 Thiamine Injection 100 mg/mL 1 ML 22.59 879(E) 24.02.2023 452 Timolol Drops 0.5 % 1 ML 13.39 194(E) 11.01.2023 453 Tiotropium Inhalation (MDI) 9 mcg/dose 1 MD 2.78 879(E) 24.02.2023 454 Tiotropium Inhalation (DPI) 18mcg/dose 1 DP 10.70 879(E) 24.02.2023 455 Injection 50mg/mL (upto 2ml 11.78 484(E) 02.02.2023 Tramadol pack) 1 ML 456 Tranexamic acid Injection 100 mg/mL 1 ML 13.71 194(E) 11.01.2023 457 Tranexamic acid Tablet 500 mg 1 Tablet 18.54 194(E) 11.01.2023 458 Trastuzumab Injection 440mg/50mL 1 Vial 54722.18 194(E) 11.01.2023 459 Trihexyphenidyl Tablet 2mg 1 Tablet 1.36 879(E) 24.02.2023 460 Tropicamide Eye drop 1 % 1 ML 9.42 194(E) 11.01.2023 461 Valganciclovir Tablet 450 mg 1 Tablet 400.71 5939(E) 19.12.2022 462 Vancomycin Powder for Injection 500 mg 1 Vial 317.61 194(E) 11.01.2023 463 Vancomycin Powder for Injection 1000mg 1 Vial 470.23 194(E) 11.01.2023 464 Vancomycin Powder for Injection 250 mg 1 Vial 251.24 194(E) 11.01.2023 465 Vecuronium Powder for injection 10mg Each Vial 117.35 5938(E) 19.12.2022 466 Vecuronium Powder for injection 4 mg Each Vial 74.40 5938(E) 19.12.2022 467 Verapamil Tablet 80 mg 1 Tablet 1.59 484(E) 02.02.2023 468 Verapamil Tablet 40mg 1 Tablet 0.86 484(E) 02.02.2023 469 Vincristine Injection 1mg/mL 1 ML 57.51 484(E) 02.02.2023 470 Xylometazoline Nasal drops 0.05 % 1 ML 4.19 484(E) 02.02.2023 471 Xylometazoline Nasal drops 0.1% 1 ML 5.12 484(E) 02.02.2023 472 Zidovudine (A) Tablet +Lamivudine (B) 300mg(A)+150mg(B)+200mg 21.13 484(E) 02.02.2023 +Nevirapine(C) (c) 1 Tablet 473 Zidovudine (A) 21.09 87(E) 06.01.2023 +Lamivudine(B) Tablet 300mg(A)+150mg(B) 1 Tablet 474 Zoledronic acid Powder for Injection 4mg 1 Vial 2391.91 194(E) 11.01.2023 475 Zolpidem Tablet 5mg 1 Tablet 6.21 89(E) 06.01.2023 476 Zolpidem Tablet 10mg 1 Tablet 8.51 5938(E) 19.12.2022 Notes: - (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 65 formulations. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength. (c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the manufacturer shall approach NPPA for specific price approval for its formulations. (d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. (e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI @ 12.1218% for year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013. (f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director66 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1575(अ).— Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk- vk- 487¼v½ fnukad 02.02.2023 को 'kqf)&i= के साथ पढें vkn's k ds vf/kØe.k es a tgk¡ rd mldk lEcU/k uhp s dh lkj.kh ^d* से संबंथित है। uhp s nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ es a fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LrHa k ¼2½ eas dh xbZ rRLFkkuh izfof"V eas fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i es a fu;r djrh gSA @ 12.1218% @ 12.1218% (1) (2) (3) (4) (5) 1 मेंनीिोल यरू ो हेड के साथ प्लास्टिक बोतल में गैर-ग्लास कंिेनर में प्रतत लमली 0.40 पकै ेज के ललए 100 लमली पकै में इंजेक्शन 20% की ववशेष ववशेषताए ं हैं मैससच ओत्सुका फामाचस्ट्यटु टकल इंजडया प्राजलजमटेड . मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड मेससच सजर्न पैरेंटेरल प्रा. जलजमटेड 12.1218% (5) vkn's k dk- vk- 487¼v½ fnukad 02.02.2023 को 'kqf)&i= के साथ पढें 12.1218% (5)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 67 कोई अन्य जवजनमाचता िो जविेि सुजवधाओं वाले पैकेिों में मेंनीटोल यूरो हेड के साथ प्लाजस्ट्टक बोतल में गैर-ग्लास कंटेनर में पैकेि के जलए 100 जमली पैक में इंिेक्ट्िन 20% की जविेि जविेिताएं ह,ैं के जलए अलग अजधकतम मूल्य का िावा करता ह ैतो वह अलग अजधकतम मूल्य अनुमोिन के जलए एनपीपीए को आवेिन करेगा। यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐस ेसंिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप म ें इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू -च संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) (1) u II I ञ II III II IV [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1575(E).— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 487(E) dated 02.02.2023 read with corrigendum,in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:68 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Table A Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef01.04.2023 with WPI @ 12.1218%) (1) (2) (3) (4) (5) 1 Mannitol Injection 20% in 100 ml pack for Per ml 0.40 packages in non-glass container in plastic bottle with euro head having special features TABLE ‘B’ Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. 4 M/s Sachin Parenteral Pvt. Ltd. Note : (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 487(E) dated 02.02.2023 read with corrigendum(plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022over 2021in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 69 information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1576(अ).— Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk- vk- 486¼v½ fnukad 02.02.2023 को 'kqf)&i= के साथ पढें vkn's k ds vf/kØe.k eas tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* eas fofufeZr से हैं। uhp s nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ es a fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LrHa k ¼2½ eas dh xbZ rRLFkkuh izfof"V eas fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i es a fu;r djrh gSA @ 12.1218% @ 12.1218% (1) (2) (3) (4) (5) 1 मेट्रोतनडाजोल यूरो हेड के साथ प्लास्टिक बोतल में गैर-ग्लास प्रतत लमली 0.24 कंिेनर में पकै ेज के ललए 100लमली पकै में इंजेक्शन )0.5%डब्ललू/वी(/ 500 लमलीग्राम/ 100लमली ववशेष ववशेषताए ं हैं मैसस स ओत्सुका फामासटयुटिकल इंडडया प्रा .लललमिेड मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड . मेससच सजर्न पैरेंटेरल प्रा. जलजमटेड 12.1218%70 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (5) dk- vk- 486¼v½ fnukad 02.02.2023 को 'kqf)&i= के साथ पढें 12.1218% (5) कोई अन्य जवजनमातच ा िो जविेि सुजवधाओं वाले पकै ेिों में मेरोजनडािोल इंिक्ट्े िन यूरो हडे के साथ प्लाजस्ट्टक बोतल म ें गैर-ग्लास कंटेनर में पकै ेि के जलए 100जमली पैक में इंिेक्ट्िन (0.5%डब्लू/वी)/ 500 जमलीग्राम/ 100जमली जवििे जविेिताए ं ह,ैं के जलए अलग अजधकतम मूल्य का िावा करता ह ै तो वह अलग अजधकतम मूल्य अनुमोिन के जलए एनपीपीए को आवेिन करेगा। यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐस ेसंिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप म ें इलक्ट्े रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू -च संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) (1) u II I ञ II III II IV [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 71 ORDER New Delhi, the 31st March, 2023 S.O. 1576(E).— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 486(E) dated 02.02.2023 read with corrigendum, in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: Table A Price Revision as per Annual Wholesale Price Index (WPI) @ 12.1218% increase. Sl. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2023 No. with WPI @ 12.1218%) (1) (2) (3) (4) (5) 1 Metronidazole Injection (0.5%w/v) /500mg/100ml in Per ml 0.24 100ml pack for packages in non-glass container in plastic bottle with euro head having special features TABLE ‘B’ Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. 4 M/s Sachin Parenteral Pvt. Ltd Note : (a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 486(E) dated 02.02.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for year 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in72 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1577(अ).— नवम्बर 4, 6, 10, 11, 14, 16, मािच अधिक्रमण और डीपीसीओ के पैरा (1) के तहत 12.1218% के थोक मल्ू य सिू कांक )डब्लल्यूपीआई( म ेंवधृि हुई ह,ै जैसा धक 1.04.2023 स े ) ) 12.1218% (1) (2) (3) (4) (5) (6) 1 ,flVktkys kekbM dSIlwy 250 fexzk- 1 dSIlwy 4.5 5.04 ,lhVkbylSyhflfy ,afVªd dksfVM xksyh 75 fexzk- 1 xksyh 0.31 0.34 2 d ,flM ,lhVkbylSyhflfy dkWuosu'kuy@bQsjoslasV@fMLijflcy 1 xksyh 0.63 0.70 3 d ,flM @,afVªd dksfVM xksyh 150 fexzk- 4 ,flDyksohj vksjy fyD;wbZM 400 fexzk-@5 fefy- 1 fefy- 1.21 1.35[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 73 12.1218% 5 ,ycsMa ktksy vksjy fyD;wbZM 200 fexzk-@5 fefy- 1 fefy- 1.6 1.79 6 ,ycsMa ktksy xksyh 400 fexzk- 1 xksyh 6.28 7.04 7 ,ycsMa ktksy च्बेवेबल xksyh 400 fexzk- 1 xksyh 7.25 8.12 vksjy fyD;wbZM 250 fexzk-@5 fefy- ,eksDlhflfyu 1 fefy- 1.39 1.55 8 (पी( ,EQksVsfjflu ,EQksVsfjflu ch&dkWuosu'kuy batSD'ku 1 वाईल 202.81 227.39 9 ch&dkWuosu'kuy 50 fexzk-/ वाईल ,LdksZfcd ,flM xksyh 100 fexzk- 1 xksyh 0.21 0.23 10 ¼foVkfeu lh½ ,LdksZfcd ,flM xksyh 500 fexzk- 1 xksyh 1.32 1.48 11 ¼foVkfeu lh½ 12 ,VªkD;wfj;e batSD'ku 10 fexzk-@fefy- 1 fefy- 15.14 16.97 13 ,ftFkzksekblhu dSIlwy 250 fexzk- 1 dSIlwy 9.47 10.61 14 chVkesFklksu batSD'ku 4 fexzk-@fefy- 1 fefy- 4.23 4.74 jls fijVs kWjh lkys q'ku QkWj ;wt bu cqMslksukbM 1 fefy- 10.61 11.89 15 ucs qykbtj 0-5 fexzk-@fefy- jls fijVs kWjh lkys q'ku QkWj ;wt bu cqMslksukbM 1 fefy- 11.72 13.14 16 ucs qykbtj 1 fexzk-@fefy- 17 cqfiokdsu batSD'ku 0-5% ds lkFk 7-5% Xydw kst 1 fefy- 6.59 7.38 18 cqfiokdsu batSD'ku 0-50% 1 fefy- 3.94 4.41 19 cqfiokdsu batSD'ku 0-25% 1 fefy- 2.52 2.82 20 dSQhu batSD'ku 20 fexzk-@fefy- 1 fefy- 223.41 250.49 21 dSykekbu yks'ku ¼vkbZih ds vuqlkj½ 1 fefy- 0.85 0.95 22 lsfQDlhe dSIlwy 200 fexzk- 1 dSIlwy 13.09 14.67 23 dkWysdsfYlQsjksy dSIlwy 60000 vkbZ;w 1 dSIlwy 27.45 30.77 24 dkWysdsfYlQsjksy dSIlwy 1000 vkbZ;w 1 dSIlwy 4.36 4.88 vksjy fyD;wbZM 250 fexzk-@5 fefy- flizks¶yksDlkflu 1 fefy- 0.66 0.74 25 (पी( 26 Dyksehizkekbu xksyh 10 fexzk- 1 xksyh 2.54 2.84 27 Dyksehizkekbu xksyh 25 fexzk- 1 xksyh 5.55 6.22 28 Dyksehizkekbu xksyh 75 fexzk- 1 xksyh 14.68 16.45 29 DyksfVªektksy yks'ku 1% 1 fefy- 3.47 3.89 30 DyksfVªektksy isljh 100 fexzk- 1 isljh 8.93 10.01 31 DyksfVªektksy MªksIl 1% 1 fefy- 3.01 3.37 32 DyksfVªektksy Øhe 1% 1 xzke 2.68 3.00 dks&Vªk;eksDlktkys [lYQkesFkkWDlklsy xksyh 400 fexzk- ¼,½ $ 80 fexzk- ¼ch½ 1 xksyh 0.8 0.89 ¼,½$VªheFs kksizhe 33 ¼ch½]] dks&Vªk;eksDlktksy vksjy fyD;wbZM 200 fexzzk-¼,½ $ 40 1 fefy- 0.31 0.34 34 [lYQkesFkkWDlklsy fexzk- ¼ch½@5 fefy-74 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 12.1218% ¼,½$VªheFs kksizhe ¼ch½]] lkbDyksQkslQkekb xksyh 50 fexzk- 1 xksyh 3.33 3.73 35 M 36 lkbDykslfsju xksyh 250 fexzk- 1 xksyh 41.04 46.01 batSD'ku 4 fexzk-@fefy- ¼izfr iSd 10 MsDlkeFs kklksu 1 fefy- 1.4 1.56 37 fefy-½ batSD'ku 4 fexzk-@fefy- ¼izfr iSd 20 MsDlkeFs kklksu 1 fefy- 1.2 1.34 38 fefy-½ batSD'ku 4 fexzk-@fefy- ¼izfr iSd 30 MsDlkeFs kklksu 1 fefy- 0.8 0.89 39 fefy-½ 40 Mk;tsike xksyh 2 fexzk- 1 xksyh 1.28 1.43 41 Mk;tsike lqIiksftVªh 5 fexzk- 1 lqIiksftVªh 5.52 6.18 batSD'ku 10 fexzk-@fefy-¼10 fefy- iSd fMlkbDyksekbu 1 fefy- 2.96 3.31 42 से कम½ batSD'ku 10 fexzk-@fefy-¼10 fefy- और fMlkbDyksekbu 1 fefy- 1.87 2.09 43 अधिक iSd½ 44 डायजोधक्सन vksjy fyD;wbZM 0-05 fexzk-@ fefy- 1 fefy- 1.31 1.46 45 डायजोधक्सन batSD'ku 0-25 fexzk-@fefy- 1 fefy- 3.45 3.86 46 MkbyfV;ktse xksyh 30 fexzk- 1 xksyh 2.39 2.67 47 MkbyfV;ktse batSD'ku 5 fexzk-@fefy- 1 fefy- 3.12 3.49 48 MkscqVkekbu batSD'ku 50 fexzk-@fefy- 1 fefy- 8.05 9.02 49 MksDlks:fclhu batSD'ku 2 fexzk-@fefy- 1 fefy- 28.32 31.75 50 MksDlhlkblyhu xksyh 100 fexzk- 1 xksyh 1.09 1.22 MhihVh$fgc$gsi ch izfr 0-1 लाइसेंस के अनसु ार 67.47 75.64 51 oSDlhu fefy- 52 bQkohjsta xksyh 200 fexzk- (पी( 1 xksyh 20.1 22.53 batSD'ku 40 fexzk-@0-4 fefy- buksDlkikfju 0-1 fefy- 99.87 111.97 53 batSD'ku 60 fexzk-@0-6 fefy- 54 bleksyksy batSD'ku 10 fexzk-@fefy- 1 fefy- 23.53 26.38 55 bFkkecqVksy xksyh 200 fexzk- 1 xksyh 1.02 1.14 56 ¶ydw ksuktkys dSIlwy 200 fexzk- 1 dSIlwy 35.77 40.10 57 ¶ydw ksuktkys dSIlwy 150 fexzk- 1 dSIlwy 17.14 19.21 izfr 100 ¶ydw ksuktkys batSD'ku 200 fexzk-@100 fefy- 82.34 92.32 58 fefy- वाईल 59 Qqjksles kbM vksjy fyD;wbZM 10 fexzk-@fefy- 1 fefy- 2.96 3.31 batSD'ku 40 fexzk-@fefy- ¼izfr iSd 10 tsaVkekbflu 1 fefy- 1.35 1.51 60 fefy-½ batSD'ku 40 fexzk-@fefy- ¼izfr iSd 20 tsaVkekbflu 1 fefy- 1.38 1.54 61 fefy-½ batSD'ku 40 fexzk-@fefy- ¼izfr iSd 30 tsaVkekbflu 1 fefy- 1.1 1.23 62 fefy-½[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 75 12.1218% fXyljkby lcfyaxq,y xksyh 0-5 fexzk- 1 xksyh 1.13 1.26 63 VªkbZfuVªsV 64 gsyksisfjMksy batSD'ku 5 fexzk-@fefy- 1 fefy- 5.81 6.51 65 gsyksisfjMksy xksyh 20 fexzk- 1 xksyh 4.78 5.35 gsikVkbfVl ch लाइसेंस के अनसु ार 1 वाईल 4903.95 5498.39 66 bEequksXykscqfyu gSikVkbfVl ch लाइसेंस के अनसु ार 1 fefy- 70.3 78.82 67 oSDlhu 68 vkbZQksLQkekbM batSD'ku ds fy, ikmMj 2000 fexzk- 1 वाईल 573.59 643.11 69 vkbZQksLQkekbM batSD'ku ds fy, ikmMj 1000 fexzk- 1 वाईल 284.46 318.94 70 befsVuhc dSIlwy 100 fexzk- 1 dSIlwy 65.54 73.48 71 balqfyu ¼lksyqcy½ batSD'ku 40 vkbZ;w@fefy- 1 fefy- 15.15 16.98 72 bvksgsDlksy batSD'ku 300 fexzk- vk;ksfMu@fefy- 1 fefy- 15.07 16.89 73 लेवोथायरोधक्सन गोली 150 एमसीजी 1 गोली 1.52 1.70 74 fyXuksdsu batSD'ku 1% 1 fefy- 7.91 8.86 75 fyXuksdsu batSD'ku 5% Xywdkst 7-5% ds lkFk 1 fefy- 3.12 3.49 fyXuksdsu ¼,½ $ batSD'ku 2% ¼,½ $ 1%200000 ¼5 1 fefy- 0.94 1.05 76 ,Mªus kykbu ¼ch½ ,elhth@fefy-½ ¼ch½ 77 yis sjkekbM dSIlwy 2 fexzk- 1 dSIlwy 3.38 3.78 78 yksjktsike batSD'ku 2 fexzk-@fefy- 1 fefy- 7.22 8.09 79 efsuVksy batSD'ku 10% 1 fefy- 0.17 0.19 80 eQs susfed ,flM xksyh 250 fexzk- 1 xksyh 1.88 2.10 81 eFs kksVªDs lsV xksyh 5 fexzk- 1 xksyh 8.41 9.42 82 eSfFkyizsMuhlksyksu batSD'ku 40 fexzk-@fefy- 1 fefy- 40.73 45.66 batSD'ku 5 fexzk-@fefy- ¼10 fefy- और eVs ksDyksizkekbM 1 fefy- 1.45 1.62 83 अधिक iSd½ 84 मेटोक्लोप्रमाइड ओरल धलधक्वड 5 धमलीग्राम/5धम.ली. (पी) 1 धम.ली. 0.45 0.50 85 eVs ksizksyksy dSIlwy 25 fexzk- 1 dSIlwy 3.69 4.13 86 eVs ksizksyksy dSIlwy 50 fexzk- 1 dSIlwy 5.19 5.81 87 fuQsfMikbu dSIlwy 10 fexzk- 1 dSIlwy 0.85 0.95 88 धनVªksQqjuटोइन dSIlwy 100 fexzk- 1 dSIlwy 7.71 8.64 89 fuVªksQqjuटोइन vksjy fyD;wbZM 25 fexzk-@5 fefy- 1 fefy- 0.79 0.88 90 vksesizktkys xksyh 20 fexzk- 1 xksyh 3.87 4.33 91 vksesizktkys dSIlwy 10 fexzk- 1 dSIlwy 2.15 2.41 vksjy fyD;wbZM ds fy, ikmMj 20 vksesizktkys 1 xzke 1.35 1.51 92 fexzk- 93 vksesizktkys dSIlwy 40 fexzk- 1 dSIlwy 7.54 8.45 94 ओडं ान्सेट्रॉन गोली 8 धमलीग्राम 1 गोली 8.08 9.05 95 vksjy fjgkbMªs'ku ykblsla ds :i eas 1 fefy- 0.13 0.1476 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 12.1218% lkYVl 96 vkWDlhVkslhu batSD'ku 10 vkbZ;w@fefy- 1 fefy- 35.56 39.87 batSD'ku 30 fexzk-@5 fefy-batSD'ku isdyhVsDlsy 1 fefy- 192.14 215.43 97 100 fexzk-@16-7 fefy- 98 ieZsFkzhu Øhe 5% 1 xzke 1.65 1.85 99 ieZsFkzhu yks'ku 1% 1 fefy- 0.89 0.99 100 ieZsFkzhu Øhe 1% 1 xzke 1.34 1.50 1 fefy- ieZsFkzhu yks'ku 5% 0.89 0.99 101 @xzke 102 Qsuhjkekbu batSD'ku 22-75 fexzk-@fefy-¼2 fefy-½ 1 fefy- 2.46 2.75 103 Qsuhjkekbu batSD'ku 22-75 fexzk-@fefy-¼10 fefy-½ 1 fefy- 1.84 2.06 104 QsuhVksbu मोडीफाइड ररलीज xksyh 300 fexzk- 1 xksyh 5.86 6.57 105 QsuhVksbu xksyh 100 fexzk- 1 xksyh 1.57 1.76 106 QsuhVksbu xksyh 50 fexzk- 1 xksyh 0.75 0.84 107 QsuhVksbu vksjy fyD;wbZM 30 fexzk-@5 fefy- (पी) 1 fefy- 0.31 0.34 vksjy fyD;wbZM 125 fexzk-@5 fefy- QsuhVksbu 1 fefy- 0.98 1.09 108 (पी) 109 QsuhVksbu dSIlwy 300 fexzk- 1 dSIlwy 4.15 4.65 110 QsuhVksbu dSIlwy 100 fexzk- 1 dSIlwy 1.63 1.82 QkbVksesukMhvksu xksyh 10 fexzk- 1 xksyh 12.97 14.54 111 ¼foVkfeu ds1½ izsfeDl balqfyu 30%70 bta SD'ku batSD'ku 40 vkbZ;w@fefy- 1 fefy- 15.15 16.98 112 ¼jsxqyj%,uih,p½ 113 izhekDohu xksyh 2-5 fexzk- 1 xksyh 1.56 1.74 114 izksizkuksyksy dSIlwy 40 fexzk- 1 dSIlwy 3.79 4.24 115 ikbfjMksDlhu xksyh 10 fexzk- 1 xksyh 0.1 0.11 116 कुनेन batSD'ku 300 fexzk-@fefy- 1 fefy- 8.47 9.49 117 jkfeizhy dSIlwy 2-5 fexzk- 1 dSIlwy 4.16 4.66 118 jkfeizhy dSIlwy 5 fexzk- 1 dSIlwy 6.41 7.18 119 lsoks¶ywjku bugsy's ku के धलये धलक़ुड 1 fefy- 27.8 31.16 lksfM;e batSD'ku (आईपी के अनुसार) 7-5% 1 fefy- 0.9 1.00 120 ckbdkcksZusV 121 lksekVksLVkVhu batSD'ku ds fy, ikmMj 3 fexzk- 1 वाईल- 1212.01 1358.92 122 VVs ul VkWDlkbM batSD'ku (5 जमली.) 1 वाईल- 22.77 25.53 1 वाईल -¼0-5 VVs ul VkWDlkbM batSD'ku (0.5 जमली.) 11.12 12.46 123 fefy-½ 124 VªkekMksy dSIlwy 50 fexzk- 1 dSIlwy 4.3 4.82 125 VªkekMksy dSIlwy 100 fexzk- 1 dSIlwy 8.06 9.03 126 foVkfeu , xksyh 50000 vkbZ;w (च्यूएबल गोली सजहत) 1 xksyh 0.65 0.72 127 foVkfeu , batSD'ku 50000 vkbZ;w@fefy- 1 fefy- 2.02 2.26 एनएलईएम 2022 के तहत तय की गई उपरोक्त उच्चतम कीमतें थोक मूल्य सूर्कांक (डब्ल्यूपीआई) के लागू होने के बाि 1 अप्रैल 2023 से प्रभावी होंगी और िैसा दक ऊपर कॉलम (6) में जनर्िष्टच ह।ै[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 77 सधहत (5) सधहत और धफर वे 1 अप्रैल 2023 स े डब्लल्यपू ीआई 12.1218% के स्तर तक को छोड़कर( म ेंसमान वधृि कर सकत ेहैं जो उपरोक्त सारणी म ें )6( म ेंधनधदष्टच अधिकतम कीमतों स ेअधिक नहीं ह।ै (2) और व े1 अप्रैल, 2023 से एमआरपी में 12.1218% की दर से डब्लल्यपू ीआई के स्तर तक इसी तरह की वधृि कर सकते ह।ैं (6) एनोक्ट्सापैटरन इंिेक्ट्िन 40 जमलीग्राम /0.4 जम.ली. ml और 60 जमलीग्राम /0.6 जम.ली. के जलए अजधकतम कीमत ें जनधाचटरत की गई ह ैं िो क्र. स. 53 समान अनपु ात यानी 10 जमलीग्राम/0.1 जम.ली. के साथ एनोक्ट्सापैटरन की दकसी भी अन्य प्रबलता (िैसे 300 जमलीग्राम /3 जम.ली., 80 जमलीग्राम /0.8 जम.ली., 20 जमलीग्राम /0.2 जम.ली. आदि) पर भी लाग ूहोते ह।ैं ¼p½ पैजक्ट्लटैक्ट्सेल इंिेक्ट्िन 30 जमलीग्राम/5 जम.ली. और 100 जमलीग्राम/16.7 जम.ली. के जलए अजधकतम कीमतें जनधाचटरत की गई ह ैं िो क्र. स. 97 समान अनपु ात यानी 6 जमलीग्राम / जम.ली. के साथ पैजक्ट्लटैक्ट्सेल की दकसी भी अन्य ताकत (िसै े 300 जमलीग्राम /50 जम.ली., 260 जमलीग्राम /43.4 जम.ली., 250 जमलीग्राम /41.7 जम.ली., 200 जमलीग्राम /33.4 जम.ली. आदि) पर भी लाग ूहोते ह।ैं (छ) नेब्यलु ाइजर 0.5 जमलीग्राम / जम.ली. में उपयोग के जलए बुडसे ोनाइड रेजस्ट्परेटर सॉल्यिू न के जलए जनधाचटरत अजधकतम मूल्य और नेब्युलाइजर 1 जमलीग्राम / जम.ली. में उपयोग के जलए बुडसे ोनाइड रेजस्ट्परेटर सॉल्यूिन, 0.5 जमलीग्राम के 2 जम.ली. रेस्ट्प्यल्ू स और 1 जमलीग्राम के 2 जम.ली. रेस्ट्प्यूल्स पर भी 2 बार आवेिन करके लाग ू होते ह।ैं क्रमिः 0.5 जमलीग्राम और 1 जमलीग्राम के 1 जम.ली. के अजधकतम मूल्य। ¼ि½ यदि संिोधन दकया िाता ह ैतो, इसकी सर्ू ना ऐसे संिोधनों को दकए िाने के पद्रं ह दिनों के भीतर की अवजध में प्रपत्र-।। के रूप में इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सर्ू ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V ञ (4) धवक्रेता सस्ु पष्ट (ट) (1) II I (ठ) के धनमाचता अनु II III78 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] का वह II IV (ड) (ढ) गई उनका जाएगा [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1577(E).— In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11thNovember, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No.1499(E) dated 30thMarch, 2022in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the ceiling prices exclusive of goods and services tax applicable, if any, as specified in column (5) and increased by Wholesale Price Index (WPI) of 12.1218% under para 16 (1) of DPCO 2013, with effect from 1.04.2023 as specified in column (6) of the table in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) (6) (1) (2) (3) (4) (5) Acetazolamide Capsule 250mg 1 Capsule 4.5 5.04 1 Acetylsalicylic acid Enteric coated Tablet 75 mg 1 Tablet 0.31 0.34 2 Conventional/Effervescent/ Acetylsalicylic acid Dispersible/ Enteric coated 1 Tablet 0.63 0.70 3 Tablets 150 mg Acyclovir Oral liquid 400mg/5mL (p) 1 ML 1.21 1.35 4 Albendazole Oral liquid 200mg/5mL(p) 1 ML 1.6 1.79 5 Albendazole Tablet 400mg 1 Tablet 6.28 7.04 6 Albendazole Chewable Tablet 400mg 1 Tablet 7.25 8.12 7 Amoxicillin Oral liquid 250 mg/5 mL (p) 1 ML 1.39 1.55 8 Amphotericin B Amphotericin B (conventional) - Injection 1 Vial 202.81 227.39 9 50mg/vial[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 79 Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) Ascorbic acid (Vitamin Tablet 100mg 1 Tablet 0.21 0.23 10 C) Ascorbic acid (Vitamin Tablet 500mg 1 Tablet 1.32 1.48 11 C) Atracurium Injection 10 mg/ml 1 ML 15.14 16.97 12 Azithromycin Capsule250mg 1 Capsule 9.47 10.61 13 Betamethasone Injection 4mg/mL 1 ML 4.23 4.74 14 Respirator solution for use Budesonide 1 ML 10.61 11.89 15 in nebulizer 0.5mg/mL Respirator solution for use Budesonide 1 ML 11.72 13.14 16 in nebulizer 1mg/mL Injection 0.5 % with 7.5 % Bupivacaine 1 ML 6.59 7.38 17 glucose Bupivacaine Injection 0.5 % 1 ML 3.94 4.41 18 Bupivacaine Injection 0.25% 1 ML 2.52 2.82 19 Caffeine Injection 20mg/mL Per ML 223.41 250.49 20 Calamine Lotion (As per IP) 1 ML 0.85 0.95 21 Cefixime Capsule 200mg 1 Capsule 13.09 14.67 22 Cholecalciferol Capsule 60000 IU 1 Capsule 27.45 30.77 23 Cholecalciferol Capsule 1000 IU 1 Capsule 4.36 4.88 24 Ciprofloxacin Oral liquid 250mg/5mL(p) 1 ML 0.66 0.74 25 Clomipramine Tablet 10 mg 1 Tablet 2.54 2.84 26 Clomipramine Tablet 25 mg 1 Tablet 5.55 6.22 27 Clomipramine Tablet 75 mg 1 Tablet 14.68 16.45 28 Clotrimazole Lotion 1% 1 ML 3.47 3.89 29 Clotrimazole Pessary 100mg 1 Pessary 8.93 10.01 30 Clotrimazole Drops 1% 1 ML 3.01 3.37 31 Clotrimazole Cream1% 1 GM 2.68 3.00 32 Co-trimoxazole Tablet 400 mg (A) + 80 mg [Sulphamethoxazole (A) 1 Tablet 0.8 0.89 (B) 33 +Trimethoprim(B)]* Co-trimoxazole Oral liquid 200 mg (A) + 40 [Sulphamethoxazole(A) 1 ML 0.31 0.34 mg(B)/5mL(p) 34 +Trimethoprim(B)]* Cyclophosphamide Tablet 50mg 1 Tablet 3.33 3.73 3580 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) Cycloserine Tablet 250mg 1 Tablet 41.04 46.01 36 Injection 4mg/mL (Pack of Dexamethasone 1 ML 1.4 1.56 37 10ML) Injection 4mg/mL (Pack of Dexamethasone 1 ML 1.2 1.34 38 20 ML) Injection 4mg/mL (Pack of Dexamethasone 1 ML 0.8 0.89 39 30ML) Diazepam Tablet 2 mg 1 Tablet 1.28 1.43 40 1 Diazepam Suppository 5mg 5.52 6.18 41 Suppository Injection 10mg/mL (Less Dicyclomine 1 ML 2.96 3.31 42 than 10ML Pack) Injection 10mg/mL (10 ML Dicyclomine 1 ML 1.87 2.09 43 & more pack)) Digoxin Oral liquid0.05mg/mL 1 ML 1.31 1.46 44 Digoxin Injection 0.25mg/mL 1 ML 3.45 3.86 45 Diltiazem Tablet 30mg 1 Tablet 2.39 2.67 46 Diltiazem Injection 5mg/mL 1 ML 3.12 3.49 47 Dobutamine Injection 50 mg/ml 1 ML 8.05 9.02 48 Doxorubicin Injection2mg/mL 1 ML 28.32 31.75 49 Doxycycline Tablet100mg 1 Tablet 1.09 1.22 50 DPT+ Hib+ Hep B As licensed Per 0.1 ML 67.47 75.64 51 Vaccine Efavirenz Tablet 200 mg (p) 1 Tablet 20.1 22.53 52 Injection40mg/0.4mL , Enoxaparin 0.10 ML 99.87 111.97 53 injection 60mg/0.6 ml Esmolol Injection10 mg/mL 1 ML 23.53 26.38 54 Ethambutol Tablet 200mg 1 Tablet 1.02 1.14 55 Fluconazole Capsule 200mg 1 Capsule 35.77 40.10 56 Fluconazole Capsule 150mg 1 Capsule 17.14 19.21 57 Per 100 ML Fluconazole Injection 200mg/100mL 82.34 92.32 58 Vial Furosemide Oralli quid 10mg/mL 1 ML 2.96 3.31 59 Injection 40mg/mL (Pack of Gentamicin 1 ML 1.35 1.51 60 10ml) Injection 40mg/mL (Pack of Gentamicin 1 ML 1.38 1.54 61 20ml) Injection 40mg/mL Pack of Gentamicin 1 ML 1.1 1.23 62 30ml)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 81 Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) Glyceryl trinitrate Sublingual Tablet 0.5mg 1 Tablet 1.13 1.26 63 Haloperidol Injection 5mg/mL 1 ML 5.81 6.51 64 Haloperidol Tablet 20mg 1 Tablet 4.78 5.35 65 Hepatitis B As Licensed 1 Vial 4903.95 5498.39 66 immunoglobulin Hepatitis B vaccine As Licensed 1 ML 70.3 78.82 67 Powder for Injection Ifosfamide 1 Vial 573.59 643.11 68 2000mg Powder for Injection Ifosfamide 1 Vial 284.46 318.94 69 1000mg Imatinib Capsule 100mg 1 Capsule 65.54 73.48 70 Insulin (Soluble) Injection 40 IU/ml 1 ml 15.15 16.98 71 Iohexol Injection 300mg iodine/mL 1 ML 15.07 16.89 72 1.52 1.70 73 Levothyroxine Tablet 150 mcg 1 Tablet Lignocaine Injection 1% 1 ML 7.91 8.86 74 Injection 5% with 7.5% Lignocaine 1 ML 3.12 3.49 75 glucose Lignocaine (A) Injection2%(A)+1:200000(5 1 ML 0.94 1.05 76 +Adrenaline(B) mcg/mL)(B) Loperamide Capsule 2mg 1 Capsule 3.38 3.78 77 Lorazepam Injection 2mg/mL 1 ML 7.22 8.09 78 Mannitol Injection 10 % 1 ML 0.17 0.19 79 Mefenamic acid Tablet 250 mg 1 Tablet 1.88 2.10 80 Methotrexate Tablet 5mg 1 Tablet 8.41 9.42 81 Methylprednisolone Injection 40mg/mL 1 ML 40.73 45.66 82 Injection 5mg/mL (10 ML Metoclopramide 1 ML 1.45 1.62 83 & More Pack) 0.45 0.50 84 Metoclopramide Oral liquid 5mg/5mL(p) 1 ML Metoprolol Capsule 25mg 1 Capsule 3.69 4.13 85 Metoprolol Capsule 50mg 1 Capsule 5.19 5.81 86 Nifedipine Capsule10mg 1 Capsule 0.85 0.95 87 Nitrofurantoin Capsule 100 mg 1 Capsule 7.71 8.64 88 Nitrofurantoin Oral liquid 25mg/5mL(p) 1 ML 0.79 0.88 8982 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) Omeprazole Tablet 20 mg 1 Tablet 3.87 4.33 90 Omeprazole Capsule 10 mg 1 Capsule 2.15 2.41 91 Omeprazole Powder for oral liquid 20mg 1 GM 1.35 1.51 92 Omeprazole Tablet 40 mg 1 Tablet 7.54 8.45 93 8.08 9.05 94 Ondansetron Tablet 8 mg 1 Tablet Oral rehydration salts As licensed 1 ML 0.13 0.14 95 Oxytocin Injection 10IU/mL 1 ML 35.56 39.87 96 Injection 30 mg/5 mL, Paclitaxel 1 ML 192.14 215.43 97 injection 100 mg/16.7 ml Permethrin Cream 5% 1 GM 1.65 1.85 98 Permethrin Lotion 1% 1 ML 0.89 0.99 99 Permethrin Cream 1% 1 GM 1.34 1.50 100 Permethrin Lotion 5% 1 ML/GM 0.89 0.99 101 Pheniramine Injection 22.75mg/mL (2ml) 1 ML 2.46 2.75 102 Injection 22.75mg/mL Pheniramine 1 ML 1.84 2.06 103 (10ml) Modified Release Tablet Phenytoin 1 Tablet 5.86 6.57 104 300mg Phenytoin Tablet 100mg 1 Tablet 1.57 1.76 105 Phenytoin Tablet 50mg 1 Tablet 0.75 0.84 106 Phenytoin Oral liquid 30mg/5 mL(p) 1 ML 0.31 0.34 107 Phenytoin Oral liquid 125mg/5mL(p) 1 ML 0.98 1.09 108 Phenytoin Capsule 300mg 1 Capsule 4.15 4.65 109 Phenytoin Capsule 100mg 1 Capsule 1.63 1.82 110 Phytomenadione Tablet 10mg 1 Tablet 12.97 14.54 111 (Vitamin K1) Insulin Premix 30:70 Injection 40 IU /ml 1 ml 15.15 16.98 112 Injection (Regular:NPH) Primaquine Tablet 2.5mg 1 Tablet 1.56 1.74 113 Propranolol Capsule 40mg 1 Capsule 3.79 4.24 114 Pyridoxine Tablet 10mg 1 Tablet 0.1 0.11 115 Quinine Injection 300 mg/mL 1 ML 8.47 9.49 116[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 83 Ceiling Ceiling price Price Fixed (wef 1.4.2023 Name of the Scheduled Sl. No. Dosage form and strength Unit under with WPI @ Formulation NLEM, 2022 12.1218%) (Rs.) Ramipril Capsule 2.5mg 1 Capsule 4.16 4.66 117 Ramipril Capsule 5mg 1 Capsule 6.41 7.18 118 Sevoflurane Liquid for inhalation 1 ML 27.8 31.16 119 Sodium bicarbonate Injection (as per IP) - 7.5% 1 ML 0.9 1.00 120 Somatostatin Powder for Injection 3mg 1 Vial 1212.01 1358.92 121 Tetanus toxoid As licensed (5ml) 1 Vial 22.77 25.53 122 1 Vial Tetanus toxoid As licensed (0.5ml) 11.12 12.46 123 (0.5ML) Tramadol Capsule 50mg 1 Capsule 4.3 4.82 124 Tramadol Capsule 100mg 1 Capsule 8.06 9.03 125 Tablet 50000IU (including Vitamin A 1 Tablet 0.65 0.72 126 Chewable Tablet) Vitamin A Injection 50000IU/mL 1 ML 2.02 2.26 127 Notes: (a) The above mentioned ceiling prices as fixed under NLEM 2022 shall be effective from 1st April, 2023 after application of Wholesale Price Index (WPI) and as specified in column (6) above. (b) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any and then they may further make corresponding increase in MRP (excluding GST) upto the level of WPI @12.1218% with effect from 1st April, 2023 not exceeding ceiling prices as specified in column (6) in the above table. (c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus GST as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 and they may further make corresponding increase in MRP upto the level of WPI @12.1218% with effect from 1st April, 2023. (d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table. (e) The ceiling prices fixed for Enoxaparin Injection 40mg/0.4ml and 60 mg/0.6 ml at S.N. 53are also applicable to any other strengths (such as 300mg/3ml, 80mg/0.8ml, 20mg/0.2ml etc.) of the Enoxaparin with same ratio i.e. 10mg/0.1ml). (f) The ceiling prices fixed for Paclitaxel Injection 30 mg/5 mL and 100mg/16.7 ml at S.N. 97 are also applicable to any other strengths (300mg/50ml, 260mg/43.4ml, 250mg/41.7ml, 200mg/33.4ml etc.) of the Paclitaxel with same ratio i.e. 6mg/ml). (g) The ceiling prices fixed for Budesonide Respirator solution for use in nebulizer 0.5mg/mL and Budesonide Respirator solution for use in nebulizer 1mg/mL are also applicable to 2ml respules of 0.5mg and 2ml respules of 1mg by applying 2 times of the ceiling prices of 1 ml respules of 0.5 mg and 1 mg respectively. (h) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price84 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (MRP), alongwith interest thereon from the date of overcharging. (i) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (j) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (k) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (l) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (m) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (n) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1578(अ).— नवम्बर 4, 6, 10, 11, 14, 16, तथा के , (जिसको संजिप्त रूप में एनपीपीए कहा िाता है), और डीपीसीओ के पैरा (1) के तहत 12.1218% के थोक मल्ू य सिू कांक )डब्लल्यपू ीआई( म ें वधृि हुई है, जैसा धक 1.04.2023 से ) ) 12.1218% (1) (2) (3) (4) (5) (6) 1 इंिेक्ट्िन के जलए पाउडर एमोजक्ट्सजसजलन 1 वाईल 22.11 24.79 250 जमलीग्राम 2 इंिेक्ट्िन के जलए पाउडर एमोजक्ट्सजसजलन 1 वाईल 48.74 54.64 500 जमलीग्राम[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 85 3 अजैजथयोप्राइन गोली 25 जमलीग्राम (पी) 1 गोली 6.46 7.24 4 एजजथ्रोमाइजसन गोली 1000 जमलीग्राम 1 गोली 51.53 57.77 5 बेंजोइल पेरोक्ट्साइड िेल 3.5% 1 ग्राम 9.02 10.11 6 सेफ्यूरोजक्ट्सम गोली 500 जमलीग्राम 1 गोली 45.87 51.43 7 सैसे पाउडर/ ग्रेनुअल्स/ कॉलेकैजल्सफेरॉल 1 ग्राम 30.31 33.98 60000 आईयू 8 डेक्ट्सामेथासोन गोली 4 जमलीग्राम 1 गोली 4.12 4.61 9 आइवरमेजक्ट्टन गोली 6 जमलीग्राम 1 गोली 19.25 21.58 10 आइवरमेजक्ट्टन गोली 12 जमलीग्राम 1 गोली 33.33 37.37 11 जलनेिोजलड गोली 300 जमलीग्राम 1 गोली 20.2 22.64 12 इंिेक्ट्िन 1 जमलीग्राम / 1 मेटोप्रोलोल 3.03 3.39 .ली.जम जम.ली. 13 प्रोप्रानोलोल कैप्सूल 20 जमलीग्राम 1 कैप्सूल 2.1 2.35 14 प्रोप्रानोलोल कैप्सूल 10 जमलीग्राम 1 कैप्सूल 1.78 1.99 15 वैनकॉमायजसन कैप्सूल 250 जमलीग्राम 1 कैप्सूल 135.91 152.38 एनएलईएम 2022 के तहत तय की गई उपरोक्त उच्चतम कीमतें थोक मल्ू य सर्ू काकं (डब्ल्यूपीआई) के लागू होने के बाि 1 अप्रैल 2023 से प्रभावी होंगी और िैसा दक ऊपर कॉलम (6) में जनर्िष्टच ह।ै सधहत (5) सधहत और दफर व े1 अप्रैल 2023 से डब्ल्यूपीआई 12.1218% के स्ट्तर तक को छोड़कर) में समान वृजि कर सकते हैं िो उपरोक्त सारणी में (6) में जनर्िष्टच अजधकतम कीमतों से अजधक नहीं ह।ै (2) और व े1 अप्रैल, 2023 से एमआरपी में 12.1218% की दर से डब्लल्यपू ीआई के स्तर तक इसी तरह की वधृि कर सकते ह।ैं (6) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- ।। के रूप में इलक्ट्े रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू च-संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (छ( (4) धवक्रेता सस्ु पष्ट86 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ज (1) II I के धनमाचता अनु II III का वह II IV ञ (ट) गई उनका जाएगा [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1578(E).— In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11thNovember, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the ceiling prices exclusive of goods and services tax applicable, if any, as specified in column (5) and increased by Wholesale Price Index (WPI) of 12.1218% under para 16 (1) of DPCO 2013 , with effect from 1.04.2023 as specified in column (6)of the table in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Ceiling Ceiling price Price (wef 1.4.2023 Fixed with WPI @ Sl. Name of the Scheduled Dosage form and strength Unit under 12.1218%) No. Formulation NLEM, 2022 (Rs.) (1) (2) (3) (4) (5) (6) 1 Amoxicillin Powder for Injection 250 mg 1 Vial 22.11 24.79 2 Amoxicillin Powder for Injection 500 mg 1 Vial 48.74 54.64 3 Azathioprine Tablet 25mg(p) 1 Tablet 6.46 7.24 4 Azithromycin Tablet 1000mg 1 Tablet 51.53 57.77 5 Benzoylperoxide Gel 3.5% 1 GM 9.02 10.11 6 Cefuroxime Tablet 500mg 1 Tablet 45.87 51.43 7 Sachet/Granuels/Powder 60000 Cholecalciferol 1 GM 30.31 33.98 IU 8 Dexamethasone Tablet 4 mg 1 Tablet 4.12 4.61 9 Ivermectin Tablet 6mg 1 Tablet 19.25 21.58 10 Ivermectin Tablet 12mg 1 Tablet 33.33 37.37 11 Linezolid Tablet 300mg 1 Tablet 20.2 22.64 12 Metoprolol Injection 1mg/ML 1 ML 3.03 3.39 13 Propranolol Capsule 20mg 1 Capsule 2.1 2.35 14 Propranolol Capsule 10mg 1 Capsule 1.78 1.99 15 Vancomycin Capsule 250mg 1 Capsule 135.91 152.38[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 87 Notes: (a) The above mentioned ceiling prices as fixed under NLEM 2022 shall be effective from 1st April, 2023 after application of Wholesale Price Index (WPI) and as specified in column (6) above. (b) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any and then they may further make corresponding increase in MRP (excluding GST) upto the level of WPI @12.1218% with effect from 1st April, 2023 not exceeding ceiling prices as specified in column (6) in the above table. (c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus GST as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 and they may further make corresponding increase in MRP upto the level of WPI @12.1218% with effect from 1st April, 2023. (d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1579(अ).—िबदक िवाओं/फॉमूचलेिनों की कीमतें जनधाटचरत/संिोजधत, जनगरानी करने के जलए और िग (मूल्य जनयंत्रण) आििे (डीपीसीओ) के कायाचन्वयन की िखे रेख के जलए भारत सरकार के रसायन और उवचरक मंत्रालय के दिनांक 29 अगस्ट्त 1997 के संकल्प संख्या 33/7/97-PI.I के माध्यम से राष्ट्रीय औिध मूल्य जनधाचरण प्राजधकरण (NPPA) की स्ट्थापना की गई थी; और िबदक भारत सरकार द्वारा आवश्यक वस्ट्तु अजधजनयम, 1955 (1955 का 10) की धारा 3 और 5 द्वारा प्रित्त िजक्तयों का प्रयोग करते हुए दिनांक 30 मई 2013 के एस.ओ. 1349(ई) के माध्यम से डीपीसीओ, 2013 के पैरा 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,88 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 15, 16, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30 और 32 के संबंध में केंद्र सरकार के कायच करने के जलए एनपीपीए को िजक्तयों का प्रत्यायोिन दकया ह;ै 2. और िबदक आवश्यक वस्ट्तु अजधजनयम, 1955 की धारा 3 के तहत िारी डीपीसीओ, 2013 का उद्देश्य सभी को सस्ट्ती कीमतों पर आवश्यक िवाओं की उपलब्धता सुजनजित करना ह ैवस्ट्तु अजधजनयम, 1955, यह सुजनजित करने के जलए ह ैदक सभी उपलब्ध हों। 3. िबदक, औिध जवभाग (इसके बाि डीओपी के रूप में संिर्भचत) ने िग्स प्राइस कंरोल ऑडचर (इसके बाि डीपीसीओ के रूप में संिर्भचत) 2013 की अनुसूर्ी I को दिनांक 11.11.2022 के एस.ओ. 5249 (ई) के द्वारा आवश्यक िवाओं की राष्ट्रीय सूर्ी (इसके बाि एनएलईएम 2022 के रूप में संिर्भचत) के आधार पर संिोजधत दकया ह।ै 4. िबदक संिोजधत अनुसूर्ी I के तहत, कुछ नए फॉमूचलेिन िोड़े गए ह ैं िहां एक ही कंपनी के भीतर उच्च इंटर ब्रांड जभन्नता िखे ी गई ह।ै इस जवसंगजत को काफी हि तक इस तथ्य से समझाया िा सकता ह ै दक कुछ मामलों में, एक कंपनी के एक ही फॉमूचलेिन में जवजभन्न ब्रांडों के जलए 1000% तक की कीमत जभन्नता के साथ बहु प्रकार के मूल्य ह।ैं र्ूंदक ये फॉमूचलेिन एनएलईएम, उन्ह ेंएनएलईएम, 2015 के तहत इस प्रकार के गैर-अनुसूजर्त फॉमूचलेिन की कीमतों को तय करने के जलए व ेकंपजनयां स्ट्वतंत्र थीं। 5. िबदक, िवाओं पर स्ट्थायी सजमजत (एसएनसीएम) की जसफाटरि के आधार पर एनएलईएम 2022 में िाजमल नए िोड़े गए फॉमूचलेिन को आवश्यक िवाएं माना िाता ह।ै एसएनसीएम की 2022 की टरपोटच में यह भी कहा गया ह ै दक “आउट-ऑफ-पॉकेट व्यय कुल स्ट्वास्ट्थ्य व्यय का 60% से अजधक है, जिसमें िवाओं पर 40% का पयाचप्त खर्च होता ह।ै इस पृष्ठभूजम के साथ, यह सवोपटर है दक पटरवारों पर जवत्तीय बोझ को कम करने के जलए िवाओं की पहुंर् और सामथ्यच को बढाया िाए।” 6. िबदक, भारतीय प्रजतस्ट्पधाच आयोग ने 18 नवंबर 2021 को "भारत में फामाचस्ट्युटटकल सेक्ट्टर पर माकेट स्ट्टडी" िीिचक वाली अपनी टरपोटच में एक ही फॉमूचलेिन के ब्रांडों के बीर् अत्यजधक कीमत जभन्नता पर अनुभविन्य साक्ष्य भी प्रिान दकए ह।ैं टरपोटच में यह उल्लेख दकया गया ह ै दक "िैसा दक आंकड़ों से पता र्लता है, यह प्रतीत होता ह ै दक मिबूत सामान्य प्रजतस्ट्पधाच के बाविूि, प्रत्येक जर्दकत्सीय िेत्र में मौिूि जखलाजड़यों की संख्या और फॉमूचलेिनों/अणुओं के स्ट्तर के संिभच में, भारत में उपभोक्ता ब्राडं ों के जलए स्ट्पष्ट रूप से प्रीजमयम का भुगतान करते हैं”। 7. िबदक, एक कंपनी का एक ही फॉमूचलेिन जिसमें जवजभन्न ब्रांडों के जलए कई मूल्य हैं और फामाचस्ट्युटटकल िेत्र में इनजबल्ट मार्िचन और उच्च लाभ के साथ सूर्ना जविमता वाले ब्रांड, कई िवाओं को आम आिमी की पहुंर् से बाहर कर िते े हैं और जवत्तीय बोझ/गरीबी का कारण बनते ह।ैं यह एक असाधारण जस्ट्थजत ह ै िो बािार की जवफलता और लोक कल्याण के जखलाफ काम करने की ओर ले िाती ह।ै इसजलए, अनुसूजर्त फॉमूचलेिन के संबंध में सावचिजनक जहत में अंतर-ब्रांड मूल्य अंतर को कम करने के जलए एक प्रयास करना आवश्यक ह ैक्ट्योंदक इन फॉमूचलेिन को आवश्यक िवाएं माना िाता ह ैऔर पहली बार एनएलईएम, 2022 में िाजमल दकया गया है और इसजलए मूल्य जनयंत्रण से बाहर नहीं होना र्ाजहए। 8. िबदक, डीपीसीओ, 2013 के पैरा 20 के अनुसार, कोई भी जनमाचता जपछले बारह महीनों के िौरान गैर-अनुसूजर्त फॉमूचलेिन की कीमतों में 10% से अजधक की वृजि नहीं कर सकता है, िहां गैर-अनुसूजर्त फॉमूचलेिन की कीमतों म ें वृजि 10% से अजधक है, वहां जनमाचता अगले बारह महीनों के जलए एमआरपी को 10% के स्ट्तर तक कम कर िेगा। इस प्रकार, पैरा 20 ब्रांड को मान्यता नहीं िते ा है, और पैरा 20 के तहत जनगरानी फॉमूचलेिन के स्ट्तर पर की िाती ह।ै इसके अलावा, पैरा 20 उसी फॉमलूच ेिन की कीमत में वृजि को उस जस्ट्थजत के आधार पर अलग नहीं करता ह ैजिसके तहत ऐसी कीमत में वृजि हुई ह।ै सभी जस्ट्थजतयों म,ें जनमाचता कीमत को 10% के स्ट्तर तक कम करने के जलए बाध्य है। 9. िबदक, जवजभन्न ब्रांड नामों के तहत एक ही कंपजनयों द्वारा बेर् े िाने वाले एक ही फॉमूचलेिन के पीटीआर में जभन्नता में इस तरह की जवसंगजतयों को बािार की जवफलता और िन कल्याण के जखलाफ िाने वाली असाधारण पटरजस्ट्थजत माना िाता ह।ै इस प्रकार, प्राजधकरण न ेउजर्त जवर्ार-जवमिच के बाि जनणचय जलया दक सबसे कम ब्रांड/की कीमत पर दकसी जविेि कंपनी के फॉमूचलेिन के जवजभन्न ब्रांडों/पैक आकारों के पीटीआर को कैप करके बड़े अंतर ब्रांड/पैक आकार मूल्य जभन्नता को िरू करने के जलए इस तरह की कवायि करना आवश्यक हो िाता है। पैक साइि के साथ उन मामलों में 10% िहां गैर-अनुसूजर्त फॉमूचलेिन पहली बार एनएलईएम, 2022 के िायरे में आए ह।ैं 10. िबदक, पैरा 20 सजहत डीपीसीओ के प्रावधानों का उल्लंघन स्ट्वीकायच नहीं ह ै और एनएलईएम, 2022 के तहत अजधकतम कीमतों के जनधाचरण का आधार नहीं बनना र्ाजहए। इसजलए, उन मामलों में िहां गैर-अनुसूजर्त फॉमूचलेिन पहली बार एनएलईएम, 2022 के[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 89 िायरे में आत ेहैं, यदि समान फॉमलूच ेिन की कीमत में इंटर-ब्रांड जभन्नता 10% से अजधक है, तो जनमाचता DPCO, 2013 के प्रावधानों के अनुसार कीमत को 10% के स्ट्तर तक कम करने के जलए बाध्य है। 11. इसजलए, अब औिजध (मूल्य जनयंत्रण) आििे , 2013 के पैरा 19 द्वारा प्रित्त िजक्तयों का प्रयोग करते हुए, दिनांक 30 मई, 2013 के का.आ. 1394(ई) को भारत सरकार द्वारा रसायन और उवचरक मंत्रालय में िारी दकया गया, राष्ट्रीय औिध मूल्य जनधाचरण प्राजधकरण (इसके बाि एनपीपीए के रूप में संिर्भचत) एतिद्वारा लागू माल और सेवा कर, यदि कोई हो, को छोड़कर अजधकतम मूल्य जनधाचटरत करता ह।ै िैसा दक कॉलम (5) में जनर्िष्टच ह ै और डीपीसीओ 2013 के पैरा 16 (1) के तहत 12.1218% के होल सेल प्राइस इंडेक्ट्स (डब्ल्यूपीआई) से बढा है, 1.04.2023 से प्रभाव के रूप में ताजलका के कॉलम (6) में जनर्िष्टच ह।ै कजथत ताजलका के कॉलम (2) में तिनुरूपी प्रजवजष्ट में जनर्िष्टच अनुसूजर्त फॉमूचलेिन, क्रमिः कॉलम (3) और (4) में संबंजधत प्रजवजष्टयों में जनर्िष्टच खुराक का तरीका और स्ट्रेंथ और इकाई के साथ: ताजलका 12.1218% क्रम सं. (1) (2) (3) (4) (5) (6) 1 एजमकाजसन इंिेक्ट्िन 250 जमलीग्राम /जम.ली. 1 जम.ली. 48.31 54.16 2 ओरल जलदक्वड 125 जमलीग्राम /5 एमोजक्ट्ससीजलन 1 जम.ली. 0.91 1.02 जम.ली. (पी) 3 सेफ्रॉजक्ट्सम इंिेक्ट्िन 1500 जमलीग्राम 1 वाईल 302.12 338.74 4 जक्ट्लन्डामाईजसन इंिेक्ट्िन 150 जमलीग्राम / जम.ली. 1 जम.ली. 54.05 60.60 5 इंिेक्ट्िन के जलए पाउडर 100 डॉजक्ट्ससीजलन 1 वाईल 448.27 502.60 जमलीग्राम 6 जग्लसेटरन/ग्लीसेरॉल (आईपी में टॉजपकल-लोिन 1 जम.ली. 1.1 1.23 उल्लेख दकए गए अनुसार) 7 जग्लसेटरन/ग्लीसेरॉल (आईपी में टॉजपकल - क्रीम 1 ग्राम 2.11 2.36 उल्लेख दकए गए अनुसार) 8 जग्लसेटरन/ग्लीसेरॉल (आईपी में इंिेक्ट्िन 10000 आईयू 1 वाईल 827.89 928.24 उल्लेख दकए गए अनुसार) 9 जग्लसेटरन/ग्लीसेरॉल (आईपी में इंिेक्ट्िन 2000 आईयू 1 वाईल 306.49 343.64 उल्लेख दकए गए अनुसार) 10 इंसुजलन ग्लार्िचन इंिेक्ट्िन 100 आईयू / जम.ली. 1 जम.ली. 181.45 203.44 11 इंिेक्ट्िन 140 to 350 जमलीग्राम आयोहक्ट्े सोल 1 जम.ली. 12.7 14.23 आयोजडन/जम.ली. (350जमलीग्राम) 12 इंिेक्ट्िन हते ु सॉल्यूिन 20 इटरनोटेकन एर्सीएलटरहाइिटे 1 जम.ली. 860.53 964.84 जमलीग्राम/जम.ली. 13 इराकोनािोल कैप्सूल 100 जमलीग्राम 1 कैप्सूल 14.87 16.67 14 इराकोनािोल कैप्सूल 200 जमलीग्राम 1 कैप्सूल 19.73 22.12 15 लेबेटालोल गोली 100 जमलीग्राम 1 गोली 13.52 15.15 16 इंिेक्ट्िन हते ु पाउडर 500 जमलीग्राम मेरोपेनम 1 वाईल 644.82 722.98 ( राइहाइिेट के रूप में) 17 इंिेक्ट्िन के जलये पाउडर 1000 मेरोपेनम 1 वाईल 849.69 952.68 जमलीग्राम ( राइहाइिेट के रूप में ) 18 मुजपरोजसन ओइंटमेंट 2% 1 ग्राम 18.1 20.2990 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 19 जनकोटीन (जनकोटीन टरप्लेसमेंट लॉिेंग 2 जमलीग्राम 1 लॉिेंग 7.06 7.91 थेरेपी के जलए) 20 जनकोटीन (जनकोटीन टरप्लेसमेंट गम 2 जमलीग्राम 1 गम 7.66 8.58 थेरेपी के जलए) 21 जनकोटीन (जनकोटीन टरप्लेसमेंट गम 4 जमलीग्राम 1 गम 9.49 10.64 थेरेपी के जलए) 22 N जनकोटीन (जनकोटीन लॉिेंग 4 जमलीग्राम 1 लॉिेंग 8.70 9.75 टरप्लेसमेंट थेरेपी के जलए) 23 ऑरमेलोजक्ट्सफेन (सेंटक्रोमन) गोली 30 जमलीग्राम 1 गोली 7.53 8.44 24 रोटा वाईरस वैजक्ट्सन लाईसेंस के अनुसार 1 वाईल 762.14 854.52 25 सेजलसाईकाजसड ओइंटमेंट 3-6% (3%) 1 ग्राम 1.84 2.06 26 टेनेजलजग्लजप्टन गोली 20जमलीग्राम 1 गोली 9.89 11.08 27 टर्बचनाफाईन क्रीम 1% 1 ग्राम 4.69 5.25 एनएलईएम 2022 के तहत तय की गई उपरोक्त उच्चतम कीमतें थोक मूल्य सूर्कांक (डब्ल्यूपीआई) के लागू होने के बाि 1 अप्रैल 2023 से प्रभावी होंगी और िैसा दक ऊपर कॉलम (6) में जनर्िष्टच ह।ै सधहत (5) सधहत और धफर वे 1 अप्रैल 2023 से डब्लल्यपू ीआई 12.1218% के स्तर तक को छोड़कर( म ेंसमान वधृि कर सकते हैं जो उपरोक्त सारणी में )6( म ेंधनधदचष्ट अधिकतम कीमतों से अधिक नहीं ह।ै (2) और व े1 अप्रैल, 2023 से एमआरपी में 12.1218% की दर से डब्लल्यपू ीआई के स्तर तक इसी तरह की वधृि कर सकते ह।ैं (6) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र- II के रूप में इलक्ट्े रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मल्ू य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पवू च-संिोजधत अजधकतम खिु रा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (छ( (4) धवक्रेता सस्ु पष्ट ज (1) II I[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 91 के धनमाचता अनु II III का वह II IV ञ (ट) गई उनका जाएगा [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1579(E).— Whereas the National Pharmaceutical Pricing Authority (NPPA) was established vide Resolution No. 33/7/97-PI.I dated 29th August 1997 of the Government of India in the Ministry of Chemicals and Fertilizers to fix/revise, monitor prices of drugs/formulations and oversee the implementation of the Drugs (Prices Control) Order (DPCO); and whereas the Government of India by S.O. 1349(E) dated 30th May 2013 in exercise of the powers conferred by Section 3 and 5 of the Essential Commodities Act, 1955 (10 of 1955) has delegated the powers in respect of paragraphs 4,5,6,7,8,9,10,11,12,13,14,15, 16,18,19, 20,21,23,24, 25,26,27,28, 29,30 and 32 of the DPCO, 2013 to the NPPA to exercise the functions of the Central Government; 2. And whereas the aim of the DPCO, 2013 issued under section 3 of Essential Commodities Act, 1955, is to ensure that essential drugs are available to all at affordable prices. 3. Whereas, the Department of Pharmaceuticals (hereinafter referred as DOP) has amended Schedule I of the Drugs Price Control Order (hereinafter referred as DPCO) 2013 vide S.O. 5249(E) dated 11.11.2022 based on National List of Essential Medicine (hereinafter referred as NLEM 2022). 4. Whereas under the revised Schedule I, certain new formulations have been added where high Inter brand variation within the same company has been observed. This anomaly can largely be explained by the fact that in few cases, same formulation of one company is having multiple prices for various brands with price variation even upto 1000%. As these formulations were non –scheduled formulations under NLEM, 2015, ceiling price were not applicable and companies were at liberty to fix the prices of such non-scheduled formulation under NLEM, 2015. 5. Whereas, the newly added formulations are considered essential medicines and have been included in NLEM 2022 based on recommendation of Standing Committee on Medicines (SNCM). The 2022 Report of the SNCM also notes that “Out-of-pocket expenditure constitutes over 60% of total health expenditure, with a substantial 40% being incurred on medicines. With this background, it is of paramount importance that accessibility and affordability of medicines be enhanced in order to reduce the financial burden on the households.” 6. Whereas, Competition Commission of India in its Report titled “Market Study on the Pharmaceutical Sector in India” dated 18th November 2021 has also provided empirical evidence on large price variation amongst brands of the same formulation. It has been noted in the report that “As evidenced by the data, despite the seemingly strong generic competition, gauged in terms of the number of players present in each therapeutic area and at the level of formulations/molecules, consumers in India ostensibly pay a premium for brands”. 7. Whereas, the same formulation of one company having multiple prices for different brands and brands having inbuilt margins and high profits coupled with information asymmetry in the pharmaceutical sector, make many drugs beyond the reach of common man and also lead to financial burden / impoverishment. This is an extra-ordinary situation leading to market failure and working against public welfare. Therefore, it is essential to undertake an exercise to reduce the inter-brand price difference in the public interest in respect of schedule formulations since these formulations are considered to be essential medicines and have been included in the NLEM, 2022 for the first time and therefore, should not fall out of price control.92 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 8. Whereas, as per Para 20 of DPCO, 2013, no manufacturer can increase the prices of non-scheduled formulation by more than 10% during preceding twelve months, where the increase in the prices of non-scheduled formulations is beyond 10% of MRP, the manufacturer shall reduce the same to the level of 10% of MRP for next twelve months. Thus, Para 20 does not recognise the brand, and monitoring under Para 20 is done at the formulation level. Also, Para 20 does not differentiate the price increase of the same formulation based on the situation under which such price increase has occurred. In all the situations, the manufacturer is bound to reduce the price to the level of 10%. 9. Whereas, such anomalies in variation in PTR of same formulations sold by same companies under different brand names is considered to be extra ordinary circumstance leading to the market failure and against public welfare. Thus, the Authority after due deliberation decided that it becomes essential to undertake such exercise to remove huge inter brand/pack size price variation by capping the PTR of various brands/ pack sizes of a formulation of a particular company at price of the lowest brand/ pack size plus 10%in the cases where non-scheduled formulations have come in the purview of NLEM, 2022 for the first time 10. Whereas, violation of the provisions of DPCO including Para 20 is not acceptable and should not form basis for fixation of ceiling prices under NLEM, 2022. Hence, in the cases where non-scheduled formulations have come in the purview of NLEM, 2022 for the first time, if the inter-brand variation in the price of same formulation is more than 10%, the manufacturer is bound to reduce the price to the level of 10% as per the provisions of DPCO, 2013. 11. Therefore, now in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the ceiling prices exclusive of goods and services tax applicable, if any, as specified in column (5)and increased by Whole sale Price Index (WPI) of 12.1218% under para 16 (1) of DPCO 2013 , with effect from 1.04.2023as specified in column (6) of the table in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form &strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Ceiling Ceiling price Price fixed (wef 1.4.2023 Sl. Name of the Scheduled under with WPI @ Dosage form and strength Unit No. Formulation NLEM, 12.1218%) 2022 (Rs.) (1) (2) (3) (4) (5) (6) 1 Amikacin Injection 250mg/mL 1 ML 48.31 54.16 2 Amoxicillin Oral liquid 125 mg/5 mL (p) 1 ML 0.91 1.02 3 Cefuroxime Injection 1500 mg 1 Vial 302.12 338.74 4 Clindamycin Injection150mg/mL 1 ML 54.05 60.60 5 Doxycycline Power for Injection 100 mg 1 Vial 448.27 502.60 6 Glycerin/glycerol (as Topical - Lotion 1 ML 1.1 1.23 mentioned in IP) 7 Glycerin/glycerol (as Topical - Cream 1 GM 2.11 2.36 mentioned in IP) 8 Human chorionic gonado tropin Injection10000IU 1 Vial 827.89 928.24 9 Human chorionic gonado tropin Injection2000 IU 1 Vial 306.49 343.64 10 Insulin Glargine Injection 100 IU/ml 1 ML 181.45 203.44 11 Iohexol Injection 350mg iodine/mL 1 ML 12.7 14.23 12 Solution for injection Irinotecan HCltrihydrate 1 ML 860.53 964.84 20mg/mL 13 Itraconazole Capsule 100mg 1 Capsule 14.87 16.67 14 Itraconazole Capsule 200mg 1 Capsule 19.73 22.12 15 Labetalol Tablet 100 mg 1 Tablet 13.52 15.15 16 Powder for Injection 500 mg Meropenem 1 Vial 644.82 722.98 (as trihydrate) 17 Powder for Injection1000mg Meropenem 1 Vial 849.69 952.68 (as trihydrate) 18 Mupirocin Ointment 2% 1 GM 18.1 20.29 19 Nicotine (for nicotine 1 Lozenge 2mg 7.06 7.91 replacement therapy) Lozenges 20 Nicotine (for nicotine Gum 2 mg 1 Gum 7.66 8.58[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 93 replacement therapy) 21 Nicotine (for nicotine Gum 4 mg 1 Gum 9.49 10.64 replacement therapy) 22 Nicotine (for nicotine 1 Lozenge 4mg 8.7 9.75 replacement therapy) Lozenges 23 Ormeloxifene (Centchroman) Tablet 30mg 1 Tablet 7.53 8.44 24 Rota virus vaccine As licensed 1 Vial 762.14 854.52 25 Salicylicacid Ointment 3% 1 GM 1.84 2.06 26 Teneligliptin Tablet 20mg 1 Tablet 9.89 11.08 27 Terbinafine Cream 1% 1 GM 4.69 5.25 Notes: (a) The above mentioned ceiling prices as fixed under NLEM 2022 shall be effective from 1st April, 2023 after application of Wholesale Price Index (WPI) and as specified in column (6) above. (b) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any and then they may further make corresponding increase in MRP (excluding GST) upto the level of WPI @12.1218% with effect from 1st April, 2023 not exceeding ceiling prices as specified in column (6) in the above table. (c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus GST as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 and they may further make corresponding increase in MRP upto the level of WPI @12.1218% with effect from 1st April, 2023. (d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.94 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1580(अ).— िबदक रसायन और उवचरक मंत्रालय ने दिनांक 30 मई, 2013 के एस.ओ.1394 (ई) के द्वारा आवश्यक वस्ट्तु अजधजनयम, 1955 की धारा 3 और 5 द्वारा प्रित्त िजक्तयों का प्रयोग करते हुए डीपीसीओ, 2013 के जनर्िष्टच पैरा के संबंध में उक्त आििे के पैरा 19 सजहत केंद्र सरकार की ओर से राष्ट्रीय औिध मूल्य जनधाचरण प्राजधकरण (NPPA) को िजक्तयों का प्रत्यायोिन दकया ह।ै 2. िबदक, औिध जवभाग (इसके बाि डीओपी के रूप में संिर्भचत) ने िग्स प्राइस कंरोल ऑडचर (इसके बाि डीपीसीओ के रूप में संिर्भचत) 2013 की अनुसूर्ी I को दिनांक 11.11.2022 के एस.ओ. 5249 (ई) के द्वारा आवश्यक िवाओं की राष्ट्रीय सूर्ी (इसके बाि एनएलईएम 2022 के रूप में संिर्भचत) के आधार पर संिोजधत दकया ह।ै और िबदक, ऑक्ट्सीिन - औिधीय उद्देश्य के जलए लाइसेंस के रूप में और नाइरस ऑक्ट्साइड िैसा दक औिधीय उद्देश्य के जलए लाइसेंस प्राप्त ह,ै डीपीसीओ 2013 की संिोजधत अनुसूर्ी I के तहत जनधाचटरत सूत्रीकरण ह।ैं 3. िबदक एनएलईएम, 2022 के तहत ऑक्ट्सीिन को "ऑक्ट्सीिन- औिधीय उद्देश्य के जलए लाइसेंस प्राप्त" के रूप में वर्णचत दकया गया ह,ै भारत सरकार के अजधकार प्राप्त समूह (ईिी) 3, अब ईिी2 को 21.09.2019 को आयोजित अपनी बैठक में मेजडकल ऑक्ट्सीिन की उपलब्धता सुजनजित करने के जलए अजधकृत दकया गया है। ईिी2 ने एनपीपीए से मेजडकल ऑक्ट्सीिन, एलएमओ और जसलेंडर िोनों की अजधकतम कीमत पर गौर करने का अनरु ोध दकया। प्राजधकरण ने 25.09.2020 को अपनी बैठक में ईिी2 और अंतर-मंत्रालयी सजमजत की जसफाटरिों सजहत इस मुद्दे की जवस्ट्तार से िांर् की और जसलेंडर में एलएमओ और ऑक्ट्सीिन इनहले ेिन (औिधीय गैस) की कीमत को सीजमत करने का जनणचय जलया ह।ै 4. िबदक, संबंजधत फॉमूचलेिन के जलए बािार आधाटरत डेटा उपलब्ध नहीं था और एनपीपीए के जलए डीपीसीओ, 2013 की अनुसूर्ी I के तहत अजधसूजर्त सभी िवाओं की अजधकतम कीमतों को संिोजधत करना अजनवायच ह ै तादक उजर्त लाभ सुजनजित दकया िा सके, और सावचिजनक जहत की रिा के जलए ऐसी आवश्यक िवाओं के उपभोक्ताओं को सही और उजर्त सीललंग प्राईस पर िवाएं उपलब्ध कराने के जलए, मूल्य जनधाचरण के वैकजल्पक तरीकों को अपनान े की आवश्यकता है; इस संबंध में, एनपीपीए ने संबंजधत दिनांक 28.12.2022 के फॉमूचलेिन के िुलाई 2022 के मैट और पीटीआर से संबंजधत डेटा प्रिान करने के जलए कायाचलय ज्ञापन (अथाचत ओएम) 12(90)/2022/डीपी-जडवीिन/एनपीपीए/II को अपलोड दकया। 5. िबदक, अनुसूजर्त फॉमूचलेिन की अजधकतम कीमतों को तय करना आवश्यक ह ै और कोई प्रजतदक्रया प्राप्त नहीं होने के कारण, एनपीपीए न े दिनांक 05.02.2019 के कायाचलय ज्ञापन के अनुसार जवजभन्न केंद्र सरकार की एिेंसी, राज्य सरकार के अस्ट्पतालों और जनिी िेत्र के अस्ट्पतालों से िानकारी मांगी, जिसमें स्ट्पष्ट रूप से कहा गया ह ै दक "िब कोई बािार जतजथ उपलब्ध नहीं है, तो उच्चतम मूल्य की गणना संस्ट्थागत डेटा के आधार पर की िा सकती है। 6. इसजलए, अब औिजध (मूल्य जनयंत्रण) आििे , 2013 के पैरा 19 द्वारा प्रित्त िजक्तयों का प्रयोग करते हुए, दिनांक 30 मई, 2013 के का.आ. 1394 (ई) को भारत सरकार द्वारा रसायन और उवचरक मंत्रालय में िारी दकया गया था, और भारत सरकार के रसायन और उवचरक मंत्रालय (राष्ट्रीय औिध मूल्य जनधाचरण प्राजधकरण) के आििे के अजतक्रमण में, दिनांक 02.11.2018 के एसओ 5634(ई), दिनांक 25.09.2020 के एसओ3322 (ई) और समय-समय पर जवस्ट्ताटरत और ऑक्ट्सीिन के संबंध में दिनांक 30.12.2022 के[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 95 एस.ओ. 6175(ई) के द्वारा अंजतम बार 31.03.2023 तक बढाया गया और नाइरस ऑक्ट्साइड के संबंध में दिनांक 02.11.2018 के 5634(ई) और दिनांक 30.03.2022 के1499(ई), राष्ट्रीय औिध मूल्य जनधाचरण प्राजधकरण (इसके बाि एनपीपीए के रूप में संिर्भचत) एतिद्वारा लाग ू माल और सेवा कर, यदि कोई हो, को छोड़कर अजधकतम मूल्य जनधाटच रत करता ह।ै िैसा दक कॉलम (5) में जनर्िष्टच ह ै और डीपीसीओ 2013 के पैरा 16 (1) के तहत 12.1218% के थोक मूल्य सूर्कांक (डब्ल्यूपीआई) द्वारा बढाया गया ह,ै प्रभावी रूप से 1.04.2023 से ताजलका के कॉलम (6) में अनुसूजर्त के संबंध में जनर्िष्टच है। कजथत ताजलका के कॉलम (2) में संबंजधत प्रजवजष्ट में जनर्िष्टच योगों के साथ क्रमिः कॉलम (3) और (4) में संबंजधत प्रजवजष्टयों में जनर्िष्टच खुराक फॉमच और स्ट्रेंथ और इकाई: ताजलका क्रम 12.1218% सं. (1) (2) (3) (4) (5) (6) 7(a) 7(b) 1 ऑक्ट्सीिन - जलदक्वड मेजडकल उद्देश्य क्ट्यूजबक 15.18 17.02 6175(E) 30.12.2022 मेजडकल ऑक्ट्सीिन के जलये लाइसेंस मीटर 2 ऑक्ट्सीिन मेजडकल उद्देश्य क्ट्यूजबक 25.71 28.83 6175(E) 30.12.2022 (जसललंडर में) के जलये लाइसेंस मीटर 3 नाईरस ऑक्ट्साईड मेजडकल उद्देश्य क्ट्यूजबक 255.04 285.95 1499(E) 30.03.2022 के जलये लाइसेंस मीटर टटप्पजणया:ं (क) एनएलईएम 2022 के तहत तय की गई उपरोक्त उच्चतम कीमतें थोक मूल्य सूर्कांक (डब्ल्यूपीआई) के लाग ू होने के बाि 1 अप्रैल, 2023 से प्रभावी होंगी और िैसा दक ऊपर कॉलम (6) में जनर्िष्टच है। (ख) ब्रांडेड या िेनेटरक या िोनों को बेर्ने वाले अनुसूजर्त फॉमूचलेिन के सभी जनमाचता सरकार द्वारा जनधाचटरत और अजधसूजर्त अजधकतम मूल्य (लाग ू वस्ट्तु एवं सेवा कर सजहत) से अजधक कीमत पर अनुसूजर्त फॉमूचलेिन के संस्ट्करणों को संिोजधत दकया िाएगा। ऐसे सभी फॉमूचलेिन की कीमतों में जनर्िष्टच अजधकतम मूल्य से अजधक नहीं उपरोक्त ताजलका में कॉलम (5) प्लस माल और सेवा कर लागू होने पर, यदि कोई हो और दफर वे 1 अप्रैल, 2023 से प्रभावी रूप से WPI @ 12.1218% के स्ट्तर तक एमआरपी (िीएसटी को छोड़कर) म ेंसमान वृजि कर सकते ह,ैं िो अजधकतम कीमतों से अजधक नहीं ह।ै िैसा दक उपरोक्त ताजलका के कॉलम (6) में जनर्िष्टच ह।ै (ग) उपयुचक्त ताजलका में कॉलम (5) में जनर्िष्टच अजधकतम मूल्य से कम एमआरपी वाले उपयुचक्त अनसु ूजर्त फॉमूचलेिन के सभी मौिूिा जनमाचताओं और लाग ू होने वाले स्ट्थानीय कर, यदि कोई हो, डीपीसीओ, 2013 के पैराग्राफ 13 (2) के अनुसार मौिूिा एमआरपी को बनाए रखना िारी रखेंगे और व े 1 अप्रैल, 2023 से एमआरपी में 12.1218% की िर से डब्ल्यूपीआई के स्ट्तर तक इसी तरह की वजृ ि कर सकते हैं। (घ) जनमाचता माल और सेवा कर तभी िोड़ सकते ह ैं िब उन्होंने वास्ट्तव में भुगतान दकया हो या यदि यह उपरोक्त ताजलका के कॉलम (6) में उजल्लजखत अजधकतम मूल्य पर सरकार को िये हो। (ङ) संिोधन के बारे में िानकारी, यदि िी िाती ह,ै तो सरकार को या तो इलेक्ट्रॉजनक या भौजतक रूप में फॉमच- II में इस तरह के संिोधन के पंद्रह दिनों की अवजध के भीतर भेिा िाएगा और इस उप-पैराग्राफ के तहत सूर्ना िमा न करने पर कारचवाई की िाएगी। अजधकतम खुिरा मूल्य (एमआरपी) के गैर संिोधन के रूप में माना िाता ह ै और संबंजधत जनमातच ा ओवरर्ार्ििंग की तारीख से ब्याि सजहत पूव-च संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। (र्) अनुसूजर्त फॉमूचलेिन के पैक के जलए अजधकतम मूल्य संबंजधत जनमाचता द्वारा उपयुचक्त ताजलका के कॉलम (6) में जनर्िष्टच अजधकतम मूल्य के अनसु ार िग्स (मूल्य जनयंत्रण) आििे , 2013 के पैरा 11 में जनजहत प्रावधानों के अनुसार तय दकया िाएगा। जनमाचता डीपीसीओ, 2013 के पैरा 24 के अनुसार अजधसूर्ना की तारीख से फॉमच-V में एक मूल्य सूर्ी आईपीडीएमएस के माध्यम से एनपीपीए को िारी करेगा और एक प्रजत राज्य औिजध जनयंत्रक और डीलरों को प्रस्ट्तुत करेगा।96 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (छ) डीपीसीओ 2013 के पैरा 24(4) के अनुसार, प्रत्येक खुिरा जवक्रेता और डीलर मूल्य सूर्ी और पूरक मूल्य सूर्ी, यदि कोई हो, िैसा दक जनमाचता द्वारा प्रस्ट्तुत दकया गया ह,ै उस पटरसर के एक जवजिष्ट भाग पर प्रिर्िचत करेगा िहां वह व्यापार करता है। ऐसा तरीका जिससे कोई भी व्यजक्त िो परामिच लेना र्ाहता है, आसानी से पहुर्ं सके। (ि) िहां उपरोक्त ताजलका में जनर्िष्टच खुराक या स्ट्रेंथ या िोनों के साथ अनुसूजर्त फॉमूचलेिन का एक मौिूिा जनमाचता डीपीसीओ, 2013 के पैराग्राफ 2(1)(यू) के अनुसार एक नई िवा लॉन्र् करता ह,ै ऐसे मौिूिा जनमाचता डीपीसीओ, 2013 की अनुसूर्ी-।। के तहत जनर्िष्टच फॉमच I में एनपीपीए को ऐसी नई िवा की पूव चमूल्य अनुमोिन के जलए आवेिन करेंगे। (झ) (i) उपयुचक्त अनुसूजर्त फॉमूचलेिन के जनमाचता आईपीडीएमएस के माध्यम से डीपीसीओ, 2013 की अनुसूर्ी-II के फॉमच-III में अनुसूजर्त फॉमूचलेिन के उत्पािन/आयात और जबक्री के संबंध में एनपीपीए को त्रैमाजसक टरटनच प्रस्ट्तुत करेंगे। उपरोक्त अनुसूजर्त फॉमूचलेिन के उत्पािन को बंि करने का इरािा रखने वाला कोई भी जनमाचता डीपीसीओ, 2013 की अनुसूर्ी-जद्वतीय के फॉमच- IV में बंि करने की इजच्छत जतजथ से कम स े कम छह महीने पहले एनपीपीए को उत्पािन बंि करने और/या अनुसूजर्त फॉमूचलेिन के आयात के संबंध में िानकारी प्रस्ट्तुत करेगा। (ञ) अजधकतम मूल्य और यहां ऊपर जनर्िष्टच टटप्पजणयों का पालन नहीं करने वाले जनमाचता आवश्यक वस्ट्त ु अजधजनयम, 1955 के साथ पटठत िवा (कीमत जनयंत्रण) आििे , 2013 के प्रावधानों के तहत अजतटरक्त प्रभाटरत राजि को ब्याि सजहत िमा करने के जलए उत्तरिायी होंगे। (ट) इस अजधसूर्ना की उपरोक्त ताजलका के कॉलम (2) में यथा जनर्िष्टच इस प्रकार के फॉमूचलेिन की सीललंग प्राईस के िारी होने के पटरणामस्ट्वरूप, मूल्य आििे (आििे ) सीललंग अथवा य खुिरा मूल्य, यदि कोई हो, यदि उपरोक्त जतजथ से पहले िारी दकया गया ह ै को अजतक्रजमत माना िाए। [dka- la-@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1580(E).— Whereas the Ministry of Chemicals and Fertilizers vide S.O.1394 (E) dated 30th May, 2013, in exercise of the powers conferred by Section 3 and 5 of Essential Commodities Act, 1955 has delegated the powers in respect of specified Paras of the DPCO, 2013, including Para 19 of the said Order to be exercised by the National Pharmaceutical Pricing Authority (NPPA) on behalf of the Central Government. 2. Whereas, the Department of Pharmaceuticals (hereinafter referred as DOP) has amended Schedule I of the Drugs Price Control Order (hereinafter referred as DPCO) 2013 vide S.O. 5249(E) dated 11.11.2022 based on revised National List of Essential Medicine (hereinafter referred as NLEM) 2022. And whereas, Oxygen – As licensed for medicinal purposeand Nitrous Oxide As licensed for medicinal purposeare scheduled formulation under amended Schedule I of DPCO 2013. 3. Whereas Oxygen is mentioned as “Oxygen-As licensed for medicinal purpose” under NLEM, 2022, Empowered Group (EG) 3, now EG2, of the Government of India mandated to ensure availability of Medical Oxygen in its meeting held on 21.09.2020 EG2 requested NPPA to look into the ceiling price of medical oxygen, both LMO and cylinders. The Authority in its meeting on 25.09.2020 examined the issue at length including the recommendations of EG2 and inter-ministerial committee, and decided to cap the price of LMO & Oxygen Inhalation (Medicinal gas) in cylinder. 4. Whereas, market based data for the concerned formulations was not available and it is obligatory on the part of the NPPA to revise the ceiling prices of all the drugs notified under the Schedule I of DPCO, 2013 so as to ensure the benefit of fair and reasonable ceiling prices to the consumers of such essential medicines to protect public interest, there is a necessity to adopt alternative methods of price fixation; In this regard, NPPA uploaded Office Memorandum (i.e. OM) 12(90)/2022/DP- Division/NPPA/II dated 28.12.2022to provide the data regarding MAT and PTR of July 2022 of the concerned formulation. 5. Whereas, it is necessary to fix ceiling prices of scheduled formulations and as no response was received, NPPA sought information from the various Central Government agency, State Government Hospitals and Private Sector Hospital in line with OM dated 05.02.2019 which clearly states that “When no market date is available, the ceiling price may be calculated on the basis of institutional data.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 97 6. Therefore, now in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No.S.O 5634(E) dated 02.11.2018, S.O3322 (E) dated 25.09.2020, and as extended time to time and last extended upto 31.03.2023 vide S. O. 6175(E) dated 30.12.2022 with respect to Oxygen and S.O 5634(E) dated 02.11.2018 and 1499(E) dated 30.03.2022 with respect to Nitrous Oxide, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the ceiling prices exclusive of goods and services tax applicable, if any, as specified in column (5) and increased by Wholesale Price Index (WPI) of 12.1218% under para 16 (1) of DPCO 2013 , with effect from 1.04.2023 as specified in column (6)of the table in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE S. Name of the Dosage form Unit Ceiling Price Ceiling price Existing S.O. No. & No. Scheduled and Strength fixed under (wef 01.04.2023 Date Formulation NLEM 2022 with WPI @ (Rs.) 12.1218%) (1) (2) (3) (4) (5) (6) 7(a) 7(b) 1 Oxygen – Liquid As licensed Cubic 15.18 17.02 6175(E) 30.12.2022 Medical Oxygen for medical Meter purpose 2 Oxygen As licensed Cubic 25.71 28.83 6175(E) 30.12.2022 (in cylinder) for medical Meter purpose 3 Nitrous oxide As licensed Cubic 255.04 285.95 1499(E) 30.03.2022 for medical Meter purpose Notes: (a) The above mentioned ceiling prices as fixed under NLEM 2022 shall be effective from 1st April, 2023 after application of Wholesale Price Index (WPI) and as specified in column (6) above. (b) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any and then they may further make corresponding increase in MRP (excluding GST) upto the level of WPI @12.1218% with effect from 1st April, 2023 not exceeding ceiling prices as specified in column (6) in the above table. (c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus GST as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 and they may further make corresponding increase in MRP upto the level of WPI @12.1218% with effect from 1st April, 2023. (d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.98 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1581(अ).— Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2022 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ eas fofufnZ"V gS] vf/kdre dher dk s mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ es a dh xbZ rRLFkkuh izfof"V eas fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i eas fu;r djrh gSA @ 12.1218% एनअलईएम @ 12.1218% (1) (2) (3) (4) (5) (6) 1 पेन में : इंजेक्शन 100 आईयू / एमएल 1लमली 217.74 244.13 इंसुललन ग्लाथगनस एनएलईएम 2022 के तहत तय की गई उपरोक्त उच्चतम कीमतें थोक मूल्य सूर्कांक) डब्ल्यूपीआई (के लागू होने के बाि 1 अप्रैल 2023 से प्रभावी होंगी और िैसा दक ऊपर कॉलम) 6) में जनर्िष्टच ह।ै सधहत (5) सधहत और धफर वे अप्रैल 2023 से डब्लल्यपू ीआई 12.1218% के स्तर तक को छोड़कर( में समान वधृि कर सकते ह ैं जो उपरोक्त सारणी में (6( में धनधदष्टच अधिकतम कीमतों से अधिक नहीं ह।ै[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 99 (2) और व े1 अप्रैल, 2023 से एमआरपी में 12.1218% की दर से डब्लल्यपू ीआई के स्तर तक इसी तरह की वधृि कर सकते ह।ैं (6) यदि संिोधन दकया िाता ह ैतो ,इसकी सूर्ना ऐस ेसंिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-II के रूप में इलेक्ट्रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सर्ू ना प्रस्ट्ततु नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमातच ा अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवचसे अजधक की राजि ि (एमआरपी) कतम खुिरा मूल्यसंिोजधत अजध-मा करने के जलए उत्तरिायी होगा। V (छ) (4) धवक्रेता सस्ु पष्ट ज (1) II I के धनमाचता अनु II III का वह II IV ञ (ट) गई उनका जाएगा [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd ORDER New Delhi, the 31st March, 2023 S.O. 1581(E).— In exercise of the powers conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11thNovember, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the ceiling prices exclusive of goods and services tax applicable, if any, as specified in column (5) and increased by Wholesale Price Index (WPI) of 12.1218% under para 16 (1) of DPCO 2013 , with effect from 1.04.2023 as specified in column (6)of the table in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:100 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] TABLE Ceiling Ceiling price Price (wef 1.4.2023 Fixed with WPI @ Sl. Name of the Scheduled Dosage form and strength Unit under 12.1218%) No. Formulation NLEM, 2022 (Rs.) (1) (2) (3) (4) (5) (6) 1 Pen containing Insulin Injection 100 IU/ml 1 ML 217.74 244.13 Glargine Notes: (a) The above mentioned ceiling prices as fixed under NLEM 2022 shall be effective from 1st April, 2023 after application of Wholesale Price Index (WPI) and as specified in column (6) above. (b) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any and then they may further make corresponding increase in MRP (excluding GST) upto the level of WPI @12.1218% with effect from 1st April, 2023 not exceeding ceiling prices as specified in column (6) in the above table. (c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus GST as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 and they may further make corresponding increase in MRP upto the level of WPI @12.1218% with effect from 1st April, 2023. (d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 101 पटरजिष्ट ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1582(अ).— फरवरी 02 2023 (1) (2) (3) (4) (5) 51 इनहले ेशन )एमडीआई/डीपीआई*( 100 सैल्बुटामोल एमसीजी / डोज 1 एमडीआई 0.44 (1) (2) (3) (4) (5) 51 इनहले ेशन )एमडीआई/डीपीआई( 100 एमसीजी / सैल्बटु ामोल डोज 1 डोज 0.44 फरवरी 02 2023 [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd CORRIGENDUM New Delhi, the 31st March, 2023 S.O. 1582(E).— In the National Pharmaceutical Pricing Authority's notification S.O. 484(E), dated 2nd February, 2023 relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry at Sl. No. 51 of the Table, both in Hindi & English version, be read as follows: Instead of Sl. Name of the No. Scheduled Dosage form and strength Unit Ceiling Price (Rs.) Formulation (1) (2) (3) (4) (5) 51 Salbutamol Inhalation (MDI/DPI*) 100mcg/dose 1 MDI 0.44 Read as Sl. Name of the No. Scheduled Dosage form and strength Unit Ceiling Price (Rs.) Formulation (1) (2) (3) (4) (5) 51 Salbutamol Inhalation (MDI/DPI) 100mcg/dose 1 Dose 0.44 All the notes and other contents mentioned in the original order S.O. 484(E), dated 2nd February, 2023 shall remain same. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director102 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] पटरजिष्ट ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1583(अ).— फरवरी 02 2023 मैसस चओत्सुका फामाचस्ट्युटटकल इंजडया प्रा. जलजमटेड मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड मैससच ओत्सुका फामाचस्ट्युटटकल इंजडया प्रा .जलजमटेड मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड . मेससच सजर्न पैरेंटेरल प्रा. जलजमटेड फरवरी 02 2023 [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd CORRIGENDUM New Delhi, the 31st March, 2023 S.O. 1583(E).— In the National Pharmaceutical Pricing Authority's notification S.O. 487(E), dated 2nd February, 2023, relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry of the Table B, both in Hindi & English version, be read as follows: Instead of Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. Read as Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. 4 M/s Sachin Parenteral Pvt. Ltd. All the notes and other contents mentioned in the original order S.O. 487(E), dated 2nd February, 2023, shall remain same. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 103 पटरजिष्ट ubZ fnYyh] 31 ekpZ] 2023 का.आ. 1584(अ).— फरवरी 02 2023 मैससच ओत्सुका फामाचस्ट्युटटकल इंजडया प्राजलजमटेड . मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड मैसस चओत्सुका फामाचस्ट्युटटकल इंजडया प्रा. जलजमटेड मैसस चडेजनस केम लेब प्रा०जलजमटेड मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड . मेससच सजर्न पैरेंटेरल प्रा. जलजमटेड फरवरी 02 2023 [dk-a l-a@243@111@2023@,Q@Qk- la- 8¼111½@2023@Mhih@,uihih,-&fMoh&II] egkohj lSuh] mi funs'kd CORRIGENDUM New Delhi, the 31st March, 2023 S.O. 1584(E).—In the National Pharmaceutical Pricing Authority's notification S.O. 486(E), dated 2nd February, 2023, relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry of the Table B, both in Hindi & English version, be read as follows: Instead of Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. Read as Sl. No. Name of Manufacturer (1) (2) 1 M/s Otsuka Pharmaceutical India Private Ltd. 2 M/s Denis Chem Lab Ltd. 3 M/s Rusoma Laboratories Pvt. Ltd. 4 M/s Sachin Parenteral Pvt. Ltd. All the notes and other contents mentioned in the original order S.O. 486(E), dated 2nd February, 2023, shall remain same. [F. No. PN/243/111/2023/F/ F. No. 8(111)/2023/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.

Continue your research

Related Documents from Ministry of Chemicals and Fertilizers